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„I am among those who think that science has great beauty.
A scientist in his laboratory is not only a technician: he is also a child placed before natural
phenomena which impress him like a fairy tale. We should not allow it to be believed that all
scientific progress can be reduced to mechanisms, machines, gearings, even though such
machinery has its own beauty.“
Marie Curie (1933)
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Summary
Summary
Mediator is a central coactivator complex required for regulated transcription by RNA poly-
merase (Pol) II in all eukaryotes. Budding yeast Mediator has a size of 1.4 MDa and consists
of 25 subunits arranged in the head, middle, tail, and kinase modules. It is thought that
Mediator forms an interface between the general RNA polymerase (RNA Pol) II machinery
and transcriptional activators leading to promotion of pre-initiation complex (PIC) assembly.
Mediator middle module from budding yeast consists of seven subunits Med1, 4, 7, 9, 10, 21,
and 31 and was investigated during this thesis both structurally and functionally. Previously,
the structure of a subcomplex comprising the C-terminal region of Med7 (Med7C) and Med21
was solved by X-ray crystallography and protocols for obtaining larger recombinant complexes
were established in the laboratory. As structural and functional studies of Mediator are
limited by the availability of protocols for the preparation of modules, I pursued these studies
and established protocols for obtaining pure endogenous and recombinant complete Mediator
middle module.
Another subcomplex of the middle module, comprising the N-terminal part of subunit
Med7 (Med7N) and the highly conserved subunit Med31 (Soh1) was successfully crystallized
and its structure solved during this work. It is found, that it contains a unique structure
and acts also as a functional entity (termed submodule). The Med7N/31 submodule shows
a novel fold, with two conserved proline-rich stretches in Med7N wrapping around the right-
handed four-helix bundle of Med31. In vitro, Med7N/31 is required for activated transcription
and can act in trans when added exogenously. In vivo, Med7N/31 has a predominantly
positive function on the expression of a specific subset of genes, including genes involved
in methionine metabolism and iron transport. Comparative phenotyping and transcriptome
profiling identified specific and overlapping functions of different Mediator submodules.
Crystallization screening of larger middle module (sub-)complexes did not result in crys-
tal formation, even after removal of some flexible regions. Thus alternative methods were
applied to characterize the middle module topology. Native mass spectrometry reveals that
all subunits are present in equimolar stoichiometry. Ion mobility mass spectrometry, limited
proteolysis, light scattering, and small angle X-ray scattering all indicate a high degree of in-
trinsic flexibility and an elongated shape of the middle module, giving a potential explanation
of why crystallization of larger complexes was unsuccessful. Moreover, based on systematic
protein-protein interaction analysis, a new model for the subunit-subunit interaction net-
work within the middle module of the Mediator is proposed. In this model, the Med7 and
Med4 subunits serve as a binding platform to form the three heterodimeric subcomplexes
Med7N/21, Med7C/31, and Med4/9. The subunits Med1 and Med10, which bridge to the
Mediator tail module, bind to both Med7 and Med4. Furthermore, first steps in establishing
an in vitro assay to test endogenous and recombinant middle module functionality have been
initiated and will provide the basis for future studies.
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Introduction
1 Introduction
1.1 Regulation of transcription in eukaryotic cells
Transcription is the fundamental process by which cells convert the DNA-coded information
into RNA through RNA polymerase enzymes. This process enables the coded information to
be translated into proteins as well as regulation of cellular processes by non-coding RNAs.
Regulation of transcription increases the versatility and adaptability of organisms by enabling
to adapt protein expression to cellular needs. Thus, responses to external changes are enabled,
as well as cellular differentiation and development. To date, four different nuclear RNA
Pols have been identified in higher eukaryotes. In contrast, only one RNA Pol is found in
prokaryotes and archaea (Thomas and Chiang, 2006). Nevertheless, sequence and structural
comparisons reveal the evolutionary conservation of the overall architecture of RNA Pols in
the three kingdoms of life (compare Cramer, 2002; Cramer et al., 2008). In eukaryotes, RNA
Pol I synthesizes a pre-rRNA, which matures into 28S, 18S and 5.8S rRNAs which form the
major RNA sections of the ribosome (Grummt, 1999). RNA Pol III is responsible for synthesis
of structural or catalytic RNAs. It transcribes mainly 5S rRNA, tRNAs and U6 snRNA (Dieci
et al., 2007; Thomas and Chiang, 2006). RNA Pol II transcribes all protein encoding genes,
into mRNA, which serves as the template for protein synthesis (reviewed in Kornberg, 1999).
Also most snRNA and microRNA (Sharp, 1988; Lee et al., 2004) are transcribed by RNA
Pol II. A major difference compared to the other RNA Pols is the presence of an extended
and very flexible carboxy-terminal domain (CTD) on the Rpb1 subunit. It contains multiple
repeats of the heptapeptide sequence YSPTSPS. The number of these repeats increases with
genomic complexity: 26 in budding yeast, 32 in Caenorhabditis elegans, 45 in Drosophila,
and 52 in mammals (Sims et al., 2004). A fourth RNA polymerase has been identified in
plants to facilitate the production of siRNA (reviewed in Thomas and Chiang, 2006). RNA
Pols are very large multisubunit enzymes, comprising about 12 to 17 subunits with a total
molecular weight of 0.5-0.7 MDa.
Transcription is a highly regulated process, that depends on specific sets of transcription
factors and cofactors. While in bacteria σ factors play the key role in regulation (Campbell
et al., 2008), the situation in eukaryotes is much more complex. Triggering transcription
of genes by RNA Pol II requires not only signal transduction from signaling pathways to
gene-specific transcription factors, but also assembly of a many additional factors into large
transcription machineries of changing composition. Polymerase-associated factors enable the
polymerases to recognize different promoters and to transcribe different classes of genes,
to receive different regulatory signals, to direct the co-transcriptional processing of RNA
transcripts, and to couple transcription to changes in chromatin structure and modification.
1
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1.2 RNA polymerase II transcription cycle and the general
transcription machinery
Transcription can be described as a transcription cycle (Figure 1). This multistep process
can be divided in three major stages - initiation, elongation and termination.
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Figure 1: The mRNA transcription cycle.
Main phases of the transcription cycle are colored orange, important events of regulation are colored in yellow.
The circle in the middle depicts the occurrence of the events in relation to the gene. ORF = open reading
frame. Courtesy of Stefan Dengl, Gene Center Munich.
The prevailing view of transcriptional activation is that many sequence-specific regulators
interact with their cognate DNA motifs in response to cellular signals. They recruit transcrip-
tional coactivators (such as SWR1, SWI/SNF, RSC, ISWI, Mediator and SAGA) to alter the
local chromatin environment, making it accessible and facilitate assembly of the pre-initiation
complex at the promoter. The PIC, or closed complex is composed of core promoter DNA,
the general transcription factors (GTFs) and RNA Pol II (Venters and Pugh, 2009; Hahn,
2004). The general transcription factors are TFIIA, TFIIB, TFIID, TFIIE, TFIIF, TFIIS,
and TFIIH and they mediate promoter recognition and unwinding (Sikorski and Buratowski,
2009; Kim et al., 2007). A detailed listing of the factors involved in PIC assembly is given in
Table 1.
The factors and assembly pathways used to form transcriptionally competent PICs can
be promoter dependent (Müller et al., 2007; Sikorski and Buratowski, 2009; Huisinga and
Pugh, 2007). The classical TATA box is present only in 20% of yeast promoters and several
models have been proposed how PICs assemble in its absense. While in metazoans a variety
of cis-regulatory elements has been described, yeast seems to exhibit a smaller set of these
elements (compare Basehoar et al., 2004; Venters and Pugh, 2009; Sikorski and Buratowski,
2009).
During open complex formation, about 10 bases of the DNA double helix separate, and
the single-stranded DNA template strand slips into the active site, which lies in a deep
cleft in the polymerase enzyme (Hahn, 2009). Yeast RNA Pol II scans with the help of the
2
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TFIIB reader the DNA for an initiator (Inr) sequence motif that defines the transcription
start site (TSS) (Kostrewa et al., 2009) and once found it synthesizes short RNA products
(abortive initiation). As soon as a RNA of 7 bases or more is synthesized, the polymerase
releases its contacts with the promoter and initiation factors (promoter escape) to enter a
processive elongation form termed the elongation complex, which synthesizes full-length RNA
transcripts (Kostrewa et al., 2009; Hahn, 2009). The switch to productive transcription in
the elongation stage is characterized also by phosphorylation at serine 5 on the CTD repeats
of RNA Pol II. Whereas TFIIB and TFIIF dissociate from the promoter, activator, TFIID,
TFIIA, TFIIH, TFIIE and Mediator are left behind in a scaffold complex for the facilitated
reinitiation of transcription of the same gene (Hahn, 2004; Yudkovsky et al., 2000).
The polymerase moves along the DNA and links nucleotides into a pre-mRNA transcript,
whose sequence is based on the template strand. The efficiency of elongation by RNA Pol II
is regulated by a number of additional factors such as TFIIF, TFIIS, Spt4-Spt5, Spt6, FACT,
and Paf (Sims et al., 2004; Kim et al., 2007). RNA Pol II CTD acts as a “landing pad”, binding
directly to factors involved in pre-mRNA capping, 3’ end processing, transcription elonga-
tion, termination, and chromatin modification (Phatnani and Greenleaf, 2006). The change
of phosphorylation state of the CTD during transcription has been described as a phospho-
rylation cycle: Initial phosphorylation of (unphosphorylated) RNA Pol II CTD on serine 5
during PIC formation or before promoter-proximal pausing is achieved by the kinase activity
of the Kin28 subunit of TFIIH. Capping enzyme associates with the serine 5-phosphorylated
CTD and with Spt5, and the nascent RNA becomes capped during this first stage of elon-
gation. Once proper pre-mRNA capping is ensured, serine 2 residues are phosphorylated
by Bur1/2 (yeast homologs of P-TEFb) or Ctk1. Later in elongation, protein phosphatases
such as Ssu72 or Fcp1 dephosphorylate the CTD serine residues and recycle RNA Pol II for
reinitiation and subsequent rounds of transcription (Sims et al., 2004; Saunders et al., 2006;
Egloff and Murphy, 2008; Qiu et al., 2009). Additionally to these prevalent modifications, the
CTD can be also be modified by phosphorylation at serine 7, glycosylation, and by cis/trans
isomerization of prolines (Egloff et al., 2007; Meinhart et al., 2005).
Termination sites can be located up to 1 kb downstream of the poly(A) site where the
nascent transcript is 3’-processed and uncoupled from the transcription machinery by factors
that are recruited to the Ser2-phosphorylated CTD of RNA Pol II (Dengl and Cramer, 2009).
Introns can be removed by the spliceosome both cotranscriptionally and post-transcriptionally
(Bentley, 2002; Proudfoot et al., 2002). Export of mRNAs is extensively coupled to transcrip-
tion and characterized by assembly into complicated messenger ribonucleoprotein (mRNP)
particles that are exported via export factors to the cytoplasm, where they are bound by
ribosomes and translated into proteins (Köhler and Hurt, 2007).
3
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Table 1: Complexes involved in S. cerevisiae RNA Pol II PIC assembly
(Adapted from Hahn (2004); Thomas and Chiang (2006); Sikorski and Buratowski (2009))
Factor No. of Function
subunits
RNA Pol II 12 Catalyzes transcription of all mRNAs and a subset of noncoding RNAs including
snRNAs and miRNAs; CTD phosphorylation
TFIIA 2 Antirepressor; stabilizes TBP and TFIID-DNA binding; positive and negative
gene regulation
TFIIB 1 Binds TBP, RNA Pol II and promoter DNA and thereby stabilizes TBP-TATA
complex; start site selection; aids in recruitment of TFIIF/RNA Pol II
TFIID 15 TBP and 14 TBP Associated Factors (TAFs); nucleates PIC assembly either
through TBP binding to TATA sequences or TAF binding to other promoter
sequences (INR and DPE elements); coactivator activity through direct inter-
action of TAFs and gene specific activators
TFIIE 2 Helps to recruit TFIIH to promoters; stimulates helicase and kinase activities
of TFIIH; binds ssDNA and is essential for promoter melting
TFIIFa 3 Tightly associates with RNA Pol II; enhances affinity of RNA Pol II for TBP-
TFIIB-promoter complex; necessary for recruitment of TFIIE/TFIIH to the
PIC; aids in start site selection and promoter escape; enhances elongation effi-
ciency; involved in RNA Pol II recruitment to PIC and in open complex forma-
tion
TFIIS 1 Stimulates intrinsic transcript cleavage activity of RNA Pol II allowing back-
tracking to resume RNA synthesis after transcription arrest; stimulates PIC
assembly at some promoters
TFIIH 10 ATPase/helicase necessary for promoter opening and promoter clearance; heli-
case activity for transcription coupled DNA repair; kinase activity required for
phosphorylation of RNA Pol II CTD; facilitates transition from initiation to
elongation
Mediator 25 Bridges interaction between activators and basal factors; stimulates both acti-
vator dependent and basal transcription; required for transcription from most
RNA Pol II dependent promoters; kinase and acetyltransferase activity; inter-
acts with TBP, TFIIF, TFIIH and TFIIS
SAGAb 21 Interacts with activators, histone H3, TBP and TFIIA; histone-acetyltransferase
activity; deubiquitinating activity
NC2 2 Binds TBP/DNA complexes and blocks PIC assembly; can have both positive
and negative effects on transcription
Mot1 1 Induces dissociation of TBP/DNA complexes in ATP dependent manner; can
have both positive and negative effects on transcription
Tup1-Ssn6 2 Represses multiple subsets of genes when recruited to promoters by sequence-
specific DNA binding repressors
a Yeast has one extra nonessential subunit compared with other organisms studied. b Yeast also contain SLIK, a
closely related complex.
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1.3 Chromatin remodeling
Eukaryotic DNA is packed into chromatin with nucleosomes as repeating structural units.
DNA is wrapped twice around an octameric complex of histone proteins, which consists of an
histone 3-histone 4 (H3–H4) tetramer and two histone 2A–histone 2B (H2A–H2B) dimers.
The DNA between the nucleosomes is termed linker DNA. While yeast lacks histone H1,
this fifth histone helps to stabilize the formation of more compact, higher-order chromatin
structures in higher eukaryotes (Saunders et al., 2006). The regulation of gene transcription
involves a dynamic balance between genome packaging into chromatin and allowing tran-
scriptional regulators access regulatory sequences (Cairns, 2009; Clapier and Cairns, 2009).
Generally, there are two mechanisms to alter the chromatin structure and thereby enable
access to the DNA for regulatory proteins that can activate transcription: through post-
translational modification of histones and through alteration of the nucleosome structure.
Histone are predominantly modified at their flexible N-terminal tails (H2A also has a C-
terminal tail) that protrude from the core nucleosome, but also some residues within the
histone globular domain can be modified (Saunders et al., 2006). These modifications in-
clude methylation of arginine (R) residues; methylation, acetylation, ubiquitination, ADP-
ribosylation, and sumolation of lysines (K); and phosphorylation of serines and threonines.
Histone modifications are reversible, for example histone deacetylases oppose the action of
histone acetyltransferases. Modifications that are associated with active transcription, such
as acetylation of H3 and H4 or di- or trimethylation (me) of H3K4, are commonly referred to
as euchromatin modifications. Modifications that are localized to inactive genes or regions,
such as H3 K9me and H3 K27me, are often termed heterochromatin modifications (Li et al.,
2007). Typical histone modification patterns can be correlated over the length of active genes
(compare in Saunders et al., 2006, Figure 3).
Modifiers such as acetyltransferases, methyltransferases and kinases can promote or deter
the targeting or activity of chromatin remodellers on the proper nucleosome (Cairns, 2009).
Remodelers use the energy of ATP hydrolysis to change the packaging state of chromatin by
moving, exchange for histone variants, ejecting, or restructuring the nucleosomes (Clapier and
Cairns, 2009). Chromatin remodeling complexes fall into four families based upon sequence
conservation: SWI/SNF (including SWI/SNF and RSC in yeast), INO80 (including INO80
and SWR1 in yeast), ISWI, and CHD (Chd1 is a component of both the SAGA and SLIK
complexes). These complexes are often large molecular machines (compare Figure 2) that
are apparently most active on promoter nucleosomes (Cairns, 2009; Venters and Pugh, 2009).
Recent analysis revealed that two types of promoters exist: open promoters (typical for
constitutive genes) that have a depleted proximal nucleosome adjacent to the transcription
start site and covered promoters (typical for regulated genes) where the transcription start site
is often covered by nucleosomes in its repressed state. Additionally, nucleosome positioning
sequence elements determine the position of nucleosomes at these promoters (Cairns, 2009).
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1.4 Corepressors
In yeast, three major entities have been found that repress transcription initiation. Two
transcription repressors, Mot1 and NC2, act through direct interactions with TBP. Mot1 is
a Snf2 family ATPase that removes TBP from promoters. NC2 is a heterodimer that blocks
TFIIA and TFIIB from associating with the TBP–TATA complex (Pereira et al., 2003; Auble,
2009; Sikorski and Buratowski, 2009). Both NC2 and Mot1 also have positive roles at many
yeast promoters, although the mechanism by which they positively control transcription is
still under study (Mohibullah and Hahn, 2008). The Ssn6-Tup1 complex represses more than
180 genes in Saccharomyces cerevisiae (S. cerevisiae) controlled by different pathways and
is thus considered a global corepressor of transcription. Although Ssn6 and Tup1 form a
complex, it is largely accepted that Tup1 contributes the bulk of the repression activity and
Ssn6 acts as an adapter. Apparently, Tup1 utilizes multiple redundant mechanisms to repress
transcription of native genes – for e.g. nucleosome positioning, histone deacetylation, and
Mediator interference (Zhang and Reese, 2004; Hallberg et al., 2006).
1.5 Coactivator complexes
Although activators or repressors can interact directly with components associated with the
core promoter, they execute their regulation predominantly through coactivators (Fuda et al.,
2009). A number of coactivators have been isolated as large multifunctional complexes, and
biochemical, genetic, molecular, and cellular strategies have all contributed to uncovering
many of their components, activities, and modes of action. Coactivator functions can be
broadly divided into two classes: (a) adapters that direct activator recruitment of the tran-
scriptional apparatus, or (b) chromatin-remodeling or -modifying enzymes (compare Fig-
ure 2). Strikingly, several distinct coactivator complexes nonetheless share many subunits
and appear to be assembled in a modular fashion. Such structural and functional modular-
ity could provide the cell with building blocks from which to construct a versatile array of
coactivator complexes according to its needs (Näär et al., 2001).
Aside from the Mediator complex, which will be described in detail below, the SAGA
complex and its relatives (SLIK, SALSA) as well as the GTF TFIID appear to be the major
complexes in enabling activated transcription as revealed by cross-linking studies (Fishburn
et al., 2005; Reeves and Hahn, 2005). In S. cerevisiae, the coactivator complexes TFIID
and SAGA are critical for TBP recruitment (Mohibullah and Hahn, 2008). It is likely,
that coactivators act promoter-specifically, e.g. yeast TFIID tends to regulate promoters of
“housekeeping” genes, whereas yeast SAGA typically acts at highly regulated genes that are
modulated by stress. SAGA is 1.8 MDa multisubunit complex that is directly recruited to
promoters by activators and was originally identified as a histone acetyltransferase (HAT)
complex containing the HAT subunit Gcn5 (Mohibullah and Hahn, 2008; Wu et al., 2004).
Interestingly, TFIID and SAGA share a common set of TAFs (Huisinga and Pugh, 2004)
which may partially explain their overlapping functions.
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Figure 2: Transcription initiation results from an interplay of several multiprotein complexes.
In response to cellular signals, activators bind to their regulatory elements (RE), which are typically lo-
cated upstream of the promoter sequences. Coactivators are recruited that alter the chromatin environment
(Chromatin remodeling and histone modifiers such as RSC, ISWI, Swi/Snf, NuA4, Chd1, INO80, SWR1)
and facilitate assembly of the PIC at the promoter (compare Biddick and Young, 2009). The Mediator and
SAGA coactivator complexes serve at most genes as adapters that bridge interactions between activators and
the basal transcription initiation machinery. Corepressors can antagonize the formation of transcriptionally
competent PICs, predominantly by removing TBP from the TATA element.
(Proteins and complexes are drawn at relative scale.)
1.6 The Mediator complex
1.6.1 Discovery and conservation of Mediator
The first evidence for an intermediary complex was indirect and came from experiments where
one activator interfered (termed as squelched) with another in yeast and mammalian cells
in vivo (Gill and Ptashne, 1988; Triezenberg et al., 1988). Such interference was attributed
to the sequestration of a factor(s), present in a limiting amount, required for activated tran-
scription (Myers and Kornberg, 2000). Independently from these studies, R. A. Young’s
laboratory identified genes in yeast genetic screens by their ability to suppress the cold-
sensitive phenotype of RNA Pol II CTD truncation mutations. These genes encode proteins
(termed Suppressor of RNA Pol B (Srb)) which were shown to form a large complex with
RNA Pol II and some GTFs together termed RNA Pol II holoenzyme, that could support
activated transcription in vitro after supplementation with missing GTFs (Nonet and Young,
1989; Thompson et al., 1993; Koleske and Young, 1994; Hengartner et al., 1995; Liao et al.,
1995). In parallel, in the laboratory of R. D. Kornberg, attempts to purify the individual
components of the RNA Pol II machinery to homogeneity using conventional column chro-
matography led to the purification of all GTFs and a complex termed as Mediator (Kelleher
et al., 1990; Flanagan et al., 1991; Sayre et al., 1992; Svejstrup et al., 1994; Kim et al., 1994).
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Mediator turned out to be ubiquitous in eukaryotes and was also purified from human
cells (Fondell et al., 1996; Sun et al., 1998; Näär et al., 1999; Rachez et al., 1999; Ryu et al.,
1999), mouse (Jiang et al., 1998), fission yeast (Spåhr et al., 2000; Linder et al., 2008),
Drosophila (Park et al., 2001b) and plant (Bäckström et al., 2007). Biochemical purification
of Mediator complexes from different species has identified additional conserved as well as
species-specific subunits and a unified nomenclature has been proposed (Bourbon et al., 2004).
Moreover, homology analysis in many eukaryotic genomes showed not only its conservation
across the eukaryotic kingdom (Boube et al., 2002) but gave also insights into its evolution
(Bourbon, 2008). The overall Mediator structure appears to be conserved as most budding
yeast subunits have been identified also in the majority of eukaryotes. Differences occur
predominantly within the tail and the head modules. The tail module is e.g. smaller in
Schizosaccharomyces pombe (S. pombe) (lacking Med5 and Med16) compared to S. cerevisiae
but contains additional subunits in mammalians (Med23, Med25). Interestingly, the size of
individual subunits differs across species, e.g. mammalian Med1 subunit is considerably larger
when compared to S. cerevisiae (Bourbon, 2008). This reflects likely metazoan diversification
as Med1 is apparently responsible for most mammalian activator binding (Blazek et al., 2005).
1.6.2 Mediator architecture in Saccharomyces cerevisiae
Budding yeast Mediator has a molecular weight of 1.4 MDa and consists of 25 polypeptide
subunits (Table 2). Based on electron microscopy (EM) and biochemical analysis, the sub-
units have been assigned to four different modules, termed the head, middle, tail, and kinase
modules (Asturias et al., 1999; Kang et al., 2001). Later studies refined these assignments
and mapped also many subunit interactions (Guglielmi et al., 2004; Béve et al., 2005; Lar-
ivière et al., 2006; Takagi et al., 2006). While the head, middle and tail modules form the
Mediator core complex, the kinase module appears to be dissociable. Of the 25 subunits, 10
are essential for yeast viability (Myers and Kornberg, 2000). Detailed structural information
was obtained by X-ray crystallography for subunit CycC (Hoeppner2005), the subcomplexes
Med7C/21 (Baumli et al., 2005), Med18/20, and Med8C/18/20 (Larivière et al., 2006, 2008)
(“C” denotes the C-terminal portion of a subunit, “N” denotes the N-terminal portion), and
by NMR for the Med15 KIX domain (Yang et al., 2006; Thakur et al., 2008). Electron
microscopic studies of Mediator across several species (S. cerevisiae, Asturias et al. (1999);
Davis et al. (2002); Cai et al. (2009); S. pombe, Elmlund et al. (2006); mouse, Asturias
et al. (1999); and human, Taatjes et al. (2002, 2004); Knuesel et al. (2009)) show a dynamic
arrangement of the modules and hence the exact Mediator architecture is still a matter of
debate. For instance in S. pombe, the reversibly associated kinase module has been found by
cryo-EM at 28 Å resolution located near to the middle module, thereby sterically blocking
binding of RNA Pol II if present (Elmlund et al., 2006). In contrast, for human Mediator,
a 38 Å reconstruction has been published in which the kinase module was found at the tail
module instead (Knuesel et al., 2009). The very low-resolution cryo-EM structure of budding
yeast Mediator (Asturias et al., 1999) has recently been replaced by a 28 Å reconstruction
suggesting an additional arm domain that was defined on independent mobility comparisons
of Mediator portions (Cai et al., 2009).
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Table 2: Mediator subunits S. cerevisiae.
(Adapted from Myers and Kornberg (2000); Bourbon et al. (2004); Guglielmi et al. (2004); Béve et al. (2005))
Subunit S. cerevisiae Protein Module Essential for Activity
alias mass (kDa) viability
Med1 Med1 64 Middle No
Med2 Med2 48 Tail No Activator binding
Med3 Pgd1/Hrs1 43 Tail No Activator binding
Med4 Med4 32 Middle Yes
Med5 Nut1 129 Tail No Histone acetyltransferase
Med6 Med6 33 Head Yes
Med7 Med7 26 Middle Yes
Med8 Med8 25 Head Yes TBP binding
Med9 Cse2 17 Middle No
Med10 Nut2 18 Middle Yes
Med11 Med11 15 Head Yes
Med12 Srb8 167 Kinase No
Med13 Srb9/Ssn2 160 Kinase No
Med14 Rgr1 123 Middle/Tail Yes
Med15 Gal11 120 Tail No Activator binding
Med16 Sin4/Ssn4 111 Tail No
Med17 Srb4 78 Head Yes
Med18 Srb5 34 Head No
Med19 Rox3/Nut3/Ssn7 25 (unclear) No
Med20 Srb2/Hrs2 23 Head No TBP binding
Med21 Srb7 16 Middle Yes
Med22 Srb6 14 Head Yes
Med31 Soh1 15 Middle No
Cdk8 Srb10/Ssn3 63 Kinase No Cyclin dependent kinase
CycC Srb11/Ssn8 38 Kinase No Cyclin
1.6.3 Mediator in transcriptional activation and repression
Mediator forms an interface between both the general RNA Pol II machinery and transcrip-
tional activators and thereby promotes PIC assembly (Cantin et al., 2003). Recent data
suggest a model in that Mediator plays an active role in transmitting information from
activators to the transcriptional machinery and is itself subject to regulation (e.g. phos-
phorylation) which may explain Mediators’ dual ability to act as both a coactivator and a
corepressor (Biddick and Young, 2005).
In contrast to mammalian Mediator, where mostly Med1 binds directly to activators, in
S. cerevisiae and other lower eukaryotes Med15 is the primary subunit for direct activator
binding. Med15 is a large subunit located in the tail module (Figure 2 and Table 2) and bears
a KIX and presumably also other activator binding domains (Thakur et al., 2008; Jedidi et al.,
2010). Recruitment of Mediator to GAL promoters was found to be independent of the RNA
Pol II transcription machinery and core promoter elements (Kuras et al., 2003). Similarly,
recruitment of the subcomplex Med2/3/15 by Gcn4 in a med16∆ strain was independent of
the rest of Mediator in vivo (Zhang et al., 2004).
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Besides activator binding, the tail modules was also found to involved in histone acetylation
as the Med5 subunit contains histone–acetyltransferase (HAT) activity (Lorch et al., 2000).
Generally, acetylated nucleosomes are associated with a loosening of DNA and consequent
increased access of the transcriptional machinery to the promoter (Biddick and Young, 2005).
Med5 is not essential like all tail subunits (except for Med14), but this activity may be
promoter-specific or redundant with other HATs.
Like TFIID (Stringer et al., 1990) and SAGA (Mohibullah and Hahn, 2008), Mediator can
bind directly to TBP. The N-terminal domain of Med8 (Larivière et al., 2006) and also (but
more weakly) Med20 (Koleske et al., 1992) bind to TBP in vitro and apparently mediate in
a bipartite manner the attachment of Mediator. The head module has direct interactions
also with TFIIH (Esnault et al., 2008) and with a RNA Pol II-TFIIF complex (Takagi et al.,
2006). TFIIH and TFIIE are recruited independently of RNA Pol II in a Mediator-dependent
fashion (Esnault et al., 2008). Additionally, binding of TFIIB with Mediator head and middle
modules was found using insect cell extracts (Kang et al., 2001), but remains unconfirmed
using recombinant complexes (personal communication with S. Baumli; Takagi et al., 2006).
However, although evidence for direct binding is unclear, TFIIB recruitment is Mediator-
dependent whereas Mediator recruitment is TFIIB-independent (Baek et al., 2006).
The association of Mediator with RNA Pol II, and its function in transcription, depends
on the RNA Pol II CTD. Mediator is able to bind an unphosphorylated glutathione S-
transferase-CTD fusion protein in vitro (Myers et al., 1998) and can be displaced from RNA
Pol II using the monoclonal antibody 8WG16, which specifically recognizes the CTD repeat
(Kim et al., 1994; Svejstrup et al., 1997). Mediator also interacts with RNA Pol II domains
outside of the CTD (Asturias et al., 1999; Davis et al., 2002; Cai et al., 2009). The Mediator
kinase module was found to phosphorylate the CTD at serine 5 (Liao et al., 1995; Hengartner
et al., 1998; Borggrefe et al., 2002) and to stimulate the kinase activity of TFIIH via Kin28,
the primary CTD kinase (Kim et al., 1994; Myers et al., 1998). Studies have shown that
phosphorylated, elongating RNA Pol II is not associated with Mediator (Svejstrup et al.,
1997) and indeed, CTD hyperphosphorylation has been reported to be sufficient to dissociate
holo-RNA Pol II (Max et al., 2007). In agreement, inhibition of the kinase activity leads to
trapped PICs incapable of transcription elongation (Liu et al., 2004).
In addition to playing a role in activator-dependent transcription, Mediator stimulates also
basal transcription in vitro (reviewed in Myers and Kornberg, 2000; Biddick and Young, 2005).
Biochemical studies have shown a requirement for Med18 and Med20 for basal transcription
in a crude extract (Thompson et al., 1993) but no such dependence in a system reconstituted
from highly purified transcription proteins (Sayre et al., 1992; Kim et al., 1994). Likewise,
it was found that human Mediator is not essential for basal transcription by purified RNA
Pol II and GTFs, but is essential for basal transcription in nuclear extracts that contain
a more physiological set of factors (Baek et al., 2006). A similar pattern of dependence
was also found for RNA Pol II CTD (Li et al., 1994), suggesting that basal transcription
is dependent on Mediator to overcome a repressor, and that Mediator acts on the CTD in
order to do so (Biddick and Young, 2005). High levels of TFIIB can bypass the Mediator
requirement for basal transcription and RNA Pol II recruitment in HeLa nuclear extract,
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thus indicating a conditional restriction on TFIIB function and a key role of Mediator in
overcoming this restriction. In mammalian cells, Gdown1 was suggested to have this role,
but as it is apparently absent in yeast, this may reflect a metazoan-specific regulatory feature
(Hu et al., 2006). Additionally, an earlier rate-limiting step involved formation of a TFIID-
Mediator-promoter complex in immobilized template assays (Baek et al., 2006). These key
roles in basal transcription have led to a debate about whether Mediator should be classified as
a GTF (Thompson and Young, 1995; Holstege et al., 1998; Mittler et al., 2001; Wu et al., 2003;
Baek et al., 2006; Lewis and Reinberg, 2003; Takagi and Kornberg, 2006). Some genomewide
location analyses in S. cerevisiae and S. pombe found Mediator upstream of almost all active
genes and some inactive genes (Andrau et al., 2006; Zhu et al., 2006), but under different
growth conditions Mediator did not localize to many active promoters (Fan et al., 2006).
Thus, unlike the GTFs and RNA Pol II, the correlation between Mediator presence and
transcription activity is less clear and Mediator functions may be promoter-specific (Sikorski
and Buratowski, 2009).
Although the majority of findings point to Mediator’s role as a coactivator, there is also
strong evidence that suggests a negative role for Mediator in transcription as well. Espe-
cially the reversibly associated kinase module is mainly involved in transcription repression,
notably through phosphorylation of the CTD domain of Rpb1 RNA Pol II subunit (Holstege
et al., 1998; Liao et al., 1995), but also through phosphorylation of Ste12, Gcn4 and Msn2
transcription activators (Nelson et al., 2003; Chi et al., 2001). Moreover, cryo-EM studies in
S. pombe suggested that the kinase module sterically blocks binding of RNA Pol II if present
(Elmlund et al., 2006). Mediator mutants can lead also to increased transcription rates at
some genes (Sternberg et al., 1987; Jiang and Stillman, 1992; Nishizawa, 2001; van de Peppel
et al., 2005), but this effect may be indirect through post-transcriptional modifications, by
alteration of expression levels of DNA-binding repressor proteins such as Mig1, Rox1, Ume6
(Biddick and Young, 2005) or by decreased recruitment of a general corepressor like the
Ssn6-Tup1 complex (Papamichos-Chronakis et al., 2000). It can be speculated as well, that
in some mutants Mediator is locked in an active state for some gene promoters. In general,
given the complexity of transcriptional regulation in which Mediator is involved, it seems
likely that improper coordination leads to negative regulation.
Even though Mediator may have a key role in coordinating transcription initiation (possibly
in a checkpoint model), other coactivators are usually required at promoters in vivo. Thus,
a number of studies (reviewed in Biddick and Young, 2009) led to the currently prevailing
hypothesis that activators are specifically targeted to a gene through a DNA-binding domain
and then recruit an array of coactivators via interactions with their activation domains (com-
pare Bhoite et al., 2001; Cosma et al., 2001; Bryant and Ptashne, 2003; Swanson et al., 2003;
Yoon et al., 2003; Bhaumik et al., 2004; Cheng et al., 2004; Gao et al., 2004; Lemieux and
Gaudreau, 2004; Qiu et al., 2004; Govind et al., 2005; Larschan and Winston, 2005; Qiu et al.,
2005; Leroy et al., 2006; Black et al., 2006; Young et al., 2008). Analysis of the recruitment
at a variety of promoters showed that the order is promoter-specific. However, even in cases
where activators interact with many of the same coactivators, that activator can function in
more than one way (Biddick and Young, 2009). More recently, replacement of histone H2A
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for the variant H2A.Z at the promoter nucleosomes -1 and +1 came into focus to have a
key role in initiation as this was required for proper recruitment of a number of coactivators
including Mediator, SAGA and Swi/Snf complexes (Lemieux et al., 2008).
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1.7 Aims and scope of this thesis
Mediator complex must convey regulatory signals from transcriptional activators to RNA
Pol II and other components of the initiation apparatus. This is possible as the Mediator
modules serve various functions (as outlined previously): the tail module binds to activators
and repressors (Han et al., 2001; Jeong et al., 2001; Thakur et al., 2008; Zhang et al., 2004),
the middle and head modules contact RNA Pol II (Davis et al., 2002) and the general ma-
chinery (Baek et al., 2006; Esnault et al., 2008; Kang et al., 2001; Larivière et al., 2006),
and the kinase module has inhibitory functions (Elmlund et al., 2006; van de Peppel et al.,
2005). Unlike RNA Pol II (Cramer et al., 2008), the precise Mediator architecture and how
Mediator functions mechanistically, is not well understood – mainly because atomic struc-
tures of Mediator modules or its subcomplexes are lacking. Such information would clarify
the relative orientation of Mediator subunits within and between modules. On the functional
level, gene expression studies with Mediator deletion mutants have implicated the tail in
regulating sporulation genes and genes for oxidative phosphorylation, the tail and middle
modules in regulating low-iron response and heat shock genes, the head module in regulat-
ing conjugation genes, and the kinase module in regulating genes required during nutrient
starvation (Béve et al., 2005; Larivière et al., 2008; Singh et al., 2006; van de Peppel et al.,
2005). Additionally, only recently it became clear that the modules may contain structurally
and functionally distinct submodules, such as the Med8C/18/20 submodule of the Mediator
head (Larivière et al., 2006, 2008).
Thus I aimed at filling this gap and proposed, to obtain structural and functional informa-
tion on the module level – more precisely on the Mediator middle module from S. cerevisiae,
a well-suited model organism for studying eukaryotic transcription. The central conserved
part of the Mediator termed as middle module is apparently composed of Med1, Med4, Med7,
Med9, Med10, Med21, and Med31. Structural studies of this core modules however require
its preparation in large quantities and pure form. Thus far, only the head module is avail-
able in reconstituted form (Takagi et al., 2006). Previous work in the Cramer laboratory
by Sonja Baumli led to a recombinant coexpression and purification strategy for a 6-subunit
middle module comprising Med4/7/9/10/21/31. Based on this work, I aimed at crystalliz-
ing the module or suitable subcomplexes of it by repetitive limited proteolysis and removal
of flexible regions. Obtained crystals would have been used for structure determination by
cryo-crystallography with the help of synchrotron radiation and anomalous scattering. As
a side goal, this required an in-depth understanding of the middle module intra-molecular
interactions. The observed structural interactions should be correlated with their functional
roles in vitro and in vivo. Another side-goal of this work was to optimize and extend the
Escherichia coli (E. coli) coexpression strategy to the complete 7-subunit middle module and
establish a functional assay to characterize its activity.
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2 Materials and Methods
2.1 Materials
2.1.1 Bacterial strains
Table 3: E. coli strains.
Strain Genotype Source
XL-1 Blue rec1A; endA1 ; gyrA96 ; thi-1 ; hsdR17 ; supE44 ; relA1 ; lac[F´
proAB lacIqZ∆M15 Tn10 (Tetr)]
Stratagene
BL21-CodonPlus (DE3)RIL B; F−; ompT ; hsdS(rB
− mB
−); dcm+; Tetr; gal λ(DE3);
endA; Hte [argU, ileY, leuW, Camr]
Stratagene
Rosetta B834 (DE3) F−; ompT ; hsdSB(rB
− mB
−); dcm+; metB Novagen
2.1.2 Yeast strains
Table 4: List of S. cerevisiae strains used or generated within this study.
Strain Genotype Source
wt BY4741; MATa; his3∆1; leu2∆0; met15∆0; ura3∆0 Euroscarf Y00000
wt BY4742; MATα ; his3∆1; leu2∆0; lys2∆0; ura3∆0 Euroscarf Y10000
wt BY4743; MATa/MATα; his3∆1/his3∆1;
leu2∆0/leu2∆0; met15∆0/MET15 ; LYS2/lys2∆0;
ura3∆0/ura3∆0
Euroscarf Y20000
MED7/med7∆ BY4743; YOL135C::kanMX4/YOL135C Euroscarf Y26285
MED7 shuﬄe Y26285 sporulated; MATa or MATα;
YOL135C::KanMX4/p20062 (cognate clone plasmid)
this work
med31∆ BY4741; YGL127C::kanMX4 Euroscarf Y04494
med7N∆ BY4741; YOL135C::YOL135DN84-ClonNAT this work
med7N/31∆ BY4741; YOL135C::YOL135DN84-ClonNAT ;
YGL127C::kanMX4
this work
wt/ Med18-TAP BY4741; YGR104C::YGR104C-TAP-URA3 this work
med31∆/
Med18-TAP
BY4741; YGL127C::kanMX4 ;
YGR104C::YGR104C-TAP-URA3
this work
med7N∆/
Med18-TAP
BY4741; YOL135C::YOL135DN84-ClonNAT ;
YGR104C::YGR104C-TAP-URA3
this work
continued on next page
14
Materials and Methods
Table 4: List of S. cerevisiae strains used or generated within this study.
Strain Genotype Source
med7N/31∆ /
Med18-TAP
BY4741; YOL135C::YOL135DN84-ClonNAT ;
YGL127C::kanMX4 ;
YGR104C::YGR104C-TAP-URA3
this work
dst1∆ BY4741; YGL0143W::kanMX4 Euroscarf Y04411
med18∆ Y24734 sporulated; MATa or MATα;
YGR104C::kanMX4
Larivière et al. (2008)
med8C∆ Y23333 sporulated; MATa or MATα;
YBR193C::kanMX4
Larivière et al. (2008)
cycC∆ BY4741; YNL025C::kanMX4 Euroscarf Y05351
med1∆ BY4741; YPR070W::kanMX4 Euroscarf Y05489
med9∆ BY4741; YNR010W::kanMX4 Euroscarf Y05385
med2∆ BY4742; YDL005C::kanMX4 Euroscarf Y13701
med3∆ BY4741; YGL025C::kanMX4 Euroscarf Y04393
med5∆ BY4741; YGL151W::kanMX4 Euroscarf Y04518
med14∆/MED14 BY4743; YLR073C::kanMX4/YLR073C Euroscarf Y22682
MED14 shuﬄe BY4743; MATa or MATα; sporulated;
YLR073C::kanMX4/pRS316-MED14
this work
med10∆/MED10 BY4743; YPR168W::kanMX4/YPR168W Euroscarf Y25583
MED10 shuﬄe BY4743; MATa or MATα; sporulated;
YPR168W::kanMX4/pRS316-MED10
this work
med4∆/MED4 BY4743; YOR174W::kanMX4/YOR174W Euroscarf Y22430
MED4 shuﬄe BY4743; MATa or MATα; sporulated;
YPR168W::kanMX4/pRS316-MED4
this work
med19∆ W303; MATa or MATα; leu2∆3; 112 trp1∆1;
can1∆100; ura3∆1; ade2∆1; his3∆11-15;
YBL093C::ClonNAT
S. Jellbauer (Gene
Center)
med19∆ BY4741; YBL093C::clonNAT S. Jellbauer (Gene
Center)
MED19 shuﬄe BY4741; YBL093C::clonNAT/pUG36-med19 S. Jellbauer (Gene
Center)
med19∆ / Med7-TAP BY4741; YBL093C::clonNAT ;
YOL135C::YOL135C-TAP-kanMX4
this work
med19∆ /
Med18-TAP
BY4741; YBL093C::clonNAT ;
YGR104C::YGR104C-TAP-kanMX4
this work
med19∆ /
Med15-TAP
BY4741; YBL093C::clonNAT ;
YOL051W::YOL051W-TAP-KanMX4
this work
Med18-3xFlag BY4741; YGR104C::YGR104C-3xFlag-His3MX this work
Med18-3xFlag /
Med7-TAP
BY4741; YGR104C::YGR104C-3xFlag-His3MX ;
YOL135C::YOL135C-TAP-kanMX4
this work
Med15-3xFlag BY4742; YOL051W::YOL051W-3xFlag-His3MX this work
continued on next page
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Table 4: List of S. cerevisiae strains used or generated within this study.
Strain Genotype Source
Med15-3xFlag /
med19∆ / Med7-TAP
BY4741; YBL093C::clonNAT ;
YOL135C::YOL135C-TAP-kanMX4 ;
YOL051W::YOL051W-3xFlag-His3MX
this work
Med18-3xFlag /
med19∆ / Med7-TAP
BY; MATa; mated; YBL093C::clonNAT ;
YOL135C::YOL135C-TAP-kanMX4 ;
YGR104C::YGR104C-3xFlag-His3MX
this work
Med14-TAP BY4741; YLR051C::YLR051C-TAP-URA3 this work
med20∆ /
Med14-TAP
BY4741; YHR041C::kanMX4 ;
YLR051C::YLR051C-TAP-URA3
this work
med31∆ /
Med14-TAP
BY4741; YGL127C::kanMX4 ;
YLR051C::YLR051C-TAP-URA3
this work
2.1.3 Plasmids
Table 5: List of vectors for recombinant S. cerevisiae Mediator middle module subunits and
interaction assays.
Vector Inserts Type Restriction sites Reference
pSB45 MED7 (103-222) pET21b Nhe I, EcoR I S. Baumli
MED21 -His6 Sal I, Not I
pSB48 MED7 (103-222) pET24b Nhe I, EcoR I S. Baumli
MED21 -His6 Sal I, Not I
pSB60 MED10 pET21b Nde I, EcoR I S. Baumli
pSB77 MED10 -His6 pET24b Nde I, Not I S. Baumli
pSB91 MED4 pET21b Nde I, Not I S. Baumli
pSB102 MED31 -His6 pET24d Nco I, EcoR I S. Baumli
pSB104 MED10 pET21b Nhe I, EcoR I S. Baumli
MED7 Nco I, Sal I
MED21 Nde I, Xho I
pSB118 MED9 pET21b Nde I, BamH I S. Baumli
MED4 Nde I, Xho I
pTK01 MED10 pET21b Nhe I, EcoR I this work
MED7 (1-205) EcoR I, Sal I
MED21 Nde I, Xho I
pTK02 MED10 pET21b Nhe I, EcoR I this work
MED7 Nco I, Sal I
MED21 (1-130) Sal I, Xho I
pTK03 MED10 pET21b Nhe I, EcoR I this work
MED7 (1-205) EcoR I, Sal I
MED21 (1-130) Sal I, Xho I
pTK04 MED31 -His6 pET24d Nco I, EcoR I this work
MED6 -StrepII Sal I, Not I
continued on next page
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Table 5: List of vectors for recombinant S. cerevisiae Mediator middle module subunits and
interaction assays.
Vector Inserts Type Restriction sites Reference
pTK06 MED10 (8-157) pET21b Nhe I, EcoR I this work
MED7 (1-205) EcoR I, Sal I
MED21 (1-130) Sal I, Xho I
pTK07 MED10 (41-157) pET21b Nhe I, EcoR I this work
MED7 (1-205) EcoR I, Sal I
MED21 (1-130) Sal I, Xho I
pTK08 MED10 (68-157) pET21b Nhe I, EcoR I this work
MED7 (1-205) EcoR I, Sal I
MED21 (1-130) Sal I, Xho I
pTK09 MED10 (8-147) pET21b Nhe I, EcoR I this work
MED7 (1-205) EcoR I, Sal I
MED21 (1-130) Sal I, Xho I
pTK10 MED10 (41-147) pET21b Nhe I, EcoR I this work
MED7 (1-205) EcoR I, Sal I
MED21 (1-130) Sal I, Xho I
pTK11 MED10 (68-147) pET21b Nhe I, EcoR I this work
MED7 (1-205) EcoR I, Sal I
MED21 (1-130) Sal I, Xho I
pTK12 MED10 pET21b Nhe I, EcoR I this work
MED7 (1-211) EcoR I, Sal I
MED21 Sal I, Xho I
pTK13 MED10 (12-157) pET21b Nhe I, EcoR I this work
MED7 EcoR I, Sal I
MED21 Sal I, Xho I
pTK14 MED10 (12-157) pET21b Nhe I, EcoR I this work
MED7 (1-211) EcoR I, Sal I
MED21 Sal I, Xho I
pTK15 MED9 pET21b Nde I, BamH I this work
MED4 (1-250) Sal I, Xho I this work
pTK16 MED7 pET21b Nhe I, EcoR I this work
MED21 Sal I, Xho I this work
pTK17 MED9 pET21b Nde I, BamH I this work
MED4 (21-250) Sal I, Xho I this work
pTK18 MED10 (8-157) pET21b Nhe I, EcoR I this work
MED7 EcoR I, Sal I
MED21 Sal I, Xho I
pTK19 MED10 (41-157) pET21b Nhe I, EcoR I this work
MED7 EcoR I, Sal I
MED21 Sal I, Xho I
pTK20 MED10 (68-157) pET21b Nhe I, EcoR I this work
MED7 EcoR I, Sal I
MED21 Sal I, Xho I
pTK21 MED10 (8-147) pET21b Nhe I, EcoR I this work
continued on next page
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Table 5: List of vectors for recombinant S. cerevisiae Mediator middle module subunits and
interaction assays.
Vector Inserts Type Restriction sites Reference
MED7 EcoR I, Sal I
MED21 Sal I, Xho I
pTK22 MED10 (41-147) pET21b Nhe I, EcoR I this work
MED7 EcoR I, Sal I
MED21 Sal I, Xho I
pTK23 MED10 (68-147) pET21b Nhe I, EcoR I this work
MED7 EcoR I, Sal I
MED21 Sal I, Xho I
pTK24 MED31 -His6 pET24d Nco I, EcoR I this work
MED7 (1-101) Sal I, Not I
pTK25 MED7 (1-101) pET21b EcoR I, Sal I this work
pTK26 His6-thrombin-MED31 pET28b Nde I, Not I this work
pTK27 MED7 (1-80) pET21b EcoR I, Sal I this work
pTK28 MED7 (1-83) pET21b EcoR I, Sal I this work
pTK29 MED7 (1-89) pET21b EcoR I, Sal I this work
pTK30 MED7 (1-92) pET21b EcoR I, Sal I this work
pTK31 MED31 -His6 pET24d Nco I, EcoR I this work
MED6 (1-199)-StrepII Sal I, Not I
pTK32 MED31 -His6 pET24d Nco I, EcoR I this work
MED6 (1-203)-StrepII Sal I, Not I
pTK33 MED31 -His6 pET24d Nco I, EcoR I this work
MED6 (1-207)-StrepII Sal I, Not I
pTK34 MED31 -His6 pET24d Nco I, EcoR I this work
MED6 (1-189)-StrepII Sal I, Not I
pTK35 StrepII-MED1 pET24d Nco I, Not I this work
pTK36 MED1 -StrepII pET24d Nco I, Not I this work
pTK37 His6-MED14 pET21b Eco RI, Xho I this work
pTK38 MED14 -His6 pET21b Eco RI, Xho I this work
pTK39 MED7 (1-95) pET21b EcoR I, Sal I this work
pTK40 C. Glabrata MED7 (1-95) pET21b Nde I, Not I this work
pTK53 His6-thrombin-ESS1 pET28b Nde I, Not I this work
pTK54 SET2 -His6 pET24d Nhe I, Xho I this work
pTK55 SET2WW-His6 pET24d Nco I, Xho I this work
pTK56 MED31 -His6 pET21b Xba I, Eco RI this work
pTK57 PCF11 CID-His6 pET21b Xba I, Not I H. Kettenberger
pTK60 MED7 (19-83) pET21b EcoR I, Sal I this work
pTK61 MED7 (22-84) pET21b EcoR I, Sal I this work
pTK62 MED7 (1-61) pET21b EcoR I, Sal I this work
pTK63 MED7 (1-67) pET21b EcoR I, Sal I this work
pTK64 StrepII-MED7 (20-83) pET21b NdeI, Sal I this work
pTK65 StrepII-MED7 (23-83) pET21b NdeI, Sal I this work
pTK66 StrepII-MED7 (1-61) pET21b NdeI, Sal I this work
pTK67 StrepII-MED7 (1-66) pET21b NdeI, Sal I this work
continued on next page
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Table 5: List of vectors for recombinant S. cerevisiae Mediator middle module subunits and
interaction assays.
Vector Inserts Type Restriction sites Reference
pTK68 StrepII-MED7 (1-83) pET21b NdeI, Sal I this work
pTK69 StrepII-MED4 (19-250) pET21b Sal I, Xho I this work
pTK70 His6-thrombin-MED9 pET28b Nde I, Sal I this work
pTK71 His6-thrombin-MED9 (63-149) pET28b Nde I, Sal I this work
pTK72 His6-thrombin-MED9 (1-18) pET28b Nde I, Sal I this work
pTK73 His6-thrombin-MED9 (1-22) pET28b Nde I, Sal I this work
pTK74 His6-thrombin-MED9 ∆(19-63) pET28b Nde I, Sal I this work
pTK75 His6-thrombin-MED9 ∆(19-53) pET28b Nde I, Sal I this work
pTK76 His6-thrombin-MED9 ∆(23-63) pET28b Nde I, Sal I this work
pTK77 His6-thrombin-MED9 ∆(23-53) pET28b Nde I, Sal I this work
pTK78 StrepII-MED31 pET24d Nco I, Not I this work
pTK79 MED7 (1-83) (12...18 YSPTSPS) pET21b EcoR I, Sal I this work
pTK80 MED7 (1-83) (13...19 YSPTSPS) pET21b EcoR I, Sal I this work
pTK81 MED7 (1-83) (66...72 YSPTSPS) pET21b EcoR I, Sal I this work
pTK82 MED7 (1-83) (65...71 YSPTSPS) pET21b EcoR I, Sal I this work
pTK84 MED7 (1-83) (12...18 SPSTPSY) pET21b EcoR I, Sal I this work
pTK86 MED7 (1-83) (12...18 YSPTDPS) pET21b EcoR I, Sal I this work
pTK88 MED7 (1-83) (12...18 YSPTRPS) pET21b EcoR I, Sal I this work
pTK90 MED7 (1-83) (12...18 YDPTSPS) pET21b EcoR I, Sal I this work
pTK92 StrepII-MED7 (1-83) pET24a Nde I, Sal I this work
pTK93 MED9 (1-63) pET21b Nde I, Sal I this work
pTK94 MED9 (1-80) pET21b Nde I, Sal I this work
pTK95 MED9 (64-149) pET21b Nde I, Sal I this work
pTK96 MED9 (81-149) pET21b Nde I, Sal I this work
pTK97 MED10 (1-73) pET21b Nde I, EcoR I this work
pTK98 MED10 (74-157) pET21b Nde I, EcoR I this work
pTK99 MED31 -His6 pET24d Nco I, EcoR I this work
StrepII-MED7 (1-83) Sal I, Not I
pTK100 MED4 -His6 pET24a Nde I, Not I this work
pTK101 StrepII-MED14 (1-259) pET24d Nco I, Xho I this work
pTK102 StrepII-MED14 (1-528) pET24d EcoRI, Xho I this work
pTK103 StrepII-MED14 (1-745) pET24d EcoRI, Xho I this work
pTK104 StrepII-MED1 pET24d Nco I, Sal I this work
MED14 (1-259) Sal I, Not I
pTK105 StrepII-MED1 pET24d Nco I, Sal I I this work
MED14 (1-528) Sal I, Not I
pTK106 StrepII-MED1 pET24d Nco I, Sal I I this work
MED14 (1-745) Sal I, Not I this work
pTK107 MED1 pET24d Nco I, Sal I this work
pTK112 MED31 -His6 pET24d Nco I, EcoR I this work
MED14 (1-259) Sal I, Not I
pTK113 MED9 pCDFDuet-1 Asi SI, BamH I (MCS2) this work
MED4 Nde I, Xho I (MCS2) this work
continued on next page
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Table 5: List of vectors for recombinant S. cerevisiae Mediator middle module subunits and
interaction assays.
Vector Inserts Type Restriction sites Reference
pTK114 StrepII-MED1 pCDFDuet-1 Nco I, Not I (MCS1) this work
MED9 Asi SI, BamH I (MCS2)
MED4 Nde I, Xho I (MCS2)
pTK126 MED10 pET21b Nhe I, EcoR I this work
MED7 (Q198Stop) Nco I, Sal I this work
MED21 Nde I, Xho I this work
pTK127 MED10 pET21b Nhe I, EcoR I this work
MED7 Nco I, Sal I this work
MED21 (L76P) Nde I, Xho I this work
pTK128 MED10 (S124Stop) pET21b Nhe I, EcoR I this work
MED7 Nco I, Sal I this work
MED21 Nde I, Xho I this work
pTK129 MED31 pET24d Nco I, EcoR I this work
MED14 (1-259) Sal I, Not I this work
pTK130 His6-MED9 pCDFDuet-1 Asi SI, BamH I (MCS2) this work
MED4 Nde I, Xho I (MCS2)
pTK131 StrepII-MED1 pCDFDuet-1 Nco I, Not I (MCS1) this work
His6-MED9 Asi SI, BamH I (MCS2)
MED4 Nde I, Xho I (MCS2)
pTK133 MED31 -His6 pET24d Nco I, EcoR I this work
StrepII-MED7 (1-101) Sal I, Not I
pTK134 MED31 -His6 pET24d Nco I, EcoR I this work
MED7 (1-83) Sal I, Not I
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Table 6: List of vectors used or generated for S. cerevisiae assays and manipulations.
Vector Inserts Type Restriction sites Reference
p20062 MED7 Cognate clone Euroscarf
pBS1539 C-TAP-tag / URA3 pBS PCR-template Puig et al. (2001)
pFA6a-KanMX4 KanMX4 pFA6a PCR-template Wach et al. (1994)
pFA6a-His3MX4 His3MX4 pFA6a PCR-template Wach et al. (1997)
pFA6a-natNT2 natNT2 pFA6a PCR-template Janke et al. (2004)
pYM13 C-TAP-tag / kanMX4 pYM PCR-template Janke et al. (2004)
pZM473 3xFLAG-tag pZM PCR-template Moqtaderi and Struhl
(2008)
pTK42 MED7 (1-83) pAL- Sma I, Xba I this work
pTK43 MED7 (1-89) pAL- Sma I, Xba I this work
pTK44 MED7 (1-101) pAL- Sma I, Xba I this work
pTK45 MED7 (102-222) pAL- Sma I, Xba I this work
pTK46 MED7 pAL- Sma I, Xba I this work
pTK58 natNT2-5’UTR-MED7 pBluescript II Xho I, Xba I this work
(84-222)-3’UTR KS-
pTK59 natNT2-5’UTR-MED7
(84-222)-3’UTR
pRS315 Sal I, Xba I this work
pTK83 5’UTR-MED7 pBluescript II Xho I, EcoRV this work
(84-222)-3’UTR-NATNT2 KS-
pTK108 5’UTR-MED14 -3’UTR pRS316 Sal I, Not I this work
pTK109 5’UTR-MED14
(1-259)-3’UTR
pRS315 Sal I, Not I this work
pTK110 5’UTR-MED14
(1-528)-3’UTR
pRS315 Sal I, Not I this work
pTK111 5’UTR-MED14
(1-745)-3’UTR
pRS315 Sal I, Not I this work
pTK115 5’UTR-MED14 -3’UTR pRS315 Sal I, Not I this work
pTK116 5’UTR-MED10 -3’UTR pRS316 Sal I, Not I this work
pTK117 5’UTR-MED10 -3’UTR pRS315 Sal I, Not I this work
pTK118 5’UTR-MED10
(1-123)-3’UTR
pRS315 Sal I, Not I this work
pTK119 5’UTR-MED10
(74-157)-3’UTR
pRS315 Sal I, Not I this work
pTK120 5’UTR-MED10
(74-123)-3’UTR
pRS315 Sal I, Not I this work
pTK132 5’UTR-MED10
(S124Stopp)-3’UTR
pRS315 Sal I, Not I this work
pTK121 5’UTR-MED4 -3’UTR pRS316 Sal I, Not I this work
pTK122 5’UTR-MED4 -3’UTR pRS315 Sal I, Not I this work
pTK123 5’UTR-MED4
(67-284)-3’UTR
pRS315 Sal I, Not I this work
pTK124 5’UTR-MED4
(67-250)-3’UTR
pRS315 Sal I, Not I this work
pTK125 5’UTR-MED4
(67-193)-3’UTR
pRS315 Sal I, Not I this work
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2.1.4 Media and additives
Table 7: Media for E. coli and S. cerevisiae.
Media Application Description
LB E. coli culture 1% (w/v) tryptone; 0.5% (w/v) yeast extract;
0.5% (w/v) NaCl
SOB E. coli transformation 2% (w/v) tryptone; 0.5% (w/v) yeast extract;
8.55 mM NaCl; 2.5 mM KCl; 10 mM MgCl2
SOC E. coli transformation SOB + 20 mM glucose (before use)
Minimal medium SeMet labeling 7.5 mM (NH4)2SO4; 8.5 mM NaCl; 55 mM KH2PO4;
100 mM K2HPO4; 1mM MgSO4; 20 mM glucose,
1 µg/l trace elements (Cu2+, Mn2+, Zn2+, Mo42−),
10 mg/l thiamine; 10 mg/l biotine; 1 mg/l Ca2+;
1 mg/l Fe2+; 100 mg/l amino acids (A, C, D, E, F,
G, H, I, K, L, N, P, Q, R, S, T, V, W, Y); 50 mg/l
selenomethionine
YPD Yeast culture 2% (w/v) peptone; 2% (w/v) glucose; 1% (w/v) yeast
extract
Synthetic defined (SD) Yeast culture Nitrogen and carbon sources, vitamins, trace ele-
ments, minerals according to ForMedium with specific
drop outs; only essential amino acids; pH 5.6-6.0
Synthetic complete (SC) Yeast culture 0.69% (w/v) nitrogen base; 0.6% (w/v) CSM amino
acid drop out mix; 2% (w/v) glucose; pH 5.6-6.0
5-FOA plates Yeast culture SC (-ura) + 0.01% (w/v) uracil; 0.2% (w/v) 5-FOA
Pre-sporulation plates Yeast culture 1% (w/v) KCH3COO; 0.1% (w/v) yeast extract;
0.079% (w/v) CSM amino acid complete mix;
0.25% (w/v) glucose; pH 5.6-6.0
Sporulation plates Yeast culture 1% (w/v) KCH3COO; 0.079% (w/v) CSM amino acid
complete mix; pH 5.6-6.0
Table 8: Media additives for E. coli and S. cerevisiae.
Additive Description Stock solution Applied concentration
IPTG E. coli induction 1 M in H20 0.5 mM
Ampicillin Antibiotic 100 mg/ml in H20 100 µg/ml for E. coli cul-
ture, 50 µg/ml for yeast cul-
ture
Kanamycin Antibiotic 30 mg/ml in H20 30 µg/ml for E. coli culture
Chloramphenicol Antibiotic 50 mg/ml in EtOH 50 µg/ml for E. coli culture
Streptomycin Antibiotic 50 mg/ml in EtOH 50 µg/ml for E. coli culture
Tetracyclin Antibiotic 12.5 mg/ml in 70% EtOH 12.5 µg/ml for yeast culture
Geneticin (G418) Antibiotic 200 mg/ml in H20 200 µg/ml for yeast culture
Nourseothricin (clonNAT) Antibiotic 100 mg/ml in H20 100 µg/ml for yeast culture
2.1.5 Buffers and solutions
Standard buffers and solutions were prepared according to Sambrook and Russell (2001).
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Table 9: General buffers, dyes and solutions.
Name Description Application
4x Stacking gel buffer 0.5 M Tris; 0.4% (w/v) SDS; pH 6.8 at 25°C SDS-PAGE
4x Separation gel buffer 3 M Tris; 0.4% (w/v) SDS; pH 8.9 at 25°C SDS-PAGE
Electrophoresis buffer 25 mM Tris; 0.1% (w/v) SDS; 250 mM glycine SDS-PAGE
5x SDS sample buffer 250 mM Tris/HCl pH 7.0 at 25°C; 50% (v/v); glycerol;
0.5% (w/v) bromophenol blue; 7.5% (w/v) SDS;
12.5% (w/v) β-mercaptoethanol
SDS-PAGE
Gel staining solution 50% (v/v) Ethanol; 7% (v/v) acetic acid;
0.125% (w/v) Coomassie Brilliant Blue R-250
Coomassie staining
Gel destaining solution 5% (v/v) Ethanol; 7% (v/v) acetic acid Coomassie staining
2x Western transfer buffer 2.4% (w/v) glycin; 0.8% (w/v) Tris; 40% (v/v)
methanol
Wester blotting
Blotting buffer 10% (v/v) methanol in ddH2O Edman sequencing
Swelling buffer 200 mM Tris/HCl pH 8.5 at 25°C; 2% (w/v) SDS Edman sequencing
100x PI 0.028 mg/ml leupeptin; 0.137 mg/ml pepstatin A;
0.017 mg/ml PMSF; 0.33 mg/ml benzamidine; in
100% EtOH p.a.
Protease inhibitor mix
TBE 8.9 mM Tris; 8.9 mM boric acid; 2 mM EDTA (pH 8.0,
25°C)
Agarose gels
6x Loading buffer 10 mM Tris pH 7.6; 0.0015% (w/v) bromphenol blue;
0.0015% (w/v) xylene cyanol; 60% (v/v) glycerol;
100 mM EDTA; 1% SDS
Agarose gels
TFB-1 30 mM KOAc; 50 mM MnCl2; 100 mM RbCl; 10 mM
CaCl2; 15% (v/v) glycerol; pH 5.8 at 25°C
Chemically competent cells
TFB-2 10 mM MOPS pH 7.0 at 25°C; 10 mM RbCl; 75 mM
CaCl2; 15% (v/v) glycerol
Chemically competent cells
Triple trafo buffer 100 mM CaCl2, 10% (w/v) glycerol Chemically competent cells
LiAc buffer 1 M Li acetate; pH 7.5 adjusted with acetic acid Yeast transformation
Buffer A 50 mM Tris pH 8.0; 150 mM NaCl; 10 mM
β-mercaptoethanol
Recombinant proteins
Buffer B 50 mM Tris pH 8.0; 100 mM NaCl; 10 mM
β-mercaptoethanol
Recombinant proteins
Buffer C 50 mM MES pH 6.5; 150 mM NaCl; 10 mM
β-mercaptoethanol
Recombinant proteins
Buffer D 20 mM Tris pH 8.0; 150 mM NaCl; 10 mM
β-mercaptoethanol
Recombinant proteins
Buffer E 50 mM Tris pH 8.0; 150 mM NaCl; 10% (v/v) glycerol;
10 mM β-mercaptoethanol
Recombinant proteins
Buffer F 150 mM KCl, 10 mM Hepes pH 7.3, 5 mM DTT Recombinant proteins
Buffer G 50 mM Hepes pH 7.5; 150 mM NaCl; 10 mM
β-mercaptoethanol
Recombinant proteins
Avidin 50 µmol/l avidin; 50% (w/v) glycerin; 20 mM Tris pH
8.0; 150 mM NaCl; 10 mM β-mercaptoethanol
StrepII-purification
50x d-Desthiobiotin 125 mM d-desthiobiotin; in 500 mM Tris pH 8.0 StrepII-purification
TAP/FLAG buffer I 50mM Tris pH 7.5; 250 mM NaCl; 1.5 mM MgCl2;
0.1% (v/v) NP40 (Igepal CA-630); 1x PI
TAP- or FLAG-purification
TAP/FLAG buffer II 50mM Tris pH 7.5; 100 mM NaCl; 1.5 mM MgCl2;
0.1% (v/v) NP40 (Igepal CA-630); 1x PI
TAP- or FLAG-purification
TEV cleavage buffer TAP buffer II + 1 mM DTT; 0.5 mM EDTA TAP-purification
Calmodulin buffer TAP buffer II + 2 mM CaCl2; 1 mM DTT TAP-purification
TAP elution buffer 10 mM Tris pH 8.0, 20 mM EGTA TAP-purification
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2.2 General methods
2.2.1 Preparation and transformation of competent cells
Chemically competent E. coli cells were prepared from LB overnight pre-cultures. 200 ml
LB medium (supplemented with antibiotics if appropiate) were inoculated to a start optical
density at 600 nm (OD600 nm) of 0.05, grown at 37°C and chilled on ice for 10 min once
OD600 nm=0.5 was reached. Following steps were carried out at 4°C. Cells were centrifuged
at 3200g for 10 min, washed with 50 ml TFB-1 buffer, centrifuged again and the pellet
resuspended in 4 ml TFB-2 buffer. Aliquots were frozen in liquid nitrogen and cells stored at
-80°C. Cells were transformed by heat shock typically using 100 ng (single transformation) or
150 ng (double transformation) vector, or 5-10 µl ligation product. Cells were incubated on
ice for 10 min prior to heat shock at 42°C for 1 min in a water bath. Cells were subsequently
cooled on ice for 1 min, 250 µl LB medium added and incubated for 1 h at 37°C vigorously
shaking in a thermomixer (Qiagen). Cells were plated onto selective plates and incubated
over night at 37°C.
For triple transformations, cotransformed cells containing already two vectors were made
chemically competent again. One inoculation loop cells were scraped off from selective plates,
resuspended in 500 µl Triple trafo buffer and incubated on ice 30 min. Cells were centrifuged
for 15 sec at 18000g and 4°C, resuspended again in 50 µl Triple trafo buffer and used directly
for heat shock transformation.
Electrocompetent E. coli cells were prepared from SOB overnight pre-cultures. Precultures
at OD600 nm=3.0 were used to inoculate 1 l (prewarmed) SOB main cultures in 5 l shake
flasks to yield a start OD600 nm=0.03. Cells were grown at 37°C and chilled on ice for
15 min once OD600 nm=0.5 was reached. Following steps were carried out at 4°C. Cells were
split in 4 portions, centrifuged at 3200g for 10 min and washed with each 100 ml ice-cold,
sterile water. Cells were centrifuged again and each pellet washed in 2.5 ml cold, sterile
10% (v/v) glycerol. Cells were pooled, centrifuged again and resuspended in 1.5 ml cold,
sterile 10% (v/v) glycerol. Aliquots were frozen in liquid nitrogen and cells stored at -80°C.
Cells were electrotransformed typically using 5 µl ligation product using pre-chilled 0.2 cm
electroporation cuvettes (Bio-Rad) after 5 min incubation on ice. Cuvettes were pulsed with
2.5 kV (MicroPulser, Bio-Rad) and immediately mixed with 1 ml ice-cold SOC medium. Cells
were incubated vigorously shaking in a thermomixer (Qiagen) for 1 h for recovery prior to
plating onto selective plates.
Chemical competent yeast cells were prepared from precultures in YPD overnight pre-
cultures grown at 30°C. One hundred ml main cultures were inoculated with a start OD600 nm
of 0.2 and grown until OD600 nm=0.8 was reached. Cells were split in two portions, centrifuged
at 1250g for 5 min, washed with each 25 ml sterile water and centrifuged again. The pellets
were resuspended in 1 ml 1:10 LiAc buffer, centrifuged at 18000g for 15 sec and resuspended
to yield 500 µl each. Cells were vortexed, pooled, incubated 10 min to over night and
aliquoted to 100 µl portions. After centrifugation, supernatants were discarded and cells used
either directly for highest competence or stored at -80°C after addition of 240 µl 50% (w/v)
PEG 3350. Following PEG 3350 addition, 36 µl 1 M LiAc, 50 µl pre-heated (10 minutes
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at 95°C, then put on ice) salmon sperm DNA (2 mg/ml) and 34 µl DNA/water mixture
was added. Typically, either 1-5 µg of linear DNA or 200 ng plasmid DNA was used for
transformation. Samples were vortexed vigorously for 1 min and incubated 30 min at 30°C.
Cells were heat shocked for 25 min at 42°C in a water bath. Samples were centrifuged at 5200g
for 15 sec and pellets resuspended in 1 ml YPD without antibiotics. Cells were incubated
for at least 1 h up to over night at 30°C rotation for recovery, then centrifuged at 1250g for
5 min, resuspended in 200 µl 1xTE buffer and plated onto selective plates.
2.2.2 Cloning and mutagenesis
Polymerase Chain Reaction (PCR) primers were typically designed by using the software
Primer Designer (now Sci-Ed Software) including an appropiate overhang of several nu-
cleotides at the 5’ end (to ease restriction cleavage), followed by the restriction side and
at least 20 nt complementary to the sequence of the gene of interest. Purification-tags were
introduced either by in-frame cloning into according vectors or by PCR. Additional riboso-
mal binding sites for multicistronic vectors were introduced as described in Baumli (2005).
Sequencing primers were usually around 20 nt long. PCR reactions were carried out with Her-
culase or Herculase II polymerases (Stratagene), Pwo SuperYield DNA Polymerase (Roche),
Phusion High-Fidelity DNA Polymerase (Finnzymes) or Taq polymerase (Fermentas) ac-
cording to requirements. Reaction were typically performed at 50 µl scale and contained
polymerase specific buffers, 1-30 ng plasmid template or 100-200 ng genomic DNA template,
0.2 mM dNTP-mix, 0.5 µM forward and reverse primer each, and variable amounts of poly-
merase (0.5-5U), salt and DMSO. Theoretical annealing temperatures were calculated with
the Primer Designer software using the empirical method of Rychlik et al. (1990). Thermo-
cycling programs were adjusted to the specific needs of the individual reactions, especially
in terms of annealing temperature and elongation times, and usually contained 30 cycles
(Biometra T3000 Thermocycler).
PCR products were purified using PCR-purification kits (Qiagen or Metabion). PCR
products and and vectors were digested using restriction endonucleases (NEB and Fermentas)
as recommended by the vendor and vectors dephosphorylated by addition of 1U FastAP
enzyme (Fermentas) following incubation for 10 min at 37°C and heat inactivation for 5 min
at 75°C. Samples were separated by agarose gel electrophoresis (typically 1% w/v) in 1xTBE
buffer and visualized by ethidiumbromide or SYBR Safe DNA gel stain (1:10 000, Invitrogen).
DNA fragments were extracted and purified using the QIAquick Gel Extraction Kit (Qiagen).
PCR products and linearized vectors were ligated using 5U of T4 DNA ligase (Fermentas)
in 20 µl volume in corresponding buffer for 1 h at 20°C or over night at 16-18°C. Variable
ratios of vector to PCR product were usually applied (2:15, 2:5, 5:5 v/v) such that the insert
was in 5- to 10-fold excess. Ligation products were transformed as described in 2.2.1. Single
clones from selective plates were used to inoculate 5 ml overnight cultures. Plasmids were
isolated from the E. coli clones using Miniprep purification kits (Qiagen or Metabion) and
verified by restriction analysis and DNA sequencing (Eurofins MWG).
Site-directed mutagenesis (based on a modified protocol from Mirijam Zeller, Uni Regens-
burg) was utilized to introduce point mutations into vectors. Usually, 10 ng of template
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vector was used in the mutational PCR with Pfu polymerase (Fermentas). Primers typically
exhibited 20 complementary nucleotides neighbouring each site of the mutation. PCR re-
actions were performed with low annealing temperatures (45-50°C) and 2 min/kb extension
time. Following, parental vector (containing methylated DNA) was digested by 10U DpnI
(Fermentas) for 1 h at 37°C and the reaction directly transformed into competent cells.
For the introduction of several point mutations and loop-deletions, the overlap extension
method was used. Here, two overlapping PCR-products are produced with primers carrying
the desired mutation. In a second PCR reaction these products were used as a template
to produce the gene of interest containing the mutation. The resulting PCR product was
digested and ligated into the corresponding vector.
2.2.3 Protein expression in E. coli and selenomethionine labeling
Recombinant proteins were routineously expressed in E. coli BL21-CodonPlus (DE3)RIL
cells (Stratagene). Plasmids with desired protein variants were transformed as described as
described in 2.2.1. Cells were grown at 37°C in LB medium including antibiotics up to an
OD600 nm of 0.5 to 0.8. Cells were cooled on ice for 30 min, induced by addition of 0.5 mM
IPTG and grown at 18°C over night. Cells were harvested by centrifugation at 3500g and
4°C for 10 min, resuspended in lysis buffer (see below) and flash frozen in liquid nitrogen.
Cell pellets were stored at -80°C.
Selenomethionine labeling was performed using E. coli Rosetta B834 (DE3) cells (Novagen)
essentially as described (Budisa et al., 1995; Meinhart et al., 2003). Transformed cells were
grown in LB medium including antibiotics unti an OD600 nm of 0.6 was reached. Cells were
harvested, washed and resuspended in minimal medium supplemented with selenomethionine
(50 mg/l) and antibiotics. Cells were grown for an additional OD600 nm of 0.2 before induction
and overnight expression.
2.2.4 Tandem affinity purification
Tandem affinity purification (TAP) was carried out with tagged strains (see below, 2.2.8) ac-
cording to the original protocol (Rigaut et al., 1999; Puig et al., 2001) with some modifications
(Larivière et al., 2008).
2.2.5 Protein Analysis
Determination of protein concentrations
Total protein concentrations were usually determined by a Bradford assay (Bradford, 1976)
at OD595 nm using dye reagent (Bio-Rad) according to the according to the manufacturer’s
instructions. Reference curves were generated for each new batch of dye reagent using bovine
serum albumin (Fraktion V, Roth). Alternatively, protein concentrations were calculated
from the absorption rate by OD280 nm measurement using a ND-1000 (NanoDrop) spec-
trophotometer. Individual molar absorption coefficients for the used proteins were calculated
with the help of the ProtParam software (Gasteiger et al., 2005).
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SDS-Polyacrylamid gel electrophoresis
Electrophoretic separation of protein was routineously conducted by SDS-PAGE with 15%-
19% acrylamide gels (with acrylamide:bisacrylamide = 37.5:1) according to Laemmli (1970)
in BioRad gel systems. For protein samples requiring broader or higher resolution separation,
pre-casted NuPAGE Novex bis-Tris minigels (Invitrogen) were used according to the man-
ufacturer’s instructions. Gels were stained with Coomassie gel staining solution for 20 min
and destained over night in gel destaining solution (see Table 9).
Edman sequencing
For N-terminal sequencing, proteins were separated on SDS-PAGE, stained with Coomassie
blue and either transferred by Western blotting or by passive adsorption onto PVDF me-
branes. Western blotting was performed using Western transfer buffer in Mini Trans-Blot
Cells (Bio-Rad) according to the manufacturer’s instructions. For passive adsorption trans-
fer, bands of interest were excised from the gel, dried in a speed-vac and rehydrated in 20 µl
swelling buffer at room temperature. Next 100 µl of ddH2O was added to set up a concentra-
tion gradient together with a small piece of pre-wet (ethanol) PVDF membrane (Schleicher
& Schuell). Once the solution turned blue, 10 µl of methanol was added as a catalyst and
the sample incubated for 1-4 days until the transfer was complete (clear solution and blue
PVDF membrane). The membrane was washed 5 times with 10% methanol by vortexing
for 30 sec each time. The protein was N-terminally sequenced from the dry membrane in a
PROCISE 491 sequencer (Applied Biosystems).
2.2.6 Limited proteolysis analyses
Limited proteolysis time courses were performed to both identify stable protein fragments
and durations suitable for obtaining medium size fragments for further analysis in case of
more complex digestion patterns. Time courses were typically performed using chymotrypsin,
trypsin or Glu-C proteases at 37°C with indiviual samples analyzed at 1, 3, 10, 30 and 60 min.
Digests were performed using 20 to 50 µg protein or protein complex with protease (e.g. 0.2 µg
of chymotrypsin, Sigma C3142) in their gel filtration buffer supplemented with 4 M CaCl2.
The reactions were stopped by the addition of SDS sample buffer and were heated immediately
to 95°C for 10 min.
For analysis of more complex digestion patterns, purified 3-, 4- and 6-subunit middle mod-
ule complexes were subjected to limited proteolysis for 10 min using chymotrypsin and after
stopping the reaction by addition of a protease inhibitor mixture, loaded onto a Superose 6
gel filtration column (GE Healthcare). For proteolysis, 1 µg of sample was used for 3- and
4-subunit, and 2 µg for the 6-subunit middle module. Bands of interest in individual peaks
were analyzed on SDS-PAGE after TCA precipitation by mass-spectrometry and Edman-
sequencing.
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2.2.7 Crystallization screening with middle module complexes
Initial crystallization screening were performed by the sitting-drop (vapor diffusion) method
using commercial screens. In-house screens were set up using a Hydra II crystallization
robot producing 200 or 500 nl drops in Corning 96-well crystallization plates. Usually a
reducing agent, e.g. 5 mM TCEP or 10 mM DTT, was added to the drop or reservoir. Prior
to setting up the screen, optimum protein concentrations for crystallization screening were
determined. This was achieved by visual control of the behavior of equal volume drops of
protein solution and the no. 1 and 6 screening solutions of the Hampton Crystal Screen 1.
Plates were incubated at 4 or 20°C and inspected regularly from one day up to 90 days.
Crystallization screening for the 7-subunit middle module complex was performed by the
Crystallization Facility at the MPI of Biochemistry, Munich. Potential protein crystals were
tested by diffraction measurement, by Izit Crystal Dye (Hampton Research) staining or by the
crush test. Promising initial crystals were refined in 24-well hanging drop plates (Easy Xtal
Tool, Qiagen) by varying the pH, precipitant and additive concentrations of initial conditions.
2.2.8 Yeast genetics and assays
Gene disruption and epitope-tagging
To disrupt genes or placing purification tags onto proteins of interest, S. cerevisiae cells were
transformed (see 2.2.1) with linearized DNA or PCR products that allowed for homologous
recombination (Baudin et al., 1993). Genomic DNA of potential positive clones was isolated
using the DNeasy Blood & Tissue Kit (Qiagen) with a yeast-specific protocol on a QiaCube
robot (Qiagen). Genomic manipulations were verified by performing test-PCR reaction with
primers upstream and downstream of the mutated site and DNA sequencing after agarose
gel separtion and isolation of the PCR-product.
Sporulation and tetrade dissection
Diploid BY yeast strains were usually sporulated by streaking them out as a thin layer
onto pre-sporulation plates. Cells were incubated at 30°C for 2 days, then restreaked onto
sporulation plates and both incubated minimally for 3 days more. In difficult cases, liquid
sporulation medium was used alternatively. Sporulation was monitored by light microscopy.
For tetrad dissection, a loop of sporulated cells was incubated at 30°C with glusulase (Perkin
Elmer) diluted 1:10 in 100 µl sterile water to digest the ascal sac and to release the tetrad.
Micromanipulation was performed on a Singer MSM Tetrad Dissection Microscope.
Mating
Mating types were determined by PCR analysis using three primers (oligo 1: agtcacatcaa-
gatcgtttatgg, oligo 2: gcacggaatatgggactacttcg, oligo 3: actccacttcaagtaagagtttg) simultane-
ously. Strains were mated from cultures grown until OD600 nm=0.2 in YPD. Cells from one µl
culture each were resuspended in 100 µl YPD and one strain added to the other. Both strains
were allowed to settle and incubated over night at 30°C, shaking in a thermomixer. Cells
28
Materials and Methods
were selected on double-selection plates (including restreaking) and potential positive clones
analyzed by PCR as described above. In cases were certain genotypes in a haploid strain
were desired, strains were sporulated as described above.
Complementation assays
Yeast shuﬄe strains were generated by transforming a rescue plasmid carrying an URA3
marker and a gene of interest into diploid strains exhibiting only one intact copy of that
gene. Cells were sporulated, tetrades dissected and selected for having both the genomic gene
knock-out and the rescue plasmid. These shuﬄe strains were then transformed with plasmids
carrying a LEU2 marker and mutant variants of the gene of interest. Transformants were
dotted onto 5-FOA and YPD plates to test if the mutant variants could complement the loss
of the rescue plasmid.
Phenotyping assays
Phenotype analyses of Mediator subunit deletion mutants were performed from cultures
grown to stationary phase. Cells were diluted to an OD600 nm of 1.0, washed, and spotted
in serial dilution onto plates. Assays were mostly performed as described (Hampsey, 1997).
For synthetic defined (SD) (-met) and SD (-SO2−4 ) and for 6-azauracil plate assays, strains
with methionine or uracil auxotrophy were transformed with pRS411 or pRS316 plasmids,
respectively. Siderophore uptake assays were performed with SD plates containing 500 mM
bathophenanthroline disulphonic acid and 10 mM of siderophores.
2.2.9 Bioinformatic tools
Protein and gene sequences were retrieved from the NCBI or Saccharomyces cerevisiae genome
databases. Sequence data was visualized and processed using the following software applica-
tions: Bioedit (Hall, 2005), VectorNTI (Invitrogen), Serial Cloner (http://serialbasics.
free.fr) and Staden/GAP4 (http://staden.sourceforge.net). Bioinformatic analysis
were performed mostly using the Bioinformatics Toolkit (Biegert et al., 2006). Multiple
sequence alignments were generated using MUSCLE (Edgar, 2004). Protein secondary struc-
tures were predicted by HHpred (Soeding et al., 2005), I-Tasser (Zhang, 2008), PSIpred
(Jones, 1999) and CDM (Sen et al., 2006).
2.3 Recombinant Med7N/31
2.3.1 Preparation of recombinant Med7N/31
The gene encoding S. cerevisiae Med31 was cloned into a pET-28b vector (Novagen) using
the NdeI/NotI restriction sites, resulting in a thrombin-cleavable N-terminal hexahistidine
tag. DNA encoding Med7 residues 1–83 was cloned into a pET21b vector through the EcoRI
and SalI restriction sites. E. coli BL21 (DE3) RIL cells (Stratagene) were cotransformed
with the two plasmids and grown in LB medium at 37°C to an optical density at OD600 nm
of 0.6. Expression was induced with 0.5 mM IPTG for 16 h at 18°C. Selenomethionine
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labelling was carried out as described in 2.2.3. For protein purification, cells were lysed
using a highpressure homogenizer (Avestin) in buffer A (see Table 9). After centrifugation,
imidazole was added to a final concentration of 20 mM to the supernatant and loaded onto a
3 ml Ni-NTA column (Qiagen) equilibrated with buffer A containing 20 mM imidazole. The
column was washed with 20 column volumes (CVs) of buffer A containing 20 mM imidazole
and eluted with buffer A containing 200 mM imidazole. Following overnight cleavage with
thrombin, proteins were purified by anion exchange chromatography (MonoQ). The column
was equilibrated with buffer B, and proteins were eluted with a linear gradient of 20 CVs
from 100 mM to 1 M NaCl in buffer B. After concentration, the sample was applied to a
Superdex-200 size exclusion column (GE Healthcare) equilibrated with buffer C.
2.3.2 X-ray structure determination
For crystallization, pure Med7N/31 was concentrated to 50 mg/ml, and 5 mM DTT was
added. Crystals were grown at 20°C in hanging drops over reservoirs containing 50 mM MES
pH 5.6, 1.8 M Li2SO4, and 10 mM MgCl2. Crystals we harvested by gradually adding ethy-
lene glycol to a final concentration of 10% (v/v) and were flash-cooled in liquid nitrogen.
Diffraction data were collected at 100 K on a MARCCD 225 and on a PILATUS 6M detector
at the Swiss Light Source (SLS), Villigen, Switzerland (native data set and mutant data
set, respectively) and on a MARCCD 165 detector at the Berliner Elektronenspeicherring-
Gesellschaft für Synchrotronstrahlung m.b.H. BESSY (SAD data set). Diffraction data for
selenomethionine-labeled Med7N/31 was processed using XDS and XSCALE (Kabsch, 1993).
Program SOLVE (Terwilliger, 2003) identified six selenium sites that were used for phasing.
Solvent flattening, two-fold non-crystallographic symmetry averaging, and initial model build-
ing was done with RESOLVE (Terwilliger, 2003). The resulting electron density map allowed
for manual building of most Med7N and Med31 using COOT (Emsley and Cowtan, 2004).
The model was refined using conjugate gradient minimization in the programs CNS (Brünger
et al., 1998), REFMAC (Murshudov et al., 1997), and Phenix (Adams et al., 2002). The
asymmetric unit contained two Med7N/31 heterodimers that deviate only at the C-termini
of the proteins. The mutant structure was solved by molecular replacement using Phaser
(McCoy et al., 2007) and processed accordingly. The structures and diffraction data of wild-
type Med7N/31 and the mutant complex Med7 (1–83) (12...18 YSPTSPS)/Med31 (mutant 6;
Table 12) have been deposited in the Protein Data Bank under accession codes 3FBI and
3FBN, respectively.
2.3.3 Yeast strains and growth assays
The heterozygous MED7/med7∆ strain was obtained from Euroscarf (Frankfurt, Germany)
and transformed with the cognate gene clone plasmid pYCG_YOL135C (containing a URA3
marker). Diploids were sporulated and tetrads were dissected on YPD plates. To assess
functionality, pAL-med7 1–83, pAL-med7 1–101, pAL-med7 101–222, pAL-med7 1–222, or pRS315-
med7 84–222 were transformed into the MED7 shuﬄe strain. Transformants were dotted onto
5-FOA and YPD plates. Yeast knockout strains were obtained from Euroscarf. All strains
30
Materials and Methods
exhibited a BY background and were, with the exception of med2∆ and med18∆, MATa.
Deletion of the N-terminal region of Med7 (residues 1–83) was obtained by homologous recom-
bination after transforming only the C-terminal part (residues 84–222) fused to a ClonNAT
marker into either WT or med31∆ strains. Additionally, a C-terminal TAP-tag on Med18
was introduced using an URA3 marker into wild-type, med31∆, med7N∆, and med7N/31∆
strains.
2.3.4 In vitro transcription assays
In vitro transcription assays were performed for this work by Martin Seizl as follows: Nuclear
extracts were prepared from 3 l of culture as described by the Hahn laboratory (www.fhcrc.
org/labs/hahn/). Plasmid transcription was performed essentially as described (Ranish
and Hahn, 1991). Transcription reactions were carried out in a 25 µl volume. The reaction
mixture contained 100 µg nuclear extract, 150 ng of pSH515 plasmid, 1x transcription buffer
(10 mM HEPES pH 7.6, 50 mM potassium acetate, 0.5 mM EDTA, and 2.5 mM magnesium
acetate), 2.5 mM DTT, 192 µg of phosphocreatine, 0.2 mg of creatine phosphokinase, 10U
of RNase inhibitor (GE Healthcare), and 100 µM nucleoside triphosphates. For activated
transcription, 150 ng of Gal4–VP16 or 200 ng of Gal4–Gal4AH was added. The reaction was
incubated at room temperature for 40 min and then stopped with 180 µl of 100 mM sodium
acetate, 10 mM EDTA, 0.5% sodium dodecyl sulphate, and 17 µg of tRNA/ml. Samples were
extracted with phenol–chloroform and precipitated with ethanol. Transcripts were analysed
by primer extension essentially as described (Ranish and Hahn, 1991). Instead of the 32P-
labeled lacI oligo, 0.125 pmol of a fluorescently labeled 50-FAM-oligo was used. Quantification
was performed with a Typhoon 9400 and the ImageQuant Software (GE Healthcare).
2.3.5 Gene expression profiling analysis
All experiments were performed in synthetic complete medium with 2% glucose. For microar-
ray analysis, three independent colonies were used for inoculation, and overnight cultures were
diluted in fresh medium to OD600 nm=0.1 (25 ml cultures, 160 r.p.m. shaking incubator 30°C).
Cells were harvested by centrifugation (4000 r.p.m., 3 min, 20°C) at OD600 nm=0.8. Total
RNA was prepared after cell lysis using a mixer mill (Retsch) and subsequent purification
using the RNAeasy kit (Qiagen). The total RNA preparation was treated on-column with
DNase (Qiagen). All following steps were conducted according to the Affymetrix GeneChip
Expression Analysis Technical Manual (P/N 702232 rev. 2). Briefly, one-cycle cDNA synthe-
sis was performed with 1 µg of total RNA. In vitro transcription labelling was carried out
for 16 h. The fragmented samples were hybridized for 16 h on Yeast Genome 2.0 expression
arrays (Affymetrix), washed and stained using a Fluidics 450 station, and scanned on an
Affymetrix GeneArray scanner 3000 7G. Data analysis was performed using R/Bioconductor
(Gentleman et al., 2004). S. pombe probes were filtered out prior to normalization with
the GCRMA algorithm (Wu et al., 2004). Linear model fitting and multiple testing correc-
tion using an empirical Bayes approach was performed using the LIMMA package (Smyth,
2004). Differentially expressed genes were defined as having an adjusted P-value smaller than
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0.05 and an estimated fold change of at least 2.0 (calculated as the fold change of the aver-
age expression in the triplicate measurements). Previously published transcriptome profiles
(Larivière et al., 2008) were included in further analyses by matching genes and compar-
ing fold changes. Over-represented biological processes for genes with significant expression
changes were determined using the topGO package (Alexa et al., 2006). Clustering was cal-
culated using TIGR MeV application (Saeed et al., 2003). Microarray data were submitted to
the ArrayExpress database (http://www.ebi.ac.uk/microarray) under accession number
E-MEXP-1916.
2.4 Endogeneous and recombinant Mediator middle module
2.4.1 Purification of endogenous middle module
The med19∆ yeast strain (BY4741; MATa, his3∆1, leu2∆0, met15∆0, ura3∆0, YBL093C :
:clonNAT) was obtained from Stephan Jellbauer (Gene Center Munich) and C-terminal TAP-
tags were introduced on Med7, Med15 or Med18, respectively, using a kanMX4-marker as
described in 2.2.8 using vector pYM13 (Janke et al., 2004) as PCR-template. Yeast cul-
tures were cultivated and the protein complexes purified using tandem affinity purification
as described in 2.2.4.
2.4.2 Preparation of recombinant middle module
Expression strategy and cloning
Monocistronic vectors were cloned by standard procedures as described in 2.2.2. Bi- or
tricistronic vectors were generally created by introducing additional ribosomal binding sites
by means of PCR into pET and pCDF-vectors (Novagen) as described (Baumli et al., 2005;
Baumli, 2005; Larivière et al., 2006) and illustrated in Figure 12. A detailed listing of all
vectors used and created for this study can be found in Table 5. For expression, E. coli BL21
(DE3) RIL cells (Stratagene) were transformed with one to three plasmids and grown in LB
medium at 37°C to an OD600 nm of 0.6. Expression was induced with 0.5 mM IPTG for 16 h
at 18°C. Cells were lysed using a high-pressure homogenizer (Avestin) (large-scale protein
purification) or by sonication (Branson) (small-scale pufication).
Purification
The quaternary complex Med7/10/21/31-His6 was expressed from two plasmids encoding
Med10, Med7 and Med21 in a tricistronic pET21b vector (pSB104) and Med31-His6 in a
pET24d vector (pSB102). Four liters of E. coli culture were harvested and lysed in buffer A
(see Table 9) containing protease inhibitors. After centrifugation, imidazole was added to a
final concentration of 20 mM to the supernatant and loaded onto a 3 ml Ni-NTA gravity flow
column (Qiagen) equilibrated with buffer A containing 20 mM imidazole. The column was
washed with 20 column volumes (CVs) of buffer A containing 20 mM imidazole and eluted
with buffer A containing 200 mM imidazole. The 4-subunit middle module was further
purified by anion exchange and gel filtration chromatography.
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The Med4/9 complex was coexpressed from a bicistronic pET21 vector (pSB118) using
2 l of E. coli culture. Cells were harvested and lysed in buffer D containing protease in-
hibitors. Insoluble cell debris were removed by centrifugation and the proteins purified by
ammonium sulfate precipitation and anion exchange chromatography. Ammonium sulfate
precipitation was achieved by the gradual addition of saturated (20°C) ammonium sulfate
solution up to 30% (v/v). After centrifugation the pellet was resuspended and purified on a
MonoQ 10/100 column (GE Healthcare) in buffer B using a linear gradient of 20 CVs from
100 mM to 1 M NaCl. A six subunit middle module comprising Med4/7/9/10/21/31 was
obtained by assembling the two purified subcomplexes. Assembly was performed at 20°C
on a rotating wheel with a 1.3 molar excess of Med4/9. Contaminants, excess Med4/9 and
unassembled 4-subunit middle module were separated using anion exchange chromatogra-
phy (buffer B, 20 CV from 100 mM to 1 M NaCl). Following concentration in a 100 kDa
MWCO spin concentrator (Amicon Ultra, Millipore), the 6-subunit middle module was puri-
fied to homogeneity by gel filtration chromatography using a Superose 6 size exclusion column
(GE Healthcare) with buffer A.
The complete middle module comprising Med1/4/7/9/10/21/31 was expressed from the
cotransformed vectors pSB104 (encoding Med10, Med7 and Med21), pTK26 (encoding His6
Med31) and pTK114 (encoding StrepII-tagged Med1, Med9 and Med4). After cotransfor-
mation of two vectors, cells were made competent again in order to transform the third
vector. Six liters of E. coli culture were harvested and lysed in buffer E containing pro-
tease inhibitors. After centrifugation, the complex was purified on 3x 1 ml Strep-Tactin
MacroPrep (IBA) gravity flow columns according to the manufacturer’s instructions. Af-
ter elution by d-Desthiobiotin (IBA) addition, the sample was concentrated in a 100 kDa
MWCO spin concentrator and subjected to gel filtration using a Superose 6 size exclusion
column (GE Healthcare) with buffer A.
2.4.3 Activity assay trials
Nuclear extracts from a med19∆/MED7-TAP yeast strain were generated and in vitro tran-
scription assays performed by Martin Seizl as described in 2.3.4. In this assay, addition
of either TAP-purified Mediator or recombinant middle module together with recombinant
Med19 were tested for activity. In a second aproach, middle-less Mediator complex was at-
tempted to be purified. In order to integrate a 3xFLAG-tag (Moqtaderi and Struhl, 2008)
onto Med18 in the med19∆/MED7-TAP strain, a Med18-3xFLAG/Med7-TAP was gener-
ated, both strains mated, then resulting diploid strains tetrade dissected and tested for the
desired genotype. In order to generate a Med15-3xFLAG/med19∆/MED7-TAP strain, the
3xFLAG-tag was integrated by homologous recombination. The latter strain was used for
further trials to establish middle-less Mediator purification. Cells from 2 to 4 l per experiment
were grown to an OD600 nm of 6.0 and harvested by centrifugation. Cells were lysed either
with glass beads or following a cryo-lysis protocol with ceramic grinding balls according to
Oeffinger et al. (2007) in a planetary bead mill (Fritsch PULVERISETTE 6 classic line). The
supernatant of the first purification step of the TAP-purification (see 2.2.4) was purified fur-
ther with anti-FLAG antibodies. In one series of experiments, 6F7 anti-FLAG antibody (by
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courtesy of E. Kremmer, GSF Munich) was coupled to M280 tosylactivated DynaBeads (In-
vitrogen) and used for the FLAG-purification. In a second approach anti-FLAG M2 agarose
(Sigma) was used for purification (according to the manufacturer’s instructions). Samples
were eluted with FLAG-peptide.
2.4.4 Coexpression and copurification pull-down assays
Coexpression was performed as described in 2.2.3 using 50 ml cultures for StrepII affin-
ity purifications or 7 ml cultures for Ni-NTA purifications. Cell lysates were clarified by
centrifugation and copurification pull-down assays performed in batch. StrepII affinity pu-
rifications were performed using 25 µl of Strep-Tactin MacroPrep (IBA). The clarified lysates
were incubated with the beads at 4°C on a rotating wheel for 1 h. Beads were washed with
3x1 ml of buffer A and the samples eluted by d-Desthiobiotin. Ni-NTA purifications were
performed using 40 µl of MagneHis beads (Promega). The clarified lysates were incubated
with the beads at 4°C on a rotating wheel for 15 min. Beads were washed with 2x1 ml of
buffer A and the samples eluted by 400 mM Imidazole in buffer A. Samples were analyzed
on SDS-PAGE.
2.4.5 Native mass spectrometry
Native mass spectrometry (MS) analyses for this work were performed by Kristina Lorenzen
(Utrecht University) as follows: The buffer exchange for the native MS analysis was per-
formed using 10 kDa cut off membrane spin columns (Millipore, England) by six sequential
concentration/dilution cycles against 200 mM ammonium acetate pH 6.8. The concentration
for the analysis was 5 µM (assuming intact protein complexes). Analysis of the intact protein
complex, as well as the n-propanol and DMSO measurements were carried out on a LCT mass
spectrometer (Waters, UK). Needle voltage was set to 1250 V, cone voltage varied between
100 and 150 V. Tandem mass spectrometry was performed on a modified Q-ToF, here needle
voltage was set to 1300 V and cone to 150 V. For further details see Lorenzen et al. (2007)
and references within. Ion mobility mass spectrometry (IM-MS) was carried out on a Synapt
HDMS (Waters, UK) (Pringle et al., 2007). The source pressure was set to 6.9 mbar, the
pressure in the trap was 3.5x 10-2 mbar, 0.7 mbar in the ion mobility separation (IMS) cell
and 2x 10-6 mbar in the ToF. The wave height in the IMS cell was fixed on 11.3 V and the
wave velocity set to 250 m/s. The gas used in the trap was xenon and nitrogen in the IMS
cell. Needle voltage was 1200 V and cone voltage 150 V. The bias value was set to 20 V,
trap and transfer collision energy to 12 V. Cross section calculations were done as described
by Ruotolo et al. (2008). The average volume of global proteins and protein complexes was
calculated according to Uetrecht et al. (2008).
2.4.6 Static light scattering analysis
Static light scattering analysis was performed using a Superose 6 gel filtration column (GE
Healthcare) combined with a triple detector TDA (Viscotek). Med7C/21 was analyzed in
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buffer F at a concentration of 1.8 mg/ml, Med7N/31 and Med4/7/9/10/21/31 was analyzed
in buffer A at 1.0 mg/ml. Data analysis was performed with OmniSEC software (Viscotek).
2.4.7 Small-angle X-ray scattering
Small angle X-ray scattering (SAXS) data was collected at the X33-Beamline (EMBL/DESY,
Hamburg, Germany). Scattering patterns from 6-subunit Mediator middle module solutions
comprising Med4/7/9/10/21/31 were measured in buffer A at 5 mg/ml two times in order
to exclude potential radiation damage errors. The ATSAS software package (Konarev et al.,
2006) was used for data processing.
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3 Results
3.1 Identification, structure, and functional requirement of the
Mediator submodule Med7N/31
3.1.1 Identification and crystallization of the Med7N/31 subcomplex
The Mediator middle module contains the subunits Med1, Med4, Med7, Med9 (Cse2), Med10
(Nut1), Med21 (Srb7), and Med31 (Soh1) (Guglielmi et al., 2004; Béve et al., 2005). To
work towards the structure and function of the middle module, we purified the trimeric
complex Med7/21/31 in recombinant form after bacterial coexpression of the corresponding
genes and subjected it to limited proteolysis (Methods 2.2.6). Proteolytic cleavage patterns
were consistent with two flexibly linked subcomplexes, the Med7C/21 subcomplex, which we
analyzed earlier (Baumli et al., 2005), and a subcomplex of Med31 with the N-terminal region
of Med7 (Figure 4A). We therefore coexpressed Med31 with different variants of the Med7 N-
terminal region, purified the resulting heterodimeric complexes and screened them for crystal
formation (Table 10). A complex that comprised the N-terminal region of Med7 including
part of the linker (residues 1–101) was soluble, but did not crystallize, apparently due to
flexibility in the proteolytically sensitive linker. Shorter variants resulted in initial crystal
hits that could be crystallized, but these crystals diffracted only weakly upon measurement
at the synchrotron. A complex that lacked the entire linker and included only Med7 residues
1–83 (Med7N) crystallized at a concentration of 59 mg/ml in condition 1 of Hampton Natrix
screen (50 mM MES pH 5.6, 2.0 M Li2SO4, and 10 mM MgCl2). Crystals were reproduced
in 24-well plates, refined (Figure 3) and used to solve the X-ray structure of Med7N/31 by
selenomethionine labeling and single anomalous diffraction. The structure was refined to a
free R-factor of 24.3% at 2.8 Å resolution (Table 11, Methods 2.3.2).
Figure 3: Crystals of Med7N/31 complex.
(A) Initial crystals were obtained from a 96-well
plate screening in condition 1 (50 mM MES pH 5.6,
2.0 M Li2SO4, and 10 mM MgCl2) of Hampton
Natrix screen at 20°C. (B) Refined crystals from
24-well plates (50 mM MES pH 5.6, 1.8 M Li2SO4,
and 10 mM MgCl2).
A B
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Table 10: Crystallization screening of M7N/31 complex.
Screens were performed at 20°C.
Complex Concentration Screen(s)a Buffer
Med7 (1-101)/31-His6 10 mg/ml Classic, Index, JBC I, JBC II,
Natrix, PEG/Ion, Anions, Cations,
MPD
A + 5 mM DTT
Med7 (1-101)/31-His6 23 mg/ml Classic, Index, JBC I, JBC II,
Natrix, PEG/Ion
A + 5 mM DTT
Med7 (1-101)/31-His6 47 mg/ml Classic, Index, JBC I, JBC II,
Natrix, PEG/Ion
A + 5 mM DTT
Med7 (1-80)/31-His6 57 mg/ml Classic, Index, JBC I, JBC II,
Natrix, PEG/Ion
A + 5 mM DTT
Med7 (1-83)/31-His6 65 mg/ml Classic, Index, JBC I, JBC II,
Natrix, PEG/Ion
A + 5 mM DTT
Med7 (1-80)/31-His6 43 mg/ml Classic, Index, JBC I, JBC II,
Natrix, PEG/Ion
A + 5 mM DTT
Med7 (1-92)/31-His6 50 mg/ml Classic, Index, JBC I, JBC II,
Natrix, PEG/Ion
A + 5 mM DTT
Med7 (1-80)/31-His6 85 mg/ml Classic, Index A + 5 mM DTT
Med7 (1-92)/31-His6 94 mg/ml Classic, Index, JBC I, JBC II,
Natrix, PEG/Ion
A + 5 mM DTT
Med7 (1-92)/31-His6 59 mg/ml Classic C + 5 mM DTT
Med7 (1-83)/31-His6 59 mg/ml Classic, Index, JBC I, JBC II,
Natrix, PEG/Ion
C + 5 mM DTT
Med7 (1-92)/31-His6 70 mg/ml Classic, Index, JBC I, JBC II,
Natrix, PEG/Ion
C + 5 mM DTT
a Commercial screens used for 96-well plate screening were: Index, Natrix, PEG/Ion (all Hampton), Classic screen,
pH-clear, anions suite, cations suite, classic suite (all Qiagen), JB Screen Classic HTS I S and JB Screen Classic
HTS II S (both Jena Biosciences).
Table 11: Data collection and refinement statistics for Med7N/31.
Selenomethionine SAD Native dataset, mutant
Med7 (1-83)/Med31 construct 6 (Table 12)
Data collection
Space group R 32 R 32
Cell parameters
a, b, c (Å) 174.6, 174.6, 117.8 174.2, 174.2, 115.5
α, β, γ (°) 90, 90, 120 90, 90, 120
Wavelength (Å) 0.98 0.92
Resolution range (Å)a 20-2.8 (2.97-2.80) 50-3.0 (3.18-3.00)
Completeness (%) 99.4 (98.0) 99.7 (98.2)
Unique reflections 32,854 (5,275) 13,576 (2,138)
Redundancy 11.3 (9.1) 11.2 (11.0)
Rsym (%) 6.0 (61.8) 5.0 (57.4)
<I>/<σ> 27.8 (4.1) 32.7 (5.2)
Refinement
Number of residues 282 278
Number of non-hydrogen atoms 2436 2402
rms bond deviation (Å) 0.007 0.008
rms angle deviation (°) 1.041 1.076
Ramachandran plot (%) (favored/allowed) 95.0/100.0 95.0/100.0
Rcryst (%) 19.5 17.8
Rfreeb (%) 24.3 23.1
a Highest resolution shell is shown in parenthesis. b 5% of the data were set aside for free R-factor calculation.
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Figure 4: Structure of the Med7N/31 Mediator subcomplex.
(A) Multiple sequence alignment and structural conservation of Med7 and Med31 from Saccharomyces
cerevisiae (S.c.), Schizosaccharomyces pombe (S.p.), Caenorhabditis elegans (C.e.), Drosophila melanogaster
(D.m.), Homo sapiens (H.s.) and Arabidopsis thaliana (A.t.). Secondary structure elements are indicated
above the sequences (spirals, α- and 310(η)-helices; arrows, β-strands; lines, ordered but without secondary
structure; dashed lines, disordered regions). Invariant and conserved residues are highlighted in green and
yellow, respectively. Surface accessibility is indicated below the sequences (blue, exposed; white, buried).
Cleavage sites revealed by limited proteolysis with trypsin or chymotrypsin are indicated with black arrows.
The loop between Med7N helices α1 and η2 (residues 41–55) was disordered. Sequence alignments were done
with MUSCLE (Edgar, 2004) and figures were prepared with ESPript (Gouet et al., 1999). (B) Ribbon model
representation of the Med7N/31 crystal structure. Two views are shown that are related by a 180° rotation
around the vertical axis. Med7 is depicted in orange and Med31 in green. Secondary structure elements are
labeled according to (A). These and other figures were prepared with PyMol (DeLano, 2002). (C) Ligplot view
(Wallace et al., 1995) of the interactions of the Med7N polyproline stretches pPS1 and pPS2 with Med31.
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3.1.2 The Med7N/31 structure reveals novel folds
The structure shows that Med31 forms a compact righthanded four-helix bundle, whereas
Med7N is extended and wraps around Med31 (Figure 4B). Both folds are novel, as neither
DALI nor MSD fold searches (Holm and Park, 2000; Krissinel and Henrick, 2004) produced
any hits. The Med7N/31 structure is apparently conserved among eukaryotes, as hydrophobic
core residues are identical or similar from yeast to human (Figure 4A), and many residues
in the Med7N–Med31 interface are also conserved. The Med7N–Med31 interface is mainly
hydrophobic (Figure 4), explaining why isolated recombinant Med7N or Med31 cannot be
obtained in soluble form (not shown). The Med7N/31 surface reveals several conserved, non-
charged regions (Figure 5A and B) that can account for interactions of Med7N/31 with other
subunits of the middle module (Guglielmi et al., 2004) or other potential binding partners.
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-C Med31
-C Med7N
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pPS1 Med7N pPS1 Med7N (12...18 YSPTSPS)
pPS2
CTD CTD
Figure 5: Analysis of the Med7N/31 structure.
(A) Surface conservation of the Med7N/31 subcomplex. Invariant and conserved residues are highlighted in
green and yellow, respectively. The surface is semitransparent to show the underlying residues in a stick
model. Two views are shown that are related by a 180° rotation around the vertical axis. (B) Surface
charge distribution. Red, blue, and white areas indicate negative, positive, and neutral charges, respectively.
(C) The Med7N polyproline stretches adopt a CTD-like conformation. Superimposition of Med7N pPS1 and
pPS2 (orange) with the Y(SEP)PT(SEP)PS peptide from the human Pin1 structure (1F8A, light purple).
(D) Comparison of pPS1 in the crystal structures of Med7N/31 and Med7N/31 with pPS1 mutated to a CTD
heptad repeat (mutant 6; Table 12).
3.1.3 Possible CTD mimicry by Med7N
Med7N contacts Med31 mainly through two polyproline stretches (pPS1 and pPS2; Fig-
ure 4A–C), which adopt a conformation similar to a left-handed type II polyproline helix
(Adzhubei and Sternberg, 1993). A deletion analysis revealed that both pPS1 and pPS2 were
required for the formation of a stable complex with Med31 (Table 12; constructs 2–5). pPS2
is tightly packed onto Med31, whereas pPS1 is more accessible (Figure 4C). As the C-terminal
repeat domain (CTD) of RNA Pol II is also proline rich, we compared the Med7N stretches
with known CTD peptide structures. The conformation of the CTD peptide in complex
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with the prolyl isomerase Pin1 (PDB 1F8A; Verdecia et al. (2000)) resembles the structure
of Med7N pPS1, and is also distantly related to pPS2 (Figure 5C). The CTD interacts ge-
netically and physically with Mediator (Thompson et al., 1993; Myers et al., 1998; Asturias
et al., 1999; Kang et al., 2001). Although med31 deletion does not suppress the cold-sensitive
phenotype caused by CTD truncations (Thompson et al., 1993), it is synthetically lethal with
a truncation of the CTD to only 11 intact heptad repeats (Fan et al., 1996). We therefore
speculated that the CTD may bind Med31 by replacing pPS1 and/or pPS2 of Med7N un-
der certain conditions. We could however not investigate direct CTD binding to Med31 as
isolated Med31 could not be obtained in soluble form. We therefore mutated the Med7N
pPS1 and pPS2 stretches such that their sequences correspond to the CTD repeat sequence
consensus (Table 12), and tested whether these Med7N mutants formed stable complexes
with Med31. The pPS1 mutant, but not the pPS2 mutant, formed a stable complex with
Med31 (Table 12). Crystallographic analysis of the pPS1 mutant (mutant 6; Table 12) in
complex with Med31 showed that four residues of the CTD heptad repeat (15-TSPS-18) were
ordered and bound to Med31, whereas the preceding three residues (12-YSP-14) were flexible
(Figure 5D). However, as the Med7N/31 complex also tolerated replacement of pPS1 by the
reverse CTD heptad repeat sequence (mutant 10; Table 12), and as the Med7N stretches
are present in organisms lacking the canonical CTD repeats (Stiller and Hall, 2002; Bourbon,
2008), a possible CTD mimicry by Med7N and CTD binding by Med31 remains hypothetical.
Table 12: Summary of Med7N mutant constructs of the polyproline stretches 1 and 2.
No. Med7N constructa Mutation Replaced Copurification
sequence with Med31
1 Med7 (1-83) - (crystallized construct) yes
2 Med7 (20-83) N-terminus including pPS1 removed no
3 Med7 (23-83) N-terminus including pPS1 removed no
4 Med7 (1-61) C-terminus including pPS2 removed no
5 Med7 (1-66) C-terminus including pPS2 removed no
6 Med7 (1-83) (12...18 YSPTSPS) pPS1 replaced by CTD-repeat LYPPPPP yes
7 Med7 (1-83) (13...19 YSPTSPS) pPS1 replaced by CTD-repeat YPPPPPY yes
8 Med7 (1-83) (66...72 YSPTSPS) pPS2 replaced by CTD-repeat IPPPMPK no
9 Med7 (1-83) (65...71 YSPTSPS) pPS2 replaced by CTD-repeat LIPPPMP no
10 Med7 (1-83) (12...18 SPSTPSY) pPS1 replaced by reversed
CTD-repeat
LYPPPPP yes
11 Med7 (1-83) (12...18 YSPTDPS) pPS1 replaced by mutated
CTD-repeat
LYPPPPP yes
12 Med7 (1-83) (12...18 YSPTRPS) pPS1 replaced by mutated
CTD-repeat
LYPPPPP yes
13 Med7 (1-83) (12...18 YDPTSPS) pPS1 replaced by mutated
CTD-repeat
LYPPPPP yes
a For interaction assays, Med7 (1-83), Med7 (1-61), Med7 (1-66), Med7 (20-83), Med7 (23-83) were cloned into
pET21b using NdeI/SalI, such that a N-terminal Strep-tag was introduced. With these constructs, copurification
was analyzed both via the His-tag on Med31 and via the Strep-tag on the Med7 variants.
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3.1.4 Med7N/31 is required for normal yeast growth in vivo
Med7 is essential for yeast viability in rich medium (Myers et al., 1998). To investigate which
Med7 region is required for viability, we carried out complementation studies in yeast. We
generated plasmids expressing full-length Med7, Med7N, and Med7N plus the linker part,
which was not present in the Med7C/21 structure (Baumli et al., 2005) or a Med7C variant.
Plasmids were introduced into a med7∆ strain rescued by a MED7 -encoding URA3 plasmid.
Complementation was observed with full-length MED7 or MED7C, which allows for loss of
the URA3 plasmid and growth on media containing 5-fluorotic acid (5-FOA; Figure 6A). As
the remaining linker residues (102–113) present in the Med7C/21 structure are not conserved,
we infer that only Med7C is essential for viability, whereas Med7N and the linker are not. A
strain that lacked the region encoding Med7N (med7N∆) exhibited a slowgrowth phenotype,
similar to a med31∆ strain and a double deletion strain med7N∆/med31∆ (med7N/31∆)
(Figure 6B; Table 4).
3.1.5 Med7N/31 is essential for transcription in vitro
To investigate whether the Med7N/31 subcomplex is required for activated transcription in
vitro, we used a plasmid-based in vitro transcription assay with a HIS4 core promoter and
a single upstream Gal4-binding site (Ranish et al., 1999). A nuclear extract from strain
med7N/31∆ was defective in basal transcription (not shown) and in transcription activated
with the Gal4–VP16 fusion protein or with a fusion protein of the Gal4 DNA-binding do-
main with the Gal4-Gal4 activation helix (Gal4-Gal4AH) (Figure 6C, lane 1; Figure 7, lane 1).
Addition of tandem affinity purification (TAP)-purified Mediator restored transcription (Fig-
ure 6C, lane 2), providing a positive control. Transcription could also be restored by the
addition of recombinant Med7N/31, demonstrating that the crystallized complex is function-
ally active and can act in trans without being covalently tethered to the Mediator (Figure 6C,
lanes 3–5; Figure 7, lane 2). To investigate whether loss of Med7N/31 leads to the disso-
ciation of other subunits from Mediator in vivo, we purified Mediator from deletion strains
med7N∆, med31∆, and med7N/31∆ with the use of a TAP-tag fused to Med18 (Materials
and methods 2.2.4). After purification from these deletion strains, the remainder of Mediator
stayed intact (Figure 6F). These results show that Med7N/31 forms a peripheral subcomplex
on Mediator that is required for activated transcription in our in vitro assays.
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Figure 6: Functional analysis of Med7N/31 in vivo and in vitro.
(A) Yeast complementation assays. Plasmids encoding full-length MED7 or N-terminal truncations of MED7
were cloned into the SmaI/XbaI restriction sites of a pAL vector or through SalI/XbaI into a pRS315 vec-
tor. Individual plasmids were transformed into the MED7 shuﬄe strain (Table 4) and streaked onto 5-
FOA-containing plates to shuﬄe out the MED7 encoding URA3 plasmid. Yeast cells carrying only MED7C
(102–222) are viable, whereas the Med7 N-terminal part including part of the linker (residues 1–101) can-
not rescue cell growth. (B) Mutant strains exhibit a slow-growth phenotype. Note that growth curves are
on a logarithmic scale. (C) Med7N/31 is required for Gal4–VP16-activated transcription in vitro (lane 1).
Transcription can be rescued by the addition of TAP-purified Mediator (0.2 pmol, lane 2) or recombinant
Med7N/31 (rMed7N/31, 2–200 pmol, lanes 3–5). Addition of both rMed7N/31 (2–200 pmol) and recombinant
TFIIS (rTFIIS, 20 pmol, lanes 6–8) enhances the signal. (D) A med7N/31∆ nuclear extract that was rescued
by the addition of recombinant Med7N/31 (lane 2, 200 pmol) was additionally stimulated by the addition
of TFIIS (lane 5, 60 pmol). TFIIS alone can partially compensate for loss of Med7N/31 (lanes 3 and 4,
20–60 pmol). This stimulation was not observed with a med18∆ nuclear extract that was rescued by the addi-
tion of recombinant Med18/20 (rMed18/20, lanes 7–10, 20–60 pmol). (E) TFIIS addition stimulates basal and
Gal4–VP16-activated transcription of wild-type (WT) nuclear extracts (lanes 2 and 3, and 5 and 6, respec-
tively, 20–60 pmol). Recombinant Med7/31 or Med18/20 did not stimulate WT nuclear extracts. (F) Deletion
of Med7N/31 or its subunits does not lead to loss of additional Mediator subunits. C-terminally TAP-tagged
Med18 was purified from med31∆/Med18-TAP, med7N∆/Med18-TAP, and med7N/31∆/Med18-TAP strains
as described (Materials and methods 2.2.4). Copurifying proteins were separated on a 12% NuPAGE gel
(Invitrogen), and bands were stained with Coomassie blue. The identity of all Mediator subunits was con-
firmed by mass spectrometry (the Table "Mass spectrometry analysis of Mediator TAP-tag purification" can be
viewed online at http://www.nature.com/emboj/journal/v28/n1/suppinfo/emboj2008254as1.html in Ex-
cel file format). Contaminants such as ribosomal proteins or degradation products of Mediator subunits were
especially detected at lower molecular weights and do partially overlap with smaller subunits such as Med7C.
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Figure 7: In vitro transcription assay using
Gal4-Gal4 activation-helix (Gal4-Gal4AH)
as activator.
A med7N/31∆ nuclear extract was also defective
in activated transcription using a Gal4-Gal4AH
(Carey et al., 1990) as activator (lane 1) but could
be rescued by addition of recombinant Med7N/31
(lane 2, 200 pmol). Similarly as shown in Fig-
ure 6D, the reconstituted complex could be fur-
ther stimulated by addition of recombinant TFIIS
(lane 3-5, 20-60 pmol). The assay was performed
using 100 µg of nuclear extract.
3.1.6 Med7N/31 is a functional Mediator submodule in vivo
To investigate the function of the Med7N/31 subcomplex in vivo, we carried out comparative
microarray-based gene expression profiling with the yeast deletion strains med7N∆, med31∆,
and med7N/31∆. Compared with wild-type cells, the expression profiles of the three deletion
strains showed similar overall changes illustrated by high Pearson’s correlations (Figure 8A–D;
Table 13; Table 14). A majority of changes in mRNA levels that are induced by deletion of
both Med7N and Med31 are already observed when either Med7N or Med31 is lacking from
cells. This shows that Med7N/31 serves as a functional submodule of the Mediator in vivo at
a majority of affected genes. Some differences between profiles for the med7N∆, med31∆, and
med7N/31∆ strains at selected genes (Figure 8C) indicate subunit-specific functions that may
result from additional protein interactions (unpublished data). As the majority of affected
genes is downregulated (Figure 8D), the Med7N/31 submodule has a predominantly positive
function, consistent with previous expression data on a med31∆ strain (van de Peppel et al.,
2005).
3.1.7 Med7N/31 regulates a subset of genes
Gene ontology (GO) analysis of genes with significantly changed mRNA levels revealed an
over-representation of genes involved in sulphate/methionine metabolism, iron homeostasis,
and transport functions (Table 13; Table 14B). A group of genes involved in telomere main-
tenance was also over-represented, consistent with the observation that a med31∆ strain
exhibits shortened telomers (Askree et al., 2004). The differential expression profiles for
Med7N/31 were largely distinct from the previously published profiles (Larivière et al., 2008)
of the tail subunit deletion strains med2∆ and med3∆, and correlated only moderately with
those of strains med8C∆, med18∆, and med20∆, which lack parts of the head submodule
Med8C/18/20 (Figure 8A and B). However, both the Med7N/31 and the Med8C/18/20 sub-
modules regulate genes responsible for siderophore transport and conjugation. Thus, the
Med7N/31 submodule is required not only for the regulation of a specific subset of genes but
also those genes that depend on other parts of the Mediator.
To identify transcription factors that regulate the differentially expressed genes, we used
the transcription factor to gene promoter mapping matrix from the YEASTRACT website
(Teixeira et al., 2006), and performed Fisher’s exact test with the R/Bioconductor software
(Gentleman et al., 2004) (Table 14F). This analysis revealed that the differentially expressed
genes contained over-represented target genes for certain transcription factors, including Cst6,
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Figure 8: Transcriptome profiling analysis and phenotypic correlation.
(A) Cluster diagram (Euclidean distance) of genes exhibiting significantly altered mRNA levels (at least
1.7-fold, vertical axis) for different Mediator subunit deletion strains and TFIIS (horizontal axis). Changes
in mRNA levels compared with the wild-type strain are depicted in red (up), green (down), or black (no
change). (B) Pearson’s correlation matrix for expression profiles of the Mediator middle subunit deletion
strainsmed7N∆, med31∆, med7N/31∆, the head subunitmed8C∆, med18∆, med20∆, the tail subunit deletion
strains med2∆, med3∆, and the deletion profile of the general transcription factor dst1∆ strain. (C) Venn
diagram showing the overlap between the investigatedmed31∆, med7N∆, andmed7N/31∆ strains. While these
three strains exhibit a very high overlap, the overlap with the dst1∆ strain was not regarded as statistically
significant. (D) Number of significantly altered genes of all four investigated deletion strains, split into up- and
downregulated genes. (E) Selected phenotyping analysis results. Using 10-fold serial dilutions of yeast strains
spotted onto selective agar plates, we screened for phenotypes, occurring under certain growth conditions. All
assays were compared with a control plate on YPD, synthetic complete (SC), or SD media plates. As typical
examples, the results from the growth inhibition assay on SD (-met) plates, the siderophore uptake assay
(detected using bathophenanthroline disulphonic acid (BPDS)), and the growth inhibition on paramomycin
assay are depicted.
Aft1, Msn2, Msn4, Yap family factors, Met28, Met31, Met32, Hsf1, and Pdr1. Consistent
with the GO analysis, Msn2, Msn4, and Yap family members are involved in stress response,
Cst6 regulates genes involved in telomere maintenance, and Aft1 is required for activating
the low iron response regulon through Mediator (van de Peppel et al., 2005). The mRNA
levels for these factors were unaltered in the investigated strains, except for Met28 and Msn4.
Met28 was downregulated for Med7N/31 deletions and upregulated for Med2/Med3 deletions
(Table 14G), explaining corresponding negative and positive responses, respectively, of target
genes involved in methionine and cysteine biosynthesis (Table 14D).
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Table 13: Summary of common biological terms overrepresented in GO analysis of the differ-
entially expressed genes in med31∆, med7N∆ and med7N/31∆ strains.
GO term Description med7N/31∆ submodule
(Biological Annotated Up- Down- Expected
process)a regulated regulated
GO:0015891 siderophore transport 9 7 0.3
GO:0000097 sulfur amino acid biosynthetic process 35 8 1.0
GO:0006555 methionine metabolic process 38 8 1.1
GO:0000103 sulfate assimilation 10 4 0.3
GO:0015698 inorganic anion transport
– GO:0008272 – sulfate transport 5 3 0.2
GO:0043419 urea catabolic process 2 2 0.1
GO:0000749 response to pheromone during
conjugation
– GO:0000750 – pheromone-dependent signal
transduction
28 1 4 0.8
GO:0015846 polyamine transport 11 2 1 0.3
GO:0007050 cell cycle arrest 12 1 2 0.4
GO:0000723 telomere maintenance
– GO:0007004 – telomere maintenance via telomerase 17 1 2 0.5
– GO:0016233 – telomere capping 5 1 1 0.2
GO:0001403 invasive growth (sensu Saccharomyces) 45 1 4 1.3
GO:0032147 activation of protein kinase activity 6 2 0.2
GO:0001402 signal transduction during filamentous
growth
7 1 1 0.2
GO:0008645 hexose transport 20 3 0.6
aGO terms are ranked according to the topGO weight algorithm (Alexa et al., 2006) exhibiting a score smaller than
0.02. Lower level GO terms (marked with a "–") are listed below of the hierarchically higher GO terms. For the
complete analysis including the associated genes and the analysis for the dst1∆ strain see also Tables 14B and C.
Table 14: The Table "Analysis of transcriptome profiling" could not be included here due to its
huge size but the Excel file can be viewed in online at http://www.nature.com/emboj/journal/v28/
n1/suppinfo/emboj2008254as1.html.
(A) List of up- and down-regulated genes in the yeast deletion strains med31∆, med7N∆, med7N/31∆ and
dst1∆. (B) Overrepresented biological processes and associated genes detected in the GO analysis of med31∆,
med7N∆, med7N/31∆ and dst1∆ profiles. (C) GO analysis for the med7N/31∆, med8C/18/20∆ and med2/3∆
submodule profiles. (D) GO-comparison table and visualization of the three submodule deletion profiles. The
data was split into up- and down regulated genes (red and green bars, respectively). (E) Complete list
of expression values of the yeast deletion strains med31∆, med7N∆, med7N/31∆ and dst1∆. (F) Ranking
of transcription factors based on Fisher’s exact test which are potentially regulating the differentially ex-
pressed genes in med31∆, med7N∆, med7N/31∆ and dst1∆ strains. (G) Ranking of transcription factors
based on Fisher’s exact test which are potentially regulating the differentially expressed genes in Med7N/31,
Med8C/18/20 and Med2/3 submodule deletion strains.
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3.1.8 Overlapping and specific functions of Mediator submodules
To investigate the deregulation of genes induced by disruption of Med7N/31, we analyzed
the growth of several yeast strains with deletions in Mediator genes (Table 4) on various
selective agar plates (Table 15). The phenotypes of Med7N/31 deletions correlated well with
results from transcription profiling. In the absence of methionine, these deletion strains grew
poorly (Figure 8E), consistent with the observed downregulation of genes involved in methio-
nine/sulphate metabolism. In the presence of siderophores, several deletion strains took up
more complexed iron, as indicated by a red color (Figure 8E), consistent with higher expres-
sion of siderophore transport genes (some likely regulated by Aft1). Sensitivities of the dele-
tion strains towards osmotic and cell wall stress were consistent with reported impaired cell
wall metabolism of Mediator subunit deletion strains of Schizosaccharomyces pombe (Linder
et al., 2008). A decreased sensitivity of the med31∆ and med7N/31∆ strains for the trans-
lation inhibitor paramomycin can also be explained by impaired cellular uptake or transport
(Figure 8E). Most deletion strains were further impaired in their response to temperature,
oxidative, and DNA repair stresses (Table 15). Also observed were inositol– phenotypes that
are often indicative of defects in the general transcriptional apparatus (Hampsey, 1997).
This comparative phenotyping of Mediator deletion strains showed that the med8C∆ and
med18∆ strains exhibited the most severe growth defects (Table 15), possibly reflecting an
important function of these subunits in the initiation complex assembly (Ranish et al., 1999).
Deletion of subunits Med1, Med5, or Med9 was less detrimental. In agreement with earlier
studies (van de Peppel et al., 2005), Cdk8 behaves partially contrasting with the phenotyp-
ing assays. On the transcriptome level, analyses of Med7N/31 and Med8C/18/20 submodule
deletion profiles with med2∆ and med3∆ profiles (Table 14C and D) reveal different overlaps
in enriched GO terms. Some GO terms are exclusively enriched for specific Mediator sub-
modules (e.g. telomere capping for Med7N/31), whereas other GO terms are affected for two
different submodules (e.g. siderophore transport for Med7/31 and Med8C/18/20 or serine
family amino-acid catabolism with Med8C/18/20 and Med2/3), and other GO term groups
are affected by all investigated mutations (e.g. response to pheromone). Such overlap in
the phenotyping assays (Table 15) and the GO analysis (Table 13; Table 14C and D) shows
that the characterized non-essential parts of Mediator are generally required for regulating
metabolic sensing, stress response, and amino-acid biosynthesis pathways.
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Table 15: Comparative phenotyping of Mediator deletion strains.
Sensitivity testa wt Middle Head Tail Kinase
med31∆ med7N∆ med7N/31∆ med1∆ med9∆ med8C∆ med18∆ med2∆ med3∆ med5∆ cycC∆
Siderophore-uptake SD + ferrichrome + +++ ++ ++ + + +++ +++ ++ ++ – ++
SD + ferrioxamine E + +++ ++ ++ + + +++ +++ ++ ++ – ++
Lack of amino acids SD (-met) – ++ + ++ – – +++ ++ ++ ++ – +
Growth on S-Sources SD (-SO2−4 ) + ++ + ++ – – ++ ++ + + – +++
Growth on C-Sources YP Na-acetate – ++ + + – – + +++ +++ +++ + +++
Growth on N-Sources SD urea – – + – – – ++ ++ ++ + – +
Temperature YPD 16°C – + + + + + ++ ++ ++ ++ – +
YPD 37°C – ++ + + + ++ +++ +++ ++ ++ – +++
Salt stress YPD NaCl (1 M) – ++ + + + + +++ ++ – – + ++
YPD KCl (1 M) – ++ + ++ – + +++ + + + – +
YPD LiCl (0.4 M) + + + + + ++ +++ +++ – – + ++
Cell wall stress YPD SDS (0.01 %) – + + + – – +++ +++ + + – ++
Osmotic stress YPD glycerol (2 M) – ++ ++ ++ + – +++ +++ + + – +
Oxidative stress YPD Menadione
(20 mM)
– – ++ + – – – ++ + + – –
DNA repair YPD MMS (0.05 %) – ++ ++ ++ ++ ++ ++ ++ + + + –
YPD HU (100 mM) + ++ ++ ++ + + +++ +++ ++ ++ + +++
Transcription SC (-inositol) – ++ ++ ++ – – +++ +++ ++ ++ – +
Transcription elongation SC (-ura) 6-AU
100 mg/ml)
++ + – – – – – + ++ + + –
Translation YPD cycloheximide
(0.1 mg/ml)
– +++ +++ +++ - + ++ +++ +++ +++ + +
YPD paromomycin
(2.5 mg/ml)
+++ – +++ – – – ++ ++ – – – –
Miscellaneous YPD caffeine (8 mM) + ++ + + + + ++ +++ ++ ++ – ++
Starvation YP media 6 days, 30°C,
then respotted on YPD
– ++ + + ND ND +++ +++ ND ND ND +
a All measurements are growth inhibition, except for the siderophore assay, where cellular iron content was measured. Growth inhibition (with the exception of the siderophore uptake assays)
is indicated by relative estimates (+, moderate hypersensitivity; ++, high hypersensitivity; +++, very high hypersensitivity; -, no hypersensitivity; ND, not determined).47
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3.1.9 Cooperation of Med7N/31 and TFIIS
As Med31 interacts genetically with the elongation factor TFIIS (Krogan et al., 2003; Malagon
et al., 2004; Collins et al., 2007; Guglielmi et al., 2007), we tested whether Med7N/31
cooperates with TFIIS during activated transcription in vitro. Indeed, transcription in a
med7N/31∆ nuclear extract that was rescued by recombinant Med7N/31 could be enhanced
four-fold by the addition of recombinant TFIIS using Gal4–VP16 as an activator (Figure 6D).
A stimulatory effect of TFIIS, although only about two-fold, was also seen for basal and
activated transcription in wild-type (WT) extracts (Figure 6E). Addition of TFIIS to a
med7N/31∆ extract resulted in a signal even in the absence of recombinant Med7N/31, al-
though TFIIS was not limiting in the extracts, as a three-fold higher concentration did not
further increase transcription (Figure 6D, lanes 3 and 4). TFIIS also stimulated transcription
activated with the alternative activator Gal4–Gal4AH, although only about two-fold (Fig-
ure 7). In contrast, transcription in a med18∆ extract was not enhanced at all by TFIIS
addition (Figure 6D, lanes 8 and 9) and a med18∆ extract that was rescued by the addition
of recombinant Med18/20 was not further stimulated by the addition of TFIIS (Figure 6D,
lane 10). These results show that TFIIS can partially compensate for the loss of Med7N/31,
and that highest transcript levels required the addition of both TFIIS and Med7N/31. These
observations were specific for the med7N/31∆ extract, as this effect was not obtained in cor-
responding experiments with a med18∆ extract. The results are further consistent with an
important role for TFIIS during initiation (Guglielmi et al., 2007; Kim et al., 2007).
To investigate whether TFIIS and Med7N/31 cooperate at specific genes in vivo, we de-
termined the gene expression profile for a yeast strain that lacks the gene for TFIIS, dst1
(Table 14A, B, E and F). Only 162 mRNA levels were significantly altered (at a two-fold
expression change cutoff and a false discovery rate of P<0.05; Table 14A), consistent with a
lack of a phenotype of the dst1∆ strain in rich medium (Clark et al., 1991). Pearson’s corre-
lation and GO analysis did not reveal any significant overlap between dst1∆ and med7N/31∆
profiles (Figure 8B; Table 14). Consistently, we could not detect a direct physical interac-
tion between TFIIS and recombinant Med7N/31 (not shown). Instead, analysis of synthetic
lethality partners suggests that Med31 and TFIIS are functionally connected through the
SWR1 complex that is involved in exchange of histone H2A by the variant H2A.Z (Fig-
ure 9A). Similar correlations were also found for the Mediator subunits Med1, Med9, and
Med20 (not shown). Additionally, the Mediator kinase module is a highly significant phe-
notypic suppressor of core Mediator subunits and TFIIS (Figure 9B). Taken together, the
functional cooperation of Med7N/31 and TFIIS is apparently not gene specific in vivo, but
may generally occur during initiation, and could further be linked to Swr1-dependent histone
variant exchange near transcription start sites (Santisteban et al., 2000; Zanton and Pugh,
2006; Zlatanova and Thakar, 2008).
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Figure 9: Analysis of published genetic interactions of Med31 and TFIIS.
(A) Common and disparate synthetic lethality partners of Med31 and TFIIS are depicted as nodes. (B) Com-
mon and disparate phenotypic suppression partners of Med31 and TFIIS. Figures were prepared using the
Osprey software (Breitkreutz et al., 2003) with interaction data downloaded from BioGrid database (Stark
et al., 2006). Interaction data references are available online at http://www.nature.com/emboj/journal/v28/
n1/suppinfo/emboj2008254as1.html
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3.2 Preparation and topology of the Mediator middle module
3.2.1 Endogenous Mediator middle module
It was previously reported that the middle module is lost from Mediator that is purified
from a med19∆ strain under stringent conditions (Baidoobonso et al., 2007). To purify
middle module from amed19∆ strain, we introduced a C-terminal tandem affinity purification
(TAP) tag on the middle module subunit Med7. TAP purification resulted in pure middle
module without the need for the previously used urea dissociation (Baidoobonso et al., 2007),
indicating that the tag further destabilizes the Mediator. Fusing a TAP-tag with Med15 or
Med18 did not lead to purification of individual parts of Mediator (Figure 11). The high yield
and purity of our preparation from the med19∆/MED7 -TAP strain (Figure 10C) enabled us
to determine unambiguously by mass spectrometry (Methods) that the endogenous yeast
Mediator middle module comprises the subunits Med1, Med4, Med7, Med9 (Cse2), Med10
(Nut2), Med21 (Srb7) and Med31 (Soh1), consistent with previous description (Guglielmi
et al., 2004; Béve et al., 2005; Bourbon, 2008; Linder et al., 2006).
Figure 10: Endogenous Mediator and its middle module.
(A) Schematic view of Mediator subunit arrangement and modular structure, taking into account known and
found (see below) subunit interactions. Subunits that are essential for yeast viability are outlined in yellow.
(B) Available detailed structural information on subunits and subcomplexes of Mediator (Baumli et al., 2005;
Hoeppner et al., 2005; Larivière et al., 2006; Thakur et al., 2008, this work, see 3.1). Structures are enlarged
in proportion to the full subcomplex or subunit sizes. (C) SDS-PAGE analysis of endogenous Mediator
and 7-subunit Mediator middle module purified from wild-type (left) and med19∆ yeast strains containing a
C-terminal TAP-tag on the Med7-subunit. Copurifying proteins from 4 l yeast cells were separated on a 12%
NuPAGE gel (Invitrogen), and bands were stained with Coomassie blue. The identity of all Mediator subunits
except Med31 could be confirmed by mass spectrometry (not shown).
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Figure 11: Destabilization of the Mediator complex.
Mediator has been purified in med19∆ background strains via a C-terminal TAP-tag on Med7 from the
middle module, Med18 from the head module and Med15 from the tail module. Copurifying proteins were
separated on a 12% NuPAGE gel (Invitrogen), and bands were stained with Coomassie blue. Using our strain
background, we did not observe loss of the middle module for Med18-TAP/med19∆ or Med15-TAP/med19∆
strains even after 1 M urea washing during purification (using 2 l yeast culture per lane). However, in a
Med7-TAP/med19∆ strain, the remaining modules are lost during purification even without urea treatment
and exclusively the middle module is purified.
3.2.2 Recombinant Mediator middle module
We previously used heterologous coexpression of physically associated Mediator subunits in
E. coli to obtain milligram quantities of Mediator subcomplexes of up to three subunits
(Baumli et al., 2005; Larivière et al., 2006, this work, see 3.1). Here, based on commer-
cial pET- and Duet-vectors (Novagen), we created poly-cistronic expression constructs with
additional ribosomal binding sites between middle module subunit open reading frames (Fig-
ure 12). For expression of a 4-subunit complex comprising Med7, 10, 21, and 31, we con-
structed a tricistronic pET21b vector encoding Med10, 7 and 21 (Figure 12B) and a pET24d
vector encoding C-terminally hexahistidine-tagged Med31. These vectors were cotransformed
into E. coli BL21(DE3) RIL cells (Stratagene) and after coexpression, the 4-subunit com-
plex could be purified (Figure 12B, Methods 2.4.2). To obtain a 6-subunit complex that
comprised also subunits Med4 and Med9, these two subunits were coexpressed separately
using a bicistronic pET21b vector. A partially purified Med4/9 heterodimer was assembled
with the pure 4-subunit complex and the resulting 6-subunit complex was purified to ho-
mogeneity. To obtain complete 7-subunit middle module, three vectors were cotransformed
into E. coli BL21(DE3) RIL cells, the tricistronic vector encoding Med10, 7 and 21, a vec-
tor encoding N-terminally hexahistidine-tagged Med31, and a vector encoding Med4, Med9,
and N-terminally StrepII-tagged Med1 (Figure 12C, Methods 2.4.2). After coexpression of
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the seven proteins from these three vectors, the 7-subunit module was purified in two steps,
including a StrepII affinity step (Figure 12C, Methods 2.4.2).
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Figure 12: Recombinant Mediator middle module.
(A) Recombinant coexpression of multisubunit protein complexes in E. coli is possible by using multicistronic
expression vectors, several compatible vectors cotransformed into E. coli, vectors with several promoters, and
combinations of these. (B) Coexpression of 4-subunit Mediator middle complex containing Med7/10/21/31
is accomplished using a tricistronic pET21 and a monocistronic pET24 vector. The dimeric Med4/9 complex
is coexpressed using a bicistronic pET21 vector. After cell-disruption and prepurification, both complexes
are assembled into the 6-subunit middle complex containing Med4/7/9/10/21/31 and purified further to
homogeneity. (C) Recombinant 7-subunit middle module consisting of Med1/4/7/9/10/21/31 is obtained by
coexpression using a tricistronic vector encoding for Med7/10/21, a monocistronic vector encoding for His6-
Med31 and a pCDFDuet vector with StrepII-tagged Med1 from MCS I and Med4/9 bicistronically expressed
from MCS II. Purification after cell disruption is performed by StrepII-affinity purification and subsequent gel
filtration.
3.2.3 Crystallization trials with middle module complexes
Recombinant middle module complexes and subcomplexes were tested in crystallization
screenings (Methods 2.2.7) when crystallization grade complexes could be purified (evalu-
ated by purity, stability and stoichiometry). Truncated variants – based on crystal structure
(Baumli et al., 2005), secondary structure predication and limited proteolysis – were gener-
ated to remove potential flexible regions and these complexes were screened for crystallization
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Table 16: Crystallization screening of recombinant Mediator middle module and its subparts.
All screens were performed at 20°C.
Complex Concentration Screen(s)a Buffer
Med7/21/31-His6 5 mg/ml Classic, Index, JBC I, JBC II,
Natrix, PEG/Ion, pH-clear
A + 5 mM DTT
Med7/10/21/31-His6 10 mg/ml Classic, Index, JBC I, Anions,
Cations
G + 5 mM DTT
Med7/10/21/31-His6 8, 7, 6 and 4 mg/ml JBC I G + 5 mM DTT
Med7/10/21/31-His6 3 and 6 mg/ml JBC I A + 5 mM DTT
Med7/10/21 (1-130)/31-His6 8 mg/ml Classic, Index, JBC I, Natrix,
PEG/Ion
A + 5 mM DTT
Med7 (1-205)/10 (8-157)/
21 (1-130)/31-His6
4 mg/ml Classic, Index, JBC I, Natrix,
PEG/Ion
A + 5 mM DTT
Med7 (1-205)/10 (41-157)/
21 (1-130)/31-His6
4 mg/ml Classic, Index, JBC I, Natrix,
PEG/Ion
A + 5 mM DTT
Med7 (1-205)/10 (68-157)/
21 (1-130)/31-His6
4 mg/ml Classic, Index, JBC I, Natrix,
PEG/Ion
A + 5 mM DTT
Med4/9 8 mg/ml Classic, Index, JBC I, Anions,
Cations, Natrix, PEG/Ion
G + 5 mM DTT
Med4 (21-284)/9 10 mg/ml Classic, Index, JBC I, JBC II,
Natrix, PEG/Ion
A + 5 mM DTT
Med4 (1-250)/9 10 mg/ml Classic, Index, JBC I, JBC II,
Natrix, PEG/Ion
A + 5 mM DTT
Med4 (21-250)/9 10 mg/ml Classic, Index, JBC I, JBC II,
Natrix, PEG/Ion, pH-clear
A + 5 mM DTT
Med4 (21-250)/9 ∆(19-63) 4 and 8 mg/ml Classic, Index, JBC I, JBC II,
Natrix, PEG/Ion
A + 5 mM TCEP
Med4/7/9/10/21/31-His6 5 mg/ml Classic, Index, JBC I, Natrix,
PEG/Ion, Anions, Cations, MPD
G + 5 mM DTT
StrepII-Med1/4/7/9/10/21/31-
His6
5 mg/ml Magic 1, Magic 2, Classic, Index A + 5 mM DTT
a Commercial screens used for 96-well plate screening were: Index, Natrix, PEG/Ion (all Hampton), Classic screen,
pH-clear, anions suite, cations suite, classic suite (all Qiagen), JB Screen Classic HTS I S and JB Screen Classic
HTS II S (both Jena Biosciences).
as well. Unfortunately, except for the Med7N/31 complex (see 3.1.1), no protein crystals were
obtained that could be confirmed and reproduced (Table 16). Notably, protein complex yield
of variants including Med7 (1-205) were considerably lower compared to variants including
Med7 (1-211).
3.2.4 Activity assay trials
We were interested in testing functionality of native and recombinant middle modules by
an activity assay. As an assay has not been described yet, we followed two approaches to
establish such an assay in vitro. We speculated that in a med19∆/MED7 -TAP strain some
middle module complexes might be spontaneously lost and prepared a nuclear extract from
that strain. However, addition of recombinant Med19 restored the majority of the tran-
scription activity but addition of neither native nor recombinant middle module increased
transcription levels in an in vitro transcription assay (not shown). We concluded that the
middle module is apparently not spontaneously lost in the nuclear extract but only during
TAP-purification. Thus, in a second approach, we tried to establish purification of a middle-
less Mediator similar as described by Baidoobonso et al. (2007). We intended to reconstitute
a complete Mediator complex by assembly with recombinant middle module plus Med19
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and test functionality in an in vitro transcription assay using a Mediator-depleted WT nu-
clear extract. A Med18-3xFLAG/med19∆/Med7-TAP yeast strain was generated (similar to
Baidoobonso et al. (2007) but with an additional TAP-tag on Med7 C-terminus), but liq-
uid cultures did not reach sufficient cell densities due to a severe flocculation phenotype. A
Med15-3xFLAG/med19∆/Med7-TAP yeast strain exhibited only a weak flocculation pheno-
type and was used for experiments to establish middle-less Mediator purification. In brief, the
supernatant of the Protein A purification step from TAP purification was purified further by
Anti-FLAG antibodies. These experiments (not shown) led to purification of FLAG-tag pu-
rified Mediator as shown by mass spectrometry, but complex purity was neither sufficient for
the intended assay nor to judge if the middle module was indeed lacking. As purification from
a Med15-3xFLAG strain yielded a very similar band pattern in SDS-PAGE analysis, FLAG
purification according to standard parameters (Methods 2.4.3) is apparently not sufficient to
be used in the intended assays.
3.2.5 Subunit stoichiometry
To investigate the subunit stoichiometry in the recombinant middle module and its subcom-
plexes, we used native MS that allows determination of molecular weights of entire protein
complexes (Heck, 2008; Sharon and Robinson, 2007). The detected masses were 191,650
± 60 Da for the complete 7-subunit middle module (191,335 Da expected), 124,760 ± 50 Da
for the 6-subunit complex (124,471 Da expected) and 75,840 ± 30 Da for the 4-subunit com-
plex (75,620 Da expected) (Figure 13 and 14A). We calculated expected masses taking into
account that the N-terminal methionines of Med4, 7, 10, 21 and 31 were lacking (Edman
sequencing data, not shown). The slightly higher experimental masses can be explained by
incomplete desolvation of the complexes (McKay et al., 2006). The MS analysis also revealed
that the 4- and 6-subunit complexes tend to dimerize. This is likely due to exposed hydropho-
bic surfaces, since addition of DMSO eliminated the dimers from the recorded MS spectra
(Figure 14B). These results reveal that only a single copy of each subunit is present in the
complexes and establish the equimolar subunit stoichiometry of the middle module.
Figure 13: Native mass spectrometry
analyses of Mediator middle module.
Shown are from top to bottom spectra of the
7-, 6-, and 4-subunit middle module com-
plexes. All individual subunits are present
in equimolar stoichiometry. The distribu-
tions are labeled accordingly to the corre-
sponding schematics. m/z4000 5000 6000
7000 8000
8000
m/z
m/z
2x 4-subunit
6-subunit
7-subunit
9 10
4
1
21
 C7 N7 31
9 10
4
12
C 7N 7 13
10
21
 7CN 7 31
4-subunit
54
Results
m/z
1500 2000 2500 3000 3500 4000 4500 5000 5500 6000 6500 7000 7500 8000 8500
Med 10
Med 10
Med 10
Med 10 4-SU
4-SU 4-SU
4-SU  4-SUdimer
 4-SU
dimer  4-SU
dimer
Med 21
Med 21
Med 7/31
 9
Med 10
Med 1
Hsp70  6-SU6-SU
Med 4/9
7-SU
 7-SU
7-SU 7-SU
 7-SU
7-SU
Med 4
Med 31
31
Med 1
Med 1
Hsp70
Med 4/9
Med 21 21
Med 10
Med 9
31
Med 47-subunit
A
B
4-subunit
m/z
2000 2500 3000 3500 4000 4500 5000 5500 6000 6500 7000 7500 8000 8500
Med 10
Hsp70
 6-SU
Med 4/9
Med 1
Med 21
Med 9
- Med 9
- Med 10
Hsp70
Med 1
Med 1
Hsp70
Hsp70Hsp70
Med 7+31
Med 7+21
Med 7+31
Med 7+21 4-SU
4-SU 4-SU 4-SU
 6-SU
 6-SU
 6-SU
 6-SU
Med 4
Med 4
Med 4
Med 4
Med 4
Med 4
- 31- 31
- 31
 6-SU
- Med 9
- Med 10 6-SU
 6-SU
 6-SU
 6-SU
Med 21
Med 9
Med 9
Med 9
Med 10
Med 10
Med 10
Med 10
Med 10
Med 21
Med 21Med 31
Med 31
Med 21
Med 21
Med 4/9
Med 4/9
I
II
7-subunit
6-subunit
4-subunit
C
10.8 14.4 18 21.6 10.8 14.4 18 21.6 msms
6-subunit7-subunit
9 10
4
1
12
 7CN 7 31
9 10
4
21
 C7 7N 31
9 4
6-SU
6-SU
6-SU
6-SU
6-SU
Hsp70
Hsp70
Med 4/9
Med 4/9
Med 4/9Med 4
Med 10
Med 10
Med 9
Med 9
Med 21
Med 4
6-SU Dimer 6-SU Dimer
6-subunit 9 4
9 10
4
12
 7C 7N 31
9 10
4
21
C 7 N7 31
10
21
 7C 7N 31
10
12
 C7 N7 31
Figure 14: Mass spectrometry analyses of Mediator middle modules.
(A) Native mass spectrometry analyses of Mediator middle modules. Shown are spectra of 4-, 6-, and 7-subunit
(SU) middle subcomplexes, respectively and of their subcomponents. All subunits are present in monomeric
stoichiometry. The composition of each complex and subcomplex has been confirmed by tandem MS. Hsp70
(DnaK) is a common contaminant in purifications, it has been confirmed by proteomics experiments that the
protein with the mass of 69 kDa is DnaK. (B) DMSO Spectra of the Mediator middle modules. Shown are
spectra of 4-, 6-, and 7-subunit middle subcomplexes, respectively and of their subcomponents. The marked
complexes and subcomplexes have been confirmed by Tandem MS experiments. (C) Drift time plots for 7-
and 6-subunit middle modules (charge state 27+ and 20+, respectively) analogous to Figure 18D.
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3.2.6 Module topology
We next investigated the topology of the middle module by MS analysis. We observed spon-
taneous dissociation of subunits and subcomplexes in the buffer used for the native MS ex-
periments. This effect could be enhanced by addition of DMSO or n-propanol (Figure 14).
Dissociation of the 7-subunit module revealed that Med1 could detach from the module sep-
arately, to result in the 6-subunit complex. Dissociation of the 6-subunit complex revealed a
dimer of Med4/9, confirming the interaction between those two subunits. Dissociation of the
4-subunit complex resulted in the trimers Med7/10/31 and Med7/21/31, and in the dimers
Med7/31 and Med7/21. Overall, Med7 never dissociated from the middle module, showing
it is an architectural subunit, whereas Med9 and Med10 were least stably attached. To fur-
ther analyze the module topology, we investigated fragmentation of the 4-, 6- and 7-subunit
complexes by tandem mass spectrometry. Generally consistent with solution dissociation
experiments, Med9 and Med10 readily dissociated from the complexes, whereas Med7 never
did, except to a low extend when the complete middle module was used. Taken together, the
dissociation and fragmentation experiments are consistent with earlier structural and interac-
tion analysis of the middle module and the existence of heterodimers Med7N/31, Med7C/21,
and Med4/9 within intact middle module (Baumli et al., 2005; Guglielmi et al., 2004, this
work, see 3.1).
3.2.7 Exposed regions in the middle module
To detect exposed and flexible protein regions, middle module complexes were subjected
to limited proteolysis using chymotrypsin (Methods 2.2.6). In an attempt to separate stable
fragments, we stopped proteolysis by addition of protease inhibitor at certain time points, and
subjected the samples to gel filtration. Peak fractions were TCA-precipitated and analyzed
by SDS-PAGE and Edman sequencing (Figure 13). This approach could identify stable
subcomplexes suitable for crystallization, like Med7N/31 and Med7C/21, which result from
proteolysis of a Med7/21/31 trimer (Figure 16A) (Baumli et al., 2005, this work, see 3.1).
Limited proteolysis of the 4-subunit complex revealed protease cleavage within regions
predicted to form flexible loops, but also cleavage in some helical regions of Med21 (known
structure) and Med10 (predicted) (Figure 16B, and C). Two subcomplexes were detected
based on Med7N/31 and Med7C/21 that both contain N-terminally truncated Med10 (Fig-
ure 16C). Proteolysis of the 6-subunit complex also revealed Med7C/21 and Med7N/31 in
different gel filtration fractions, but now associated with different truncated variants of Med10
(Figure 16D). Consistently, native MS analysis of an early 7-subunit complex preparation re-
vealed an intact middle module with a truncated form of Med10 that lacked 66 N-terminal
residues (not shown). Med9 showed only one chymotrypsin cleavage site and was detected
either as full-length subunit (star in Figure 16D) or as an N-terminally shortened variant
(star and triangle peak in Figure 16D). Med4 was cleaved at multiple sites, but preferentially
from the C-terminus.
This analysis supports a submodular architecture of the middle module based on the
Med7N/31 and Med7C/21 core subcomplexes connected via a flexible Med7 linker. Med4,
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9, and 10 are associated with both core subcomplexes, but their proteolytic fragments were
not sufficient to hold these subcomplexes together. The C-terminal region of Med4, the
N-terminal region of Med9, and the N-terminal region of Med10 are not stably bound to
the core subcomplexes and may be involved in contacts with other Mediator modules or ex-
ternal factors. Consistently, yeast complementation assays revealed that the flexible Med4
C-terminal residues 194-250 are required for viability, whereas the N-terminal residues 1-66
are not (Figure 15).
pRS315/MED4(67-284)
pRS315
pRS315/MED4(1-284)
YPD 5-FOA
pRS315/MED4(67-250)
pRS315/MED4(67-193)
Figure 15: Yeast complementation assay for
MED4
Plasmids encoding full-length MED4 or N- and C-
terminal truncations ofMED4 were cloned into the
SalI/NotI restrictions sites of a pRS315 vector. In-
dividual plasmids were transformed into a MED4
shuﬄe strain (EuroScarf Y22430 sporulated; MATa
or MATα; YOR174W::kanMX4/ pRS316-MED4 )
and streaked onto 5-FOA-containing plates to
shuﬄe out the MED4 encoding URA3 plasmid.
Yeast cells carrying only MED4 (67-250) are vi-
able, whereas the Med4 C-terminal part including
residues 193-250 was required to rescue cell growth.
3.2.8 Intra-module subunit interactions
To further elucidate the subunit interactions within the middle module, we used coexpres-
sion pull-down experiments (Figure 17A and Table 17). Our biochemical analysis generally
confirmed previous subunit interactions based on yeast two hybrid (Y2H) assays and im-
munoprecipitation (Guglielmi et al., 2004), but additionally allowed us to distinguish weak
and strong subunit interactions, and to detect interaction domain boundaries (Figure 17B,
C). Important findings from this analysis were the following. First, Med7N/31 neither bound
Med7C/21 nor Med4/9. For interaction of Med4/9 to any Med7-containing complex, the
Med7 linker between Med7N and Med7C was required. Second, the Med4/9 heterodimer
binds to Med1. Med4/9 heterodimer formation neither required the 18 N-terminal residues
of Med4 nor the predicted loop in Med9 comprising residues 19-63, consistent with the prior
observation that Med9 contains two domains (compare Takahashi et al., 2009). Third, Med10
and Med4 interacted weakly and Med21 stabilized this interaction. The C-terminal part of
Med10 was sufficient for binding the Med7C/21 subcomplex. Med10 was also found to stably
bind to Med14, confirming previous data (Guglielmi et al., 2004) and showing that Med14 (1-
259) is sufficient to establish a connection of middle module towards Mediator tail module.
Finally, reported Y2H interactions between Med21 and Med31 were not confirmed. Stable
expression of Med9 always required coexpression with Med4, but was not possible with Med1
or Med7, suggesting that Med9 has no direct interaction with these. Together with published
data, this analysis establishes the middle module subunit interaction network (Figure 17C).
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Figure 16: Limited proteolysis analysis of Mediator middle module.
(A) Recombinant complexes were subjected to limited proteolysis by chymotrypsin after identifying suitable
digestion durations using time courses. The samples were subjected to gel filtration, the eluting peaks pre-
cipitated by TCA, fractions separated on SDS-PAGE and subjected to Edman sequencing. (B) Secondary
structures and secondary structure predictions for yeast middle module subunits. Multiple sequence align-
ments were used whenever possible. Given are consensus predictions by HHpred (Soeding et al., 2005), I-Tasser
(Zhang, 2008), PSIpred (Jones, 1999) and CDM (Sen et al., 2006). (C) Schematic diagram of limited prote-
olysis of Med7/10/21/31 using chymotrypsin, analogous to (A). The chromatogram of undigested complex is
indicated by the black curve. Proteolytic cleavage sites are indicated above the protein cleavage schemes in
dark blue (sequenced) and light blue (estimated from SDS-PAGE). Ambiguous C-terminal sites are marked
with a tilde. In cases in which more than one N-terminus was sequenced, the alternative N-terminal cleavage
sites are marked additionally. (D) Schematic diagram of limited proteolysis results for the Med4/7/9/10/21/31
complex using chymotrypsin, analogous to (C).
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Table 17: Mediator middle module interaction assaysa.
Subunit 1 Subunit 2 Subunit 3 Subunit 4 Technique Reference
Med7 (101-222) Med21 flb – – Structure Baumli et al. (2005)
Med4 fl Med21-His6 fl – – Gel filtration Baumli et al. (2005)
Med10 fl Med21-His6 fl – – Gel filtration Baumli et al. (2005)
Med4-His6 fl Med21 fl Med7 – Gel filtration Baumli et al. (2005)
Med7 (1-83) Med31 fl – – Structure This work
StrepII-Med7
(1-101)
Med31-His6 Med4 fl Med9 fl Coexpr. &
pull-down
This work
StrepII-Med7
(1-84)
Med31-His6 Med4 fl Med9 fl Coexpr. &
pull-down
This work
StrepII-Med7
(1-84)
Med31 fl Med7 Med21 fl Coexpr. &
pull-down
This work
StrepII-Med14
(1-259)
Med10 fl – – Coexpr. &
pull-down
This work
StrepII-Med14
(1-259)
Med4 fl Med9 fl – Coexpr. &
pull-down
This work
Med21-His6 fl Med7 (104-222) Med10 (74-157) – Coexpr. &
pull-down
This work
Med10-His6 Med4* – – Coexpr. &
pull-down
This work
Med10-His6 Med4 fl* Med9 fl* – Coexpr. &
pull-down
This work
StrepII-
Med1 fl
Med4 fl Med9 fl – Coexpr. &
pull-down
This work
StrepII-
Med1 fl
Med14 (1-259)* – – Coexpr. &
pull-down
This work
StrepII-
Med1 fl
Med14 (1-259)* Med10 fl* – Coexpr. &
pull-down
This work
StrepII-
Med1 fl
Med14 (1-259) Med10 (1-73) – Coexpr. &
pull-down
This work
StrepII-
Med1 fl
Med14 (1-259) Med10 (74-157) – Coexpr. &
pull-down
This work
Med31-His6 Med7 (1-84) Med10 fl – Coexpr. &
pull-down
This work
His6-Med9 fl Med4 (19-250) – – Coexpr. &
pull-down
This work
His6-Med9
∆(19-63)
Med4 fl – – Coexpr. &
pull-down
This work
a Bold letter indicated the protein purification tags which have been used in the assay. Red subunits were not de-
tected in pull-down experiments. Weak interactions are indicated by a star. b full-length
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Figure 17: Intramolecular interactions within the middle module.
(A) Middle module subunits and subcomplexes were tested for interaction with other middle module subunits
or subcomplexes by coexpression and subsequent copurification pull-down assays. (B) Mediator middle module
interaction map based on previously published (Guglielmi et al., 2004) yeast-two-hybrid (Y2H) assays and
structural data (Baumli et al., 2005, this work, see 3.1). The length of truncated subunit variants that gave
interactions with its partner, are indicated closely to the molecules. Interactions based only on single Y2H
clones are indicated by a star. (C) Mediator middle module interaction map based on coexpression and
copurifications. The map integrates published data (Baumli et al., 2005, this work, see 3.1) with the findings
depicted in Figure 12B, C, 17A and Table 17. As coexpression and copurification was required to obtain
stable complexes, connections to more than one partner are indicated for some proteins. Weak interactions
are indicated by a star.
3.2.9 Module shape
To investigate the overall shape of the middle module in solution we used light scattering
and SAXS. Static light scattering analysis of the 6-subunit complex revealed a hydrodynamic
radius of 66 Å, 34% larger than that of Med7C/21, which exists as a heterotetramer in
solution (compare Table 18). SAXS analysis showed that the 6-subunit middle module was
partially aggregated at the high concentrations required for the analysis (Figure 18A and
Table 18). Thus we could not reliably determine the radius of gyration and could not calculate
low-resolution structural models. Nevertheless, the scattering curve shows clearly that the
middle module exhibits an elongated shape (compare Volkov and Svergun, 2003, Figure 1,
e.g. model body 10). The Kratky-plot further indicates that the protein complex is folded
and consists of a few globular areas (Figure 18B). Unfortunately, analysis of the 7-subunit
middle module by SAXS was hampered by susceptibility of the Med1 subunit to degradation
and difficulties in complex concentration.
To add support to the results obtained in solution, we used ion mobility (IM) MS analysis.
IM-MS can provide the collisional cross section (CCS), which corresponds to an averaged
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Table 18: Static light scattering (SLS) and Small-angle X-ray scattering (SAXS) measurements.
Tech-
nique
Sample RHa
(nm)
RGb
(nm)
Dim.c
(nm)
MWDd
(kDa)
MWTe
(kDa)
Oligomeric
state
Conc.
(mg/ml)
SLS Med7C/21 4.9 - 11.1 x 3.0
x 3.0
60 32 Hetero-
tetramer
1.8
SLS Med7N/31 2.6 - 4.0 x 4.5 30 27 Hetero-
dimer
1
SLS Med4/7/9/
10/21/31
6.6 - - 130 125 Hetero-
hexamer
1
SAXS Med4/7/9/
10/21/31
- 6.6 - (607) 125 - 5
a Hydrodynamic radius b Radius of gyration cDimensions from X-ray structure
dDetermined molecular weight e Theoretical molecular weight
lateral cut through the protein (Uetrecht et al., 2008). We applied IM-MS to the three
recombinant Mediator middle module complexes (Figure 18C). Calculation of calibrated CCS
revealed conformational flexibility in all complexes, consistent with our inability to crystallize
any of these complexes and published in silico analysis data (Tóth-Petróczy et al., 2008).
This becomes more clear even when looking at an averaged drift time analysis (Figure 18D
and Figure 14C). Compared to standard proteins of similar mass (Konarev et al., 2006),
the most abundant conformations for the 4- and 6-subunit complexes represented extended
structures. The conformation of the complete 7-subunit middle module was, however, more
compact (Figure 18C). The average calculated densities for the 4-, 6- and 7-subunit complexes
were 0.48, 0.50 and 0.56 g/cm3 respectively. Thus, three different experimental methods are
consistent with an elongated shape of the middle module, which is further consistent with
published cryo-electron microscopic data (Cai et al., 2009; Elmlund et al., 2006; Knuesel
et al., 2009).
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Figure 18: Shape of the middle module.
(A) The experimental SAXS curve of 6-subunit Mediator middle module indicates an elongated protein com-
plex. I0 signal intensity in comparison with the BSA standard measurement suggested a molecular weight of
the complex far above the theoretical weight. Therefore, the Guinier radius could not be reliably determined
and useful models could not be calculated. (B) The corresponding Kratky-plot shows no classical bell-shape,
but is stretched towards higher scattering angles. The complex is nevertheless folded and the plot indicates a
multidomain architecture with flexible linkers. (C) Ion mobility MS experiments. Plotted are the calibrated
collision cross sections (CCS) of the single subunits and (sub-)complexes. The graph indicates a general trend
of CCS versus mass for globular proteins (determined both experimentally (Uetrecht et al., 2008) and derived
from globular structures deposited in the PDB http://www.rcsb.org). The graph extends up to a mass of
801 kDa and a CCS of 229 nm2. Only the section relevant for the Mediator complexes is shown. The color
coding is: grey – Med21, cyan – Med9, orange – Med10, brown – Med4, dark green – Med4/7, dark blue
– Med1, blue – 4-subunit middle, red – 6-subunit middle, purple – 7-subunit middle. (D) Flexibility of the
Mediator middle module. From IM-MS measurements, we generated the averaged drift time plot (in ms) for
the 4-subunit Mediator middle (charge 16+) (shown in black). Using the Drift Scope software (Waters, UK),
we extracted the different conformations that contribute to the averaged drift time plot. We can detect up to
six conformations that make up this charge state of the 4-subunit Mediator middle in the gas phase, thereby
reflecting the flexibility of the Mediator middle module.
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4 Discussion
Understanding the mechanisms that eukaryotes use to regulate gene transcription through
Mediator on a molecular level requires a detailed analysis of its four multisubunit modules,
for which only a few partial substructures are available. Previous work in the laboratory by
Sonja Baumli focusing on the Mediator middle module from Saccharomyces cerevisiae was
continued and both structural and functional information on this module and its subparts
obtained. Structural investigations require large and very pure amounts of protein, which
can only be achieved by recombinant expression, or by recombinant coexpression which is
generally advantageous or even required for protein complexes. Recombinant expression
and purification of the Mediator middle module enabled here the detailed investigation of
the middle module topology and its functional substructures. The established coexpression
strategies may also be valuable for the preparation of other large and flexible multiprotein
complexes by coexpression in E. coli.
4.1 The Med7N/31 submodule
First, our limited proteolysis experiments of the trimeric Med7/21/31 subcomplex led to the
identification and characterization of a functional substructure of the middle module – the
Med7N/31 submodule. Med31 was initially called Soh1 as it was found in a S. cerevisiae
screen for suppressors of a hyper-recombination phenotype caused by Hpr1 deletion (Fan
and Klein, 1994), and was later described as a Mediator subunit (Gu et al., 1999; Boube
et al., 2000; Park et al., 2001a; Gu et al., 2002; Guglielmi et al., 2004; Linder and Gustafsson,
2004)4; Park et al, 2001). Med31 is one of the best conserved Mediator subunits and shows
28% sequence identity between yeast and human, but is not essential for yeast viability (Fan
and Klein, 1994). Med31 is required for telomere maintenance (Askree et al., 2004), DNA
repair (Fan and Klein, 1994), meiotic DNA processing (Jordan et al., 2007) and transposition
(Nyswaner et al., 2008). The Med31 orthologue in Drosophila is a maternal-effect gene for
segment specification during early Drosophila embryogenesis (Bosveld et al., 2008).
Here, we describe the Med31 atomic structure, its interaction with the Med7N domain, and
the functional analysis in vitro and in vivo on the transcriptome level of the highly conserved
Med7N/31 subcomplex. The Med7N/31 structure exhibits a novel fold, and together with
the previously determined Med7C/21 structure unravels the highly unusual overall structure
of Med7 (Figure 19). Med7N forms a non-essential tether for the compact peripheral Med31
subunit and is flexibly linked to Med7C, which forms an extended essential heterodimer with
Med21 (Figure 19). Other Mediator subunits may also show such an extended, modular,
and astonishing architecture. Intriguing features of the Med7N/31 structure are the two con-
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served proline-rich stretches of Med7N that bind Med31. The similarity of these stretches
to the proline-rich CTD of RNA Pol II suggests that the CTD may dynamically replace
one or both stretches and bind Med31. The Med7N stretches may also detach from Med31
and bind factors that comprise a domain that recognizes polyproline peptides, such as WW,
SH3, and GYF domains (Macias et al., 2002; Hesselberth et al., 2006; Kofler and Freund,
2006), or a proline isomerase. pPS1 contains the PPxY motif that can be bound by certain
WW domains (Espanel and Sudol, 2001). Finally, proline-rich activators could replace one
or both Med7N stretches and bind to Med31. However, individual insolubility of recombi-
nant Med31 and Med7N hampered a biochemical investigation of these models. The high
conservation of Med31 may reflect the putative CTD interaction, but may also stem from an
alternative interaction with the polymerase or other factors. A subsequent structure-based
functional analysis investigated the cooperation of Med7N/31 with TFIIS during activated
transcription, and established the subcomplex as a predominantly positive gene-regulatory
submodule at the periphery of the essential middle module of Mediator. A combination of
transcriptome analysis and phenotyping assays revealed the processes that are affected by
a lack of intact Med7N/31, including methionine metabolism and siderophore transporter
synthesis. Med7N/31 also has a role in the regulation of conjugation genes, similar to the
head submodule Med8C/18/20, and in contrast to the Mediator tail subunits Med2 and
Med3. Distinct phenotypes and mRNA levels were observed for mutants that do not contain
an intact Med7N/31 submodule, consistent with the idea that there are gene-specific and
overlapping functions associated with different Mediator submodules. The observed overlaps
in phenotyping assays and in the GO analysis of differential transcriptome data show that
metabolic sensing, stress response, and certain amino-acid biosynthesis pathways are gener-
ally affected by deletion of different Mediator submodules. At present it remains difficult
to decipher the cis-elements and trans-acting factors that underlie the observed changes in
gene expression. However, we provide evidence that Met28 and Msn4 are important tran-
scription factors involved in Med7N/31-mediated gene regulation. Msn4 is downregulated
upon Med7N/31 deletion (this study) and functions in stress response (Gasch et al., 2000;
Causton et al., 2001). Met28 is downregulated upon Med7N/31 deletion but upregulated
upon Med2/3 deletion, explaining the observed down- and upregulations in methionine and
cysteine metabolism, respectively, as a secondary effect. Differently expressed genes were also
often found to contain binding sites for Yap family transcription factors that regulate stress
response (Fernandes et al., 1997). In the future, factors may be identified that use Med7N/31
as a target for gene regulation.
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Figure 19: Structural overview of the trimeric
Med7/21/31 complex architecture.
Structures of the non-essential Med7N/31 submodule (this work)
and the previously described essential Med7C/21 subcomplex are
drawn to scale.
4.2 Mediator middle module topology
We developed and describe protocols for obtaining pure endogenous and recombinant com-
plete Mediator middle module from Saccharomyces cerevisiae consisting of seven subunits,
Med1, 4, 7, 9, 10, 21, and 31. We confirmed the subunit composition of the complete en-
dogenous S. cerevisiae middle module, after its purification from a med19∆ yeast strain. We
have used the defined middle complex preparations and its 4- and 6-subunit subcomplexes in
various biophysical assays to determine the subunit stoichiometry, subunit interactions, and
the elongated shape of the complex. Crystallization of other or larger middle module com-
plexes than the Med7N/31 or Med7C/21 was not successful, but likely explanations for this
observation became evident from our studies of the middle module topology. We found by
native MS analysis, that in our preparations all subunits are present as single copies, exclud-
ing over- or understoichiometry. Light and X-ray scattering as well as IM-MS suggest that
the 6-subunit middle module has an elongated shape. Similarly, as shown for the Med7C/21
subcomplex, this indicated an increased flexibility which is generally known to interfere with
crystallization. Interestingly, our later analysis found that the complete 7-subunit middle
module is more compact. A third feature known to interfere with crystallization are exposed,
flexible regions. Such regions were identified within the middle module (except for the Med1
subunit) and truncated middle module variants tested in crystallization screening, especially
for the 4-subunit middle module. However, detailed analysis of the subunit-subunit inter-
action network within the middle module revealed that Med7 and Med4 subunits interact
via the linker between Med7N and Med7C. Our interaction data validate most subunit con-
tacts mapped by yeast-two hybrid analysis (Guglielmi et al., 2004) but also identify a few
false positives and reveal new details about subunit interactions. Our proteolysis, interaction
experiments, and MS data all suggest that Med7 and Med4 serve as a binding platform to
form three stable heterodimers, Med7N/31, Med7C/21 and Med4/9. Thus, crystallization of
a 4-subunit middle module complex comprising only Med7/10/21/31 seems improbable. The
Med4/9 subcomplex was obtained in large and pure quantities. Flexible regions at the Med4
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C-terminus and a large loop within the Med9 N-terminal part were removed, but even after
these truncations no crystals were obtained. Interestingly, Med1 and Med10 both bridge be-
tween the heterodimers Med7C/21 and Med4/9, suggesting that the 6-subunit or 7-subunit
middle module preparation could be more suitable for crystallization. This would also reduce
exposed hydrophobic surfaces compared to only partial middle module complexes. However,
as we did not obtain any crystals of these complexes either, we believe that intrinsic flex-
ibilities have thus far impeded crystallization of the middle module. Nevertheless, as the
7-subunit middle module is generally more compact, future crystallization trials could focus
on this complex.
In order to understand how Mediator integrates regulatory signals and how it enables
activated transcription, we aimed at establishing an assay by which the activity of the essential
Mediator middle module and its parts could be elucidated. Despite extensive efforts, we were
however unable to test the functionality of the middle module in vitro. Although initial
steps have been taken, establishing such an in vitro assay for middle module-dependent
activated transcription will thus remain a future goal. Analysis of mutations in vivo using
yeast complementation assays turned out to be fruitful in general as shown for Med7 and
Med4. However, such complementation studies with Med14 and Med10 showed that this assay
is not universally suited. In this respect Med14 (1-745) could not complement in a med14
shuﬄe strain with a BY strain background although equivalent to the med14∆2 strain which
is viable and in which the complete Mediator tail module is lost (Li et al., 1995). Similarly,
Med10 (1-123) did not complement in a med10 BY background shuﬄe strain, which was
equivalent of the EWE5 strain (nut2 -1002) (Singh et al., 2006). It is possible, that the
domain boundaries for viability need to be refined for the BY background. Additionally, the
frame-shift mutation in the med14∆2 strain may have some stabilizing effect. On the other
hand, we sporulated the med10 shuﬄe strain, which had been transformed with a Med10 (1-
123) encoding plasmid and dissected tetrades. Viability statistics of the resulting spores
showed that Med10 (1-123) could complement in this assay, indicating that the previous
assay observation more likely resulted from too harsh conditions through 5-FOA selection.
Thus, future work will be required to further elucidate the activity of the essential Mediator
middle module and its parts both in vitro and in vivo.
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5 Conclusion and Outlook
During this thesis protocols were established for obtaining pure endogenous and recombinant
complete Mediator middle module from Saccharomyces cerevisiae. Extension of previous
structural and functional analyses of Mediator subcomplexes (Baumli et al., 2005; Hoeppner
et al., 2005; Larivière et al., 2006, 2008) led to the identification, structure, and in vitro and
in vivo functional analyses of the highly conserved Med7N/31 subcomplex which is formed by
the N-terminal region of Med7 (Med7N) and Med31. A combination of biochemistry, X-ray
crystallography, yeast phenotyping, and transcriptome analysis established Med7N/31 as a
structurally and functionally distinct submodule that is required for activated transcription.
Furthermore, the middle module topology was investigated in detail revealing many physical
properties including stoichiometry, subunit-subunit interactions and molecular shape. By
applying a number of experimental techniques such as mass spectroscopy, limited proteolysis,
coexpression & pull-down assays, light scattering and small angle X-ray scattering analyses,
a new model for the middle module topology was put forward and its high intrinsic flexibility
revealed experimentally for the first time.
Future goals include the following:
1. Crystallization and structure solution of larger middle module complexes.
Crystallization trials could focus on the complete 7-subunit middle module as it was
found to be more compact than for example 4- or 6-subunit middle module complexes.
A drawback with this complex, however, is the stability of Med1. Exposed regions in
this subunit could be identified as well using approaches described in this work and sta-
bility be increased upon removal of these regions. The results obtained by the topology
investigation could then guide further experiments and crystallization may become fea-
sible. However, it may be required to first obtain additional lower resolution structural
information of the middle module. While cryo-EM microscopy was not possible mainly
due to the limited size of the middle module, small-angle scattering analysis should be
highly informative if the described obstacles can be overcome. Especially, comparison
of the different recombinant middle module complexes may give interesting insights.
2. Extension of the complete middle module towards larger recombinant assemblies.
Extension of the recombinant middle module towards the tail module seems possible as
it was found that the Med10 N-terminus is flexible and exposed, but likely involved in
binding Med14. Apparently due to its large size, recombinant expression of Med14 in
E. coli was only possible with a shortened variant comprising residues 1 to 259. It has
been suggested that Med14 could be bipartite middle and tail subunit that bridges the
tail, middle and head modules (Baidoobonso et al., 2007). Therefore future investiga-
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tion could focus on this subunit, possibly after recombinant expression using another
expression system like Baculovirus. Strikingly, we did not yet succeed in assembling
recombinant middle and head module complexes, which might also enable cryo-EM
analysis of recombinant complexes.
3. Establishing an in vitro, middle module-dependent, activated transcription assay to
evaluate functionality of the middle module or variants.
Establishing such an assay was mainly hampered by difficulties in obtaining pure,
middle-less Mediator complex. To overcome this problem, the purification strategy
must be improved. For instance high-salt washing steps could be suited as Mediator
complex is known to tolerate even some urea washing (Kang et al., 2001; Baidoobonso
et al., 2007). Alternatively, additional purification steps using other principles such
as ion exchange or heparin affinity purification may be required. Once this assay is
successfully established for the complete middle module, partial assemblies as well as
mutants such as the EWE mutations (Singh et al., 2006) could be tested in transcription
activation.
4. Analysis of interactions of the middle module with activators, cofactors and the general
transcription machinery.
A number of interactions of the middle module with external factors has been suggested
(compare BioGrid database), but in most cases it needs to be still proven that these
interactions are direct. For instance we did not find a direct interaction of the middle
module with Gal4-VP16 by bandshift analysis or with TFIIS by pull-down assays (this
study) or with TFIIB by bandshift analysis (Baumli (2005)), nor stable assembly with
RNA Pol II. In the latter case, triggering CTD binding, possibly as suggested via our
model with Med31, might be a prerequisite, but interactions required for PIC assembly
may be cooperative in nature and therefore difficult to detect. Immobilized template
assays combined with both nuclear extracts and purified factors may resolve these issues
and clarify the order of events.
5. Identification of regulatory factors that govern gene regulation through Mediator sub-
modules and modeling of regulatory networks.
To reveal the underlying regulatory networks of gene regulation and how information
is transmitted through the Mediator complex will remain a long term goal. On the
submodule level, our analyses revealed already both specific and overlapping functional
requirements. Gene expression information about the function of essential Mediator
subunits or submodules can be achieved through analysis of point mutation strains
such as the EWE strains. In silico correlation allows in general identification of regu-
latory factors as shown for the Med7N/31 submodule here. But to dissect direct and
indirect regulations as well as reveal the hierarchy of the regulatory factors, is a chal-
lenge, and may only be overcome by extensive analysis of those regulatory factors and
its targets both on single promoter level and at the genome-wide scale.
68
Bibliography
Bibliography
P. D. Adams, R. W. Grosse-Kunstleve, L. W. Hung, T. R. Ioerger, A. J. McCoy, N. W. Mori-
arty, R. J. Read, J. C. Sacchettini, N. K. Sauter, and T. C. Terwilliger. PHENIX: building
new software for automated crystallographic structure determination. Acta Crystallogr D
Biol Crystallogr, 58(Pt 11):1948–1954, Nov 2002.
A. A. Adzhubei and M. J. Sternberg. Left-handed polyproline II helices commonly occur in
globular proteins. J Mol Biol, 229(2):472–93, 1993.
A. Alexa, J. Rahnenfuhrer, and T. Lengauer. Improved scoring of functional groups from
gene expression data by decorrelating GO graph structure. Bioinformatics, 22(13):1600–7,
2006.
J.-C. Andrau, L. van de Pasch, P. Lijnzaad, T. Bijma, M. G. Koerkamp, J. van de Peppel,
M. Werner, and F. C. P. Holstege. Genome-wide location of the coactivator mediator:
Binding without activation and transient Cdk8 interaction on DNA. Mol Cell, 22(2):179–
192, Apr 2006.
S. H. Askree, T. Yehuda, S. Smolikov, R. Gurevich, J. Hawk, C. Coker, A. Krauskopf,
M. Kupiec, and M. J. McEachern. A genome-wide screen for Saccharomyces cerevisiae
deletion mutants that affect telomere length. Proc Natl Acad Sci U S A, 101(23):8658–
8663, Jun 2004.
F. J. Asturias, Y. W. Jiang, L. C. Myers, C. M. Gustafsson, and R. D. Kornberg. Conserved
structures of mediator and RNA polymerase II holoenzyme. Science, 283(5404):985–987,
Feb 1999.
D. T. Auble. The dynamic personality of TATA-binding protein. Trends Biochem Sci, 34(2):
49–52, Feb 2009.
H. J. Baek, Y. K. Kang, and R. G. Roeder. Human Mediator enhances basal transcription by
facilitating recruitment of transcription factor IIB during preinitiation complex assembly.
J Biol Chem, 281(22):15172–15181, Jun 2006.
S. M. Baidoobonso, B. W. Guidi, and L. C. Myers. Med19(Rox3) regulates Intermodule
interactions in the Saccharomyces cerevisiae mediator complex. J Biol Chem, 282(8):5551–
5559, Feb 2007.
A. D. Basehoar, S. J. Zanton, and B. F. Pugh. Identification and distinct regulation of yeast
TATA box-containing genes. Cell, 116(5):699–709, Mar 2004.
A. Baudin, O. Ozier-Kalogeropoulos, A. Denouel, F. Lacroute, and C. Cullin. A simple and
efficient method for direct gene deletion in Saccharomyces cerevisiae. Nucleic Acids Res,
21(14):3329–3330, Jul 1993.
69
Bibliography
S. Baumli. Structure of the MED7/MED21 heterodimer and reconstitution of a recombinant
Mediator middle module complex. PhD thesis, University of Munich, 2005.
S. Baumli, S. Hoeppner, and P. Cramer. A conserved mediator hinge revealed in the structure
of the MED7.MED21 (Med7.Srb7) heterodimer. J Biol Chem, 280(18):18171–18178, May
2005.
S. Bäckström, N. Elfving, R. Nilsson, G. Wingsle, and S. Björklund. Purification of a Plant
Mediator from Arabidopsis thaliana Identifies PFT1 as the Med25 Subunit. Mol Cell, 26
(5):717–729, Jun 2007.
D. Bentley. The mRNA assembly line: transcription and processing machines in the same
factory. Curr Opin Cell Biol, 14(3):336–342, Jun 2002.
S. R. Bhaumik, T. Raha, D. P. Aiello, and M. R. Green. In vivo target of a transcriptional
activator revealed by fluorescence resonance energy transfer. Genes Dev, 18(3):333–343,
Feb 2004.
L. T. Bhoite, Y. Yu, and D. J. Stillman. The Swi5 activator recruits the Mediator complex
to the HO promoter without RNA polymerase II. Genes Dev, 15(18):2457–2469, Sep 2001.
R. Biddick and E. T. Young. Yeast mediator and its role in transcriptional regulation. C R
Biol, 328(9):773–782, Sep 2005.
R. Biddick and E. T. Young. The disorderly study of ordered recruitment. Yeast, 26(4):
205–220, Apr 2009.
A. Biegert, C. Mayer, M. Remmert, J. Söding, and A. N. Lupas. The MPI Bioinformatics
Toolkit for protein sequence analysis. Nucleic Acids Res, 34(Web Server issue):W335–
W339, Jul 2006. URL http://toolkit.lmb.uni-muenchen.de/.
J. C. Black, J. E. Choi, S. R. Lombardo, and M. Carey. A mechanism for coordinating
chromatin modification and preinitiation complex assembly. Mol Cell, 23(6):809–818, Sep
2006.
E. Blazek, G. Mittler, and M. Meisterernst. The mediator of RNA polymerase II. Chromo-
soma, 113(8):399–408, Mar 2005.
T. Borggrefe, R. Davis, H. Erdjument-Bromage, P. Tempst, and R. D. Kornberg. A complex
of the Srb8, -9, -10, and -11 transcriptional regulatory proteins from yeast. J Biol Chem,
277(46):44202–44207, Nov 2002.
F. Bosveld, S. van Hoek, and O. C. M. Sibon. Establishment of cell fate during early
Drosophila embryogenesis requires transcriptional Mediator subunit dMED31. Dev Biol,
313(2):802–813, Jan 2008.
M. Boube, C. Faucher, L. Joulia, D. L. Cribbs, and H. M. Bourbon. Drosophila homologs of
transcriptional mediator complex subunits are required for adult cell and segment identity
specification. Genes Dev, 14(22):2906–2917, Nov 2000.
M. Boube, L. Joulia, D. L. Cribbs, and H.-M. Bourbon. Evidence for a mediator of RNA
polymerase II transcriptional regulation conserved from yeast to man. Cell, 110(2):143–151,
Jul 2002.
70
Bibliography
H.-M. Bourbon. Comparative genomics supports a deep evolutionary origin for the large,
four-module transcriptional mediator complex. Nucleic Acids Res, 36(12):3993–4008, Jul
2008.
H.-M. Bourbon, A. Aguilera, A. Z. Ansari, F. J. Asturias, A. J. Berk, S. Bjorklund, T. K.
Blackwell, T. Borggrefe, M. Carey, M. Carlson, J. W. Conaway, R. C. Conaway, S. W.
Emmons, J. D. Fondell, L. P. Freedman, T. Fukasawa, C. M. Gustafsson, M. Han, X. He,
P. K. Herman, A. G. Hinnebusch, S. Holmberg, F. C. Holstege, J. A. Jaehning, Y.-J. Kim,
L. Kuras, A. Leutz, J. T. Lis, M. Meisterernest, A. M. Naar, K. Nasmyth, J. D. Parvin,
M. Ptashne, D. Reinberg, H. Ronne, I. Sadowski, H. Sakurai, M. Sipiczki, P. W. Sternberg,
D. J. Stillman, R. Strich, K. Struhl, J. Q. Svejstrup, S. Tuck, F. Winston, R. G. Roeder,
and R. D. Kornberg. A unified nomenclature for protein subunits of mediator complexes
linking transcriptional regulators to RNA polymerase II. Mol Cell, 14(5):553–557, Jun
2004.
M. M. Bradford. A rapid and sensitive method for the quantitation of microgram quantities
of protein utilizing the principle of protein-dye binding. Anal Biochem, 72:248–254, May
1976.
B. J. Breitkreutz, C. Stark, and M. Tyers. Osprey: a network visualization system. Genome
Biol, 4(3):R22, 2003.
A. T. Brünger, P. D. Adams, G. M. Clore, W. L. DeLano, P. Gros, R. W. Grosse-Kunstleve,
J. S. Jiang, J. Kuszewski, M. Nilges, N. S. Pannu, R. J. Read, L. M. Rice, T. Simonson, and
G. L. Warren. Crystallography & NMR system: A new software suite for macromolecular
structure determination. Acta Crystallogr D Biol Crystallogr, 54(Pt 5):905–921, Sep 1998.
G. O. Bryant and M. Ptashne. Independent recruitment in vivo by Gal4 of two complexes
required for transcription. Mol Cell, 11(5):1301–1309, May 2003.
N. Budisa, B. Steipe, P. Demange, C. Eckerskorn, J. Kellermann, and R. Huber. High-level
biosynthetic substitution of methionine in proteins by its analogs 2-aminohexanoic acid,
selenomethionine, telluromethionine and ethionine in Escherichia coli. Eur J Biochem, 230
(2):788–96, 1995.
J. Béve, G.-Z. Hu, L. C. Myers, D. Balciunas, O. Werngren, K. Hultenby, R. Wibom,
H. Ronne, and C. M. Gustafsson. The structural and functional role of Med5 in the
yeast Mediator tail module. J Biol Chem, 280(50):41366–41372, Dec 2005.
G. Cai, T. Imasaki, Y. Takagi, and F. J. Asturias. Mediator structural conservation and
implications for the regulation mechanism. Structure, 17(4):559–567, Apr 2009.
B. R. Cairns. The logic of chromatin architecture and remodelling at promoters. Nature, 461
(7261):193–198, Sep 2009.
E. A. Campbell, L. F. Westblade, and S. A. Darst. Regulation of bacterial RNA polymerase
sigma factor activity: a structural perspective. Curr Opin Microbiol, 11(2):121–127, Apr
2008.
71
Bibliography
G. T. Cantin, J. L. Stevens, and A. J. Berk. Activation domain-mediator interactions promote
transcription preinitiation complex assembly on promoter DNA. Proc Natl Acad Sci U S
A, 100(21):12003–12008, Oct 2003.
M. Carey, J. Leatherwood, and M. Ptashne. A potent GAL4 derivative activates transcription
at a distance in vitro. Science, 247(4943):710–712, Feb 1990.
H. C. Causton, B. Ren, S. S. Koh, C. T. Harbison, E. Kanin, E. G. Jennings, T. I. Lee, H. L.
True, E. S. Lander, and R. A. Young. Remodeling of yeast genome expression in response
to environmental changes. Mol Biol Cell, 12(2):323–37, 2001.
J. X. Cheng, M. Gandolfi, and M. Ptashne. Activation of the Gal1 gene of yeast by pairs of
’non-classical’ activators. Curr Biol, 14(18):1675–1679, Sep 2004.
Y. Chi, M. J. Huddleston, X. Zhang, R. A. Young, R. S. Annan, S. A. Carr, and R. J.
Deshaies. Negative regulation of Gcn4 and Msn2 transcription factors by Srb10 cyclin-
dependent kinase. Genes Dev, 15(9):1078–1092, May 2001.
C. R. Clapier and B. R. Cairns. The biology of chromatin remodeling complexes. Annu Rev
Biochem, 78:273–304, 2009.
A. B. Clark, C. C. Dykstra, and A. Sugino. Isolation, DNA sequence, and regulation of a
Saccharomyces cerevisiae gene that encodes DNA strand transfer protein alpha. Mol Cell
Biol, 11(5):2576–82, 1991.
S. R. Collins, K. M. Miller, N. L. Maas, A. Roguev, J. Fillingham, C. S. Chu, M. Schuldiner,
M. Gebbia, J. Recht, M. Shales, H. Ding, H. Xu, J. Han, K. Ingvarsdottir, B. Cheng,
B. Andrews, C. Boone, S. L. Berger, P. Hieter, Z. Zhang, G. W. Brown, C. J. Ingles,
A. Emili, C. D. Allis, D. P. Toczyski, J. S. Weissman, J. F. Greenblatt, and N. J. Krogan.
Functional dissection of protein complexes involved in yeast chromosome biology using a
genetic interaction map. Nature, 446(7137):806–810, Apr 2007.
M. P. Cosma, S. Panizza, and K. Nasmyth. Cdk1 triggers association of RNA polymerase
to cell cycle promoters only after recruitment of the mediator by SBF. Mol Cell, 7(6):
1213–1220, Jun 2001.
P. Cramer. Multisubunit RNA polymerases. Curr Opin Struct Biol, 12(1):89–97, Feb 2002.
P. Cramer, K.-J. Armache, S. Baumli, S. Benkert, F. Brueckner, C. Buchen, G. E. Damsma,
S. Dengl, S. R. Geiger, A. J. Jasiak, A. Jawhari, S. Jennebach, T. Kamenski, H. Ketten-
berger, C.-D. Kuhn, E. Lehmann, K. Leike, J. F. Sydow, and A. Vannini. Structure of
eukaryotic RNA polymerases. Annu Rev Biophys, 37:337–352, 2008.
J. A. Davis, Y. Takagi, R. D. Kornberg, and F. A. Asturias. Structure of the yeast RNA
polymerase II holoenzyme: Mediator conformation and polymerase interaction. Mol Cell,
10(2):409–415, Aug 2002.
W. L. DeLano. The PyMOL Molecular Graphics System., 2002. URL http://www.pymol.
org/.
S. Dengl and P. Cramer. Torpedo nuclease Rat1 is insufficient to terminate RNA polymerase
II in vitro. J Biol Chem, 284(32):21270–21279, Aug 2009.
72
Bibliography
G. Dieci, G. Fiorino, M. Castelnuovo, M. Teichmann, and A. Pagano. The expanding RNA
polymerase III transcriptome. Trends Genet, 23(12):614–622, Dec 2007.
R. C. Edgar. MUSCLE: multiple sequence alignment with high accuracy and high throughput.
Nucleic Acids Res, 32(5):1792–7, 2004.
S. Egloff and S. Murphy. Cracking the RNA polymerase II CTD code. Trends Genet, 24(6):
280–288, Jun 2008.
S. Egloff, D. O’Reilly, R. D. Chapman, A. Taylor, K. Tanzhaus, L. Pitts, D. Eick, and
S. Murphy. Serine-7 of the RNA polymerase II CTD is specifically required for snRNA
gene expression. Science, 318(5857):1777–1779, Dec 2007.
H. Elmlund, V. Baraznenok, M. Lindahl, C. O. Samuelsen, P. J. B. Koeck, S. Holmberg,
H. Hebert, and C. M. Gustafsson. The cyclin-dependent kinase 8 module sterically blocks
Mediator interactions with RNA polymerase II. Proc Natl Acad Sci U S A, 103(43):15788–
15793, Oct 2006.
P. Emsley and K. Cowtan. Coot: model-building tools for molecular graphics. Acta Crystal-
logr D Biol Crystallogr, 60(Pt 12 Pt 1):2126–2132, Dec 2004.
C. Esnault, Y. Ghavi-Helm, S. Brun, J. Soutourina, N. V. Berkum, C. Boschiero, F. Hol-
stege, and M. Werner. Mediator-dependent recruitment of TFIIH modules in preinitiation
complex. Mol Cell, 31(3):337–346, Aug 2008.
X. Espanel and M. Sudol. Yes-associated protein and p53-binding protein-2 interact through
their WW and SH3 domains. J Biol Chem, 276(17):14514–23, 2001.
H. Y. Fan and H. L. Klein. Characterization of mutations that suppress the temperature-
sensitive growth of the hpr1 delta mutant of Saccharomyces cerevisiae. Genetics, 137(4):
945–956, Aug 1994.
H. Y. Fan, K. K. Cheng, and H. L. Klein. Mutations in the RNA polymerase II tran-
scription machinery suppress the hyperrecombination mutant hpr1 delta of Saccharomyces
cerevisiae. Genetics, 142(3):749–759, Mar 1996.
X. Fan, D. M. Chou, and K. Struhl. Activator-specific recruitment of Mediator in vivo. Nat
Struct Mol Biol, 13(2):117–120, Feb 2006.
L. Fernandes, C. Rodrigues-Pousada, and K. Struhl. Yap, a novel family of eight bZIP
proteins in Saccharomyces cerevisiae with distinct biological functions. Mol Cell Biol, 17
(12):6982–93, 1997.
J. Fishburn, N. Mohibullah, and S. Hahn. Function of a eukaryotic transcription activator
during the transcription cycle. Mol Cell, 18(3):369–378, Apr 2005.
P. M. Flanagan, R. J. Kelleher, M. H. Sayre, H. Tschochner, and R. D. Kornberg. A mediator
required for activation of RNA polymerase II transcription in vitro. Nature, 350(6317):436–
438, Apr 1991.
J. D. Fondell, H. Ge, and R. G. Roeder. Ligand induction of a transcriptionally active thyroid
hormone receptor coactivator complex. Proc Natl Acad Sci U S A, 93(16):8329–8333, Aug
1996.
73
Bibliography
N. J. Fuda, M. B. Ardehali, and J. T. Lis. Defining mechanisms that regulate RNA polymerase
II transcription in vivo. Nature, 461(7261):186–192, Sep 2009.
C. Gao, L. Wang, E. Milgrom, and W.-C. W. Shen. On the mechanism of constitutive
Pdr1 activator-mediated PDR5 transcription in Saccharomyces cerevisiae: evidence for
enhanced recruitment of coactivators and altered nucleosome structures. J Biol Chem, 279
(41):42677–42686, Oct 2004.
A. P. Gasch, P. T. Spellman, C. M. Kao, O. Carmel-Harel, M. B. Eisen, G. Storz, D. Bot-
stein, and P. O. Brown. Genomic expression programs in the response of yeast cells to
environmental changes. Mol Biol Cell, 11(12):4241–57, 2000.
E. Gasteiger, C. Hoogland, A. Gattiker, S. Duvaud, M. Wilkins, R. Appel, and A. Bairoch.
The Proteomics Protocols Handbook, chapter Protein Identification and Analysis Tools on
the ExPASy Server, pages 571–607. Humana Press, 2005. URL http://www.expasy.ch/
tools/protparam.html.
R. C. Gentleman, V. J. Carey, D. M. Bates, B. Bolstad, M. Dettling, S. Dudoit, B. Ellis,
L. Gautier, Y. Ge, J. Gentry, K. Hornik, T. Hothorn, W. Huber, S. Iacus, R. Irizarry,
F. Leisch, C. Li, M. Maechler, A. J. Rossini, G. Sawitzki, C. Smith, G. Smyth, L. Tierney,
J. Y. H. Yang, and J. Zhang. Bioconductor: Open software development for computational
biology and bioinformatics. Genome Biology, 5:R80, 2004.
G. Gill and M. Ptashne. Negative effect of the transcriptional activator GAL4. Nature, 334
(6184):721–724, Aug 1988.
P. Gouet, E. Courcelle, D. I. Stuart, and F. Metoz. ESPript: analysis of multiple sequence
alignments in PostScript. Bioinformatics, 15(4):305–8, 1999.
C. K. Govind, S. Yoon, H. Qiu, S. Govind, and A. G. Hinnebusch. Simultaneous recruitment
of coactivators by Gcn4p stimulates multiple steps of transcription in vivo. Mol Cell Biol,
25(13):5626–5638, Jul 2005.
I. Grummt. Regulation of mammalian ribosomal gene transcription by RNA polymerase I.
Prog Nucleic Acid Res Mol Biol, 62:109–154, 1999.
J.-Y. Gu, J. M. Park, E. J. Song, G. Mizuguchi, J. H. Yoon, J. Kim-Ha, K.-J. Lee, and Y.-J.
Kim. Novel Mediator proteins of the small Mediator complex in Drosophila SL2 cells. J
Biol Chem, 277(30):27154–27161, Jul 2002.
W. Gu, S. Malik, M. Ito, C. X. Yuan, J. D. Fondell, X. Zhang, E. Martinez, J. Qin, and
R. G. Roeder. A novel human SRB/MED-containing cofactor complex, SMCC, involved
in transcription regulation. Mol Cell, 3(1):97–108, Jan 1999.
B. Guglielmi, N. L. van Berkum, B. Klapholz, T. Bijma, M. Boube, C. Boschiero, H.-M.
Bourbon, F. C. P. Holstege, and M. Werner. A high resolution protein interaction map of
the yeast Mediator complex. Nucleic Acids Res, 32(18):5379–5391, 2004.
B. Guglielmi, J. Soutourina, C. Esnault, and M. Werner. TFIIS elongation factor and Medi-
ator act in conjunction during transcription initiation in vivo. Proc Natl Acad Sci U S A,
104(41):16062–16067, Oct 2007.
74
Bibliography
S. Hahn. Structure and mechanism of the RNA polymerase II transcription machinery. Nat
Struct Mol Biol, 11(5):394–403, May 2004.
S. Hahn. Structural biology: New beginnings for transcription. Nature, 462(7271):292–293,
Nov 2009.
T. Hall. BioEdit software, Nov 2005. URL http://www.mbio.ncsu.edu/BioEdit/bioedit.
html.
M. Hallberg, G.-Z. Hu, S. Tronnersjö, Z. Shaikhibrahim, D. Balciunas, S. Björklund, and
H. Ronne. Functional and physical interactions within the middle domain of the yeast
mediator. Mol Genet Genomics, 276(2):197–210, Aug 2006.
M. Hampsey. A review of phenotypes in Saccharomyces cerevisiae. Yeast, 13(12):1099–133,
1997.
S. J. Han, J. S. Lee, J. S. Kang, and Y. J. Kim. Med9/Cse2 and Gal11 modules are required
for transcriptional repression of distinct group of genes. J Biol Chem, 276(40):37020–37026,
Oct 2001.
A. J. Heck. Native mass spectrometry: a bridge between interactomics and structural biology.
Nat Methods, 5(11):927–33, 2008.
C. J. Hengartner, C. M. Thompson, J. Zhang, D. M. Chao, S. M. Liao, A. J. Koleske,
S. Okamura, and R. A. Young. Association of an activator with an RNA polymerase II
holoenzyme. Genes Dev, 9(8):897–910, Apr 1995.
C. J. Hengartner, V. E. Myer, S. M. Liao, C. J. Wilson, S. S. Koh, and R. A. Young. Temporal
regulation of RNA polymerase II by Srb10 and Kin28 cyclin-dependent kinases. Mol Cell,
2(1):43–53, Jul 1998.
J. R. Hesselberth, J. P. Miller, A. Golob, J. E. Stajich, G. A. Michaud, and S. Fields. Com-
parative analysis of Saccharomyces cerevisiae WW domains and their interacting proteins.
Genome Biol, 7(4):R30, 2006.
S. Hoeppner, S. Baumli, and P. Cramer. Structure of the mediator subunit cyclin C and its
implications for CDK8 function. J Mol Biol, 350(5):833–842, Jul 2005.
L. Holm and J. Park. DaliLite workbench for protein structure comparison. Bioinformatics,
16(6):566–7, 2000.
F. C. Holstege, E. G. Jennings, J. J. Wyrick, T. I. Lee, C. J. Hengartner, M. R. Green, T. R.
Golub, E. S. Lander, and R. A. Young. Dissecting the regulatory circuitry of a eukaryotic
genome. Cell, 95(5):717–728, Nov 1998.
X. Hu, S. Malik, C. C. Negroiu, K. Hubbard, C. N. Velalar, B. Hampton, D. Grosu, J. Cata-
lano, R. G. Roeder, and A. Gnatt. A Mediator-responsive form of metazoan RNA poly-
merase II. Proc Natl Acad Sci U S A, 103(25):9506–9511, Jun 2006.
K. L. Huisinga and B. F. Pugh. A genome-wide housekeeping role for TFIID and a highly
regulated stress-related role for SAGA in Saccharomyces cerevisiae. Mol Cell, 13(4):573–
585, Feb 2004.
75
Bibliography
K. L. Huisinga and B. F. Pugh. A TATA binding protein regulatory network that governs
transcription complex assembly. Genome Biol, 8(4):R46, 2007.
C. Janke, M. M. Magiera, N. Rathfelder, C. Taxis, S. Reber, H. Maekawa, A. Moreno-
Borchart, G. Doenges, E. Schwob, E. Schiebel, and M. Knop. A versatile toolbox for
PCR-based tagging of yeast genes: new fluorescent proteins, more markers and promoter
substitution cassettes. Yeast, 21(11):947–62, 2004.
I. Jedidi, F. Zhang, H. Qiu, S. J. Stahl, I. Palmer, J. D. Kaufman, P. S. Nadaud, S. Mukherjee,
P. T. Wingfield, C. P. Jaroniec, and A. G. Hinnebusch. Activator Gcn4 employs multiple
segments of Med15/Gal11, including the KIX domain, to recruit mediator to target genes
in vivo. J Biol Chem, 285(4):2438–2455, Jan 2010.
C. J. Jeong, S. H. Yang, Y. Xie, L. Zhang, S. A. Johnston, and T. Kodadek. Evidence that
Gal11 protein is a target of the Gal4 activation domain in the mediator. Biochemistry, 40
(31):9421–9427, Aug 2001.
Y. W. Jiang and D. J. Stillman. Involvement of the SIN4 global transcriptional regulator
in the chromatin structure of Saccharomyces cerevisiae. Mol Cell Biol, 12(10):4503–4514,
Oct 1992.
Y. W. Jiang, P. Veschambre, H. Erdjument-Bromage, P. Tempst, J. W. Conaway, R. C.
Conaway, and R. D. Kornberg. Mammalian mediator of transcriptional regulation and its
possible role as an end-point of signal transduction pathways. Proc Natl Acad Sci U S A,
95(15):8538–8543, Jul 1998.
D. T. Jones. Protein secondary structure prediction based on position-specific scoring matri-
ces. J Mol Biol, 292(2):195–202, 1999.
P. W. Jordan, F. Klein, and D. R. F. Leach. Novel Roles for Selected Genes in Meiotic DNA
Processing. PLoS Genet, 3(12):e222, Dec 2007.
W. Kabsch. Automatic processing of rotation diffraction data from crystals of initially un-
known symmetry and cell constants. Journal of Applied Crystallography, 26(6):795–800,
Dec 1993.
J. S. Kang, S. H. Kim, M. S. Hwang, S. J. Han, Y. C. Lee, and Y. J. Kim. The structural and
functional organization of the yeast mediator complex. J Biol Chem, 276(45):42003–42010,
Nov 2001.
R. J. Kelleher, P. M. Flanagan, and R. D. Kornberg. A novel mediator between activator
proteins and the RNA polymerase II transcription apparatus. Cell, 61(7):1209–1215, Jun
1990.
A. Köhler and E. Hurt. Exporting RNA from the nucleus to the cytoplasm. Nat Rev Mol
Cell Biol, 8(10):761–773, Oct 2007.
B. Kim, A. I. Nesvizhskii, P. G. Rani, S. Hahn, R. Aebersold, and J. A. Ranish. The
transcription elongation factor TFIIS is a component of RNA polymerase II preinitiation
complexes. Proc Natl Acad Sci U S A, 104(41):16068–16073, Oct 2007.
76
Bibliography
Y. J. Kim, S. Björklund, Y. Li, M. H. Sayre, and R. D. Kornberg. A multiprotein mediator
of transcriptional activation and its interaction with the C-terminal repeat domain of RNA
polymerase II. Cell, 77(4):599–608, May 1994.
M. T. Knuesel, K. D. Meyer, A. J. Donner, J. M. Espinosa, and D. J. Taatjes. The human
CDK8 subcomplex is a histone kinase that requires Med12 for activity and can function
independently of mediator. Mol Cell Biol, 29(3):650–661, Feb 2009.
M. M. Kofler and C. Freund. The GYF domain. Febs J, 273(2):245–56, 2006.
A. J. Koleske and R. A. Young. An RNA polymerase II holoenzyme responsive to activators.
Nature, 368(6470):466–469, Mar 1994.
A. J. Koleske, S. Buratowski, M. Nonet, and R. A. Young. A novel transcription factor reveals
a functional link between the RNA polymerase II CTD and TFIID. Cell, 69(5):883–894,
May 1992.
P. V. Konarev, M. V. Petoukhov, V. V. Volkov, and D. I. Svergun. ATSAS 2.1, a program
package for small-angle scattering data analysis. Journal of Applied Crystallography, 39
(2):277–286, 2006.
R. D. Kornberg. Eukaryotic transcriptional control. Trends Cell Biol, 9(12):M46–M49, Dec
1999.
D. Kostrewa, M. E. Zeller, K.-J. Armache, M. Seizl, K. Leike, M. Thomm, and P. Cramer.
RNA polymerase II-TFIIB structure and mechanism of transcription initiation. Nature,
462(7271):323–330, Nov 2009.
E. Krissinel and K. Henrick. Secondary-structure matching (SSM), a new tool for fast protein
structure alignment in three dimensions. Acta Crystallogr D Biol Crystallogr, 60(Pt 12 Pt
1):2256–68, 2004.
N. J. Krogan, M. C. Keogh, N. Datta, C. Sawa, O. W. Ryan, H. Ding, R. A. Haw, J. Pootoolal,
A. Tong, V. Canadien, D. P. Richards, X. Wu, A. Emili, T. R. Hughes, S. Buratowski, and
J. F. Greenblatt. A Snf2 family ATPase complex required for recruitment of the histone
H2A variant Htz1. Mol Cell, 12(6):1565–76, 2003.
L. Kuras, T. Borggrefe, and R. D. Kornberg. Association of the Mediator complex with
enhancers of active genes. Proc Natl Acad Sci U S A, 100(24):13887–13891, Nov 2003.
U. K. Laemmli. Cleavage of structural proteins during the assembly of the head of bacterio-
phage T4. Nature, 227(259):680–685, 1970.
L. Larivière, S. Geiger, S. Hoeppner, S. Röther, K. Strässer, and P. Cramer. Structure and
TBP binding of the Mediator head subcomplex Med8-Med18-Med20. Nat Struct Mol Biol,
13(10):895–901, Oct 2006.
L. Larivière, M. Seizl, S. van Wageningen, S. Röther, L. van de Pasch, H. Feldmann,
K. Sträßer, S. Hahn, F. C. P. Holstege, and P. Cramer. Structure-system correlation
identifies a gene regulatory Mediator submodule. Genes Dev, 22(7):872–877, Apr 2008.
E. Larschan and F. Winston. The Saccharomyces cerevisiae Srb8-Srb11 complex functions
with the SAGA complex during Gal4-activated transcription. Mol Cell Biol, 25(1):114–123,
77
Bibliography
Jan 2005.
Y. Lee, M. Kim, J. Han, K.-H. Yeom, S. Lee, S. H. Baek, and V. N. Kim. MicroRNA genes
are transcribed by RNA polymerase II. EMBO J, 23(20):4051–4060, Oct 2004.
K. Lemieux and L. Gaudreau. Targeting of Swi/Snf to the yeast GAL1 UAS G requires the
Mediator, TAF IIs, and RNA polymerase II. EMBO J, 23(20):4040–4050, Oct 2004.
K. Lemieux, M. Larochelle, and L. Gaudreau. Variant histone H2A.Z, but not the HMG
proteins Nhp6a/b, is essential for the recruitment of Swi/Snf, Mediator, and SAGA to the
yeast GAL1 UAS(G). Biochem Biophys Res Commun, 369(4):1103–1107, May 2008.
C. Leroy, L. Cormier, and L. Kuras. Independent recruitment of mediator and SAGA by the
activator Met4. Mol Cell Biol, 26(8):3149–3163, Apr 2006.
B. A. Lewis and D. Reinberg. The mediator coactivator complex: functional and physical
roles in transcriptional regulation. J Cell Sci, 116(Pt 18):3667–3675, Sep 2003.
B. Li, M. Carey, and J. L. Workman. The role of chromatin during transcription. Cell, 128
(4):707–719, Feb 2007.
Y. Li, P. M. Flanagan, H. Tschochner, and R. D. Kornberg. RNA polymerase II initiation
factor interactions and transcription start site selection. Science, 263(5148):805–807, Feb
1994.
Y. Li, S. Bjorklund, Y. W. Jiang, Y. J. Kim, W. S. Lane, D. J. Stillman, and R. D. Korn-
berg. Yeast global transcriptional regulators Sin4 and Rgr1 are components of mediator
complex/RNA polymerase II holoenzyme. Proc Natl Acad Sci U S A, 92(24):10864–10868,
Nov 1995.
S. M. Liao, J. Zhang, D. A. Jeffery, A. J. Koleske, C. M. Thompson, D. M. Chao, M. Viljoen,
H. J. van Vuuren, and R. A. Young. A kinase-cyclin pair in the RNA polymerase II
holoenzyme. Nature, 374(6518):193–196, Mar 1995.
T. Linder and C. M. Gustafsson. The Soh1/MED31 protein is an ancient component of
Schizosaccharomyces pombe and Saccharomyces cerevisiae Mediator. J Biol Chem, 279
(47):49455–49459, Nov 2004.
T. Linder, X. Zhu, V. Baraznenok, and C. M. Gustafsson. The classical srb4-138 mutant allele
causes dissociation of yeast Mediator. Biochem Biophys Res Commun, 349(3):948–953, Oct
2006.
T. Linder, N. N. Rasmussen, C. O. Samuelsen, E. Chatzidaki, V. Baraznenok, J. Beve,
P. Henriksen, C. M. Gustafsson, and S. Holmberg. Two conserved modules of Schizosac-
charomyces pombe Mediator regulate distinct cellular pathways. Nucleic Acids Res, 36(8):
2489–2504, May 2008.
Y. Liu, C. Kung, J. Fishburn, A. Z. Ansari, K. M. Shokat, and S. Hahn. Two cyclin-dependent
kinases promote RNA polymerase II transcription and formation of the scaffold complex.
Mol Cell Biol, 24(4):1721–1735, Feb 2004.
Y. Lorch, J. Beve, C. M. Gustafsson, L. C. Myers, and R. D. Kornberg. Mediator-nucleosome
interaction. Mol Cell, 6(1):197–201, Jul 2000.
78
Bibliography
K. Lorenzen, A. Vannini, P. Cramer, and A. J. Heck. Structural biology of RNA polymerase
III: mass spectrometry elucidates subcomplex architecture. Structure, 15(10):1237–45,
2007.
M. J. Macias, S. Wiesner, and M. Sudol. WW and SH3 domains, two different scaffolds to
recognize proline-rich ligands. FEBS Lett, 513(1):30–7, 2002.
F. Malagon, A. H. Tong, B. K. Shafer, and J. N. Strathern. Genetic interactions of DST1
in Saccharomyces cerevisiae suggest a role of TFIIS in the initiation-elongation transition.
Genetics, 166(3):1215–1227, Mar 2004.
T. Max, M. Søgaard, and J. Q. Svejstrup. Hyperphosphorylation of the C-terminal repeat
domain of RNA polymerase II facilitates dissociation of its complex with mediator. J Biol
Chem, 282(19):14113–14120, May 2007.
A. J. McCoy, R. W. Grosse-Kunstleve, P. D. Adams, M. D. Winn, L. C. Storoni, and R. J.
Read. Phaser crystallographic software. Journal of Applied Crystallography, 40(4):658–674,
2007.
A. R. McKay, B. T. Ruotolo, L. L. Ilag, and C. V. Robinson. Mass measurements of increased
accuracy resolve heterogeneous populations of intact ribosomes. J Am Chem Soc, 128(35):
11433–42, 2006.
A. Meinhart, J. Blobel, and P. Cramer. An extended winged helix domain in general tran-
scription factor E/IIE alpha. J Biol Chem, 278(48):48267–48274, Nov 2003.
A. Meinhart, T. Kamenski, S. Hoeppner, S. Baumli, and P. Cramer. A structural perspective
of CTD function. Genes Dev, 19(12):1401–1415, Jun 2005.
G. Mittler, E. Kremmer, H. T. Timmers, and M. Meisterernst. Novel critical role of a human
Mediator complex for basal RNA polymerase II transcription. EMBO Rep, 2(9):808–813,
Sep 2001.
F. Müller, M. A. Demény, and L. Tora. New problems in RNA polymerase II transcription
initiation: matching the diversity of core promoters with a variety of promoter recognition
factors. J Biol Chem, 282(20):14685–14689, May 2007.
N. Mohibullah and S. Hahn. Site-specific cross-linking of TBP in vivo and in vitro reveals a
direct functional interaction with the SAGA subunit Spt3. Genes Dev, 22(21):2994–3006,
Nov 2008.
Z. Moqtaderi and K. Struhl. Expanding the repertoire of plasmids for PCR-mediated epitope
tagging in yeast. Yeast, 25(4):287–292, Apr 2008.
G. N. Murshudov, A. A. Vagin, and E. J. Dodson. Refinement of macromolecular structures
by the maximum-likelihood method. Acta Crystallogr D Biol Crystallogr, 53(Pt 3):240–255,
May 1997.
L. C. Myers and R. D. Kornberg. Mediator of transcriptional regulation. Annu Rev Biochem,
69:729–749, 2000.
L. C. Myers, C. M. Gustafsson, D. A. Bushnell, M. Lui, H. Erdjument-Bromage, P. Tempst,
and R. D. Kornberg. The Med proteins of yeast and their function through the RNA
79
Bibliography
polymerase II carboxy-terminal domain. Genes Dev, 12(1):45–54, Jan 1998.
C. Nelson, S. Goto, K. Lund, W. Hung, and I. Sadowski. Srb10/Cdk8 regulates yeast fil-
amentous growth by phosphorylating the transcription factor Ste12. Nature, 421(6919):
187–190, Jan 2003.
M. Nishizawa. Negative regulation of transcription by the yeast global transcription factors,
Gal11 and Sin4. Yeast, 18(12):1099–1110, Sep 2001.
M. L. Nonet and R. A. Young. Intragenic and extragenic suppressors of mutations in the
heptapeptide repeat domain of Saccharomyces cerevisiae RNA polymerase II. Genetics,
123(4):715–724, Dec 1989.
A. M. Näär, P. A. Beaurang, S. Zhou, S. Abraham, W. Solomon, and R. Tjian. Composite co-
activator ARC mediates chromatin-directed transcriptional activation. Nature, 398(6730):
828–832, Apr 1999.
A. M. Näär, B. D. Lemon, and R. Tjian. Transcriptional coactivator complexes. Annu Rev
Biochem, 70:475–501, 2001.
K. M. Nyswaner, M. A. Checkley, M. Yi, R. M. Stephens, and D. J. Garfinkel. Chromatin-
associated genes protect the yeast genome from Ty1 insertional mutagenesis. Genetics, 178
(1):197–214, Jan 2008.
M. Oeffinger, K. E. Wei, R. Rogers, J. A. DeGrasse, B. T. Chait, J. D. Aitchison, and M. P.
Rout. Comprehensive analysis of diverse ribonucleoprotein complexes. Nat Methods, 4(11):
951–956, Nov 2007.
M. Papamichos-Chronakis, R. S. Conlan, N. Gounalaki, T. Copf, and D. Tzamarias.
Hrs1/Med3 is a Cyc8-Tup1 corepressor target in the RNA polymerase II holoenzyme.
J Biol Chem, 275(12):8397–8403, Mar 2000.
J. M. Park, B. S. Gim, J. M. Kim, J. H. Yoon, H. S. Kim, J. G. Kang, and Y. J. Kim.
Drosophila Mediator complex is broadly utilized by diverse gene-specific transcription fac-
tors at different types of core promoters. Mol Cell Biol, 21(7):2312–2323, Apr 2001a.
J. M. Park, J. Werner, J. M. Kim, J. T. Lis, and Y. J. Kim. Mediator, not holoenzyme, is
directly recruited to the heat shock promoter by HSF upon heat shock. Mol Cell, 8(1):
9–19, Jul 2001b.
L. A. Pereira, M. P. Klejman, and H. T. M. Timmers. Roles for BTAF1 and Mot1p in
dynamics of TATA-binding protein and regulation of RNA polymerase II transcription.
Gene, 315:1–13, Oct 2003.
H. P. Phatnani and A. L. Greenleaf. Phosphorylation and functions of the RNA polymerase
II CTD. Genes Dev, 20(21):2922–2936, Nov 2006.
S. D. Pringle, K. Giles, J. L. Wildgoose, J. P. Williams, S. E. Slade, K. Thalassinos, R. H.
Bateman, M. T. Bowers, and J. H. Scrivens. An investigation of the mobility separation of
some peptide and protein ions using a new hybrid quadrupole/travelling wave IMS/oa-ToF
instrument. Int J Mass Spectrom, 261(1):1–12, 2007.
80
Bibliography
N. J. Proudfoot, A. Furger, and M. J. Dye. Integrating mRNA processing with transcription.
Cell, 108(4):501–512, Feb 2002.
O. Puig, F. Caspary, G. Rigaut, B. Rutz, E. Bouveret, E. Bragado-Nilsson, M. Wilm, and
B. Seraphin. The tandem affinity purification (TAP) method: a general procedure of
protein complex purification. Methods, 24(3):218–29, 2001.
H. Qiu, C. Hu, S. Yoon, K. Natarajan, M. J. Swanson, and A. G. Hinnebusch. An array
of coactivators is required for optimal recruitment of TATA binding protein and RNA
polymerase II by promoter-bound Gcn4p. Mol Cell Biol, 24(10):4104–4117, May 2004.
H. Qiu, C. Hu, F. Zhang, G. J. Hwang, M. J. Swanson, C. Boonchird, and A. G. Hinnebusch.
Interdependent recruitment of SAGA and Srb mediator by transcriptional activator Gcn4p.
Mol Cell Biol, 25(9):3461–3474, May 2005.
H. Qiu, C. Hu, and A. G. Hinnebusch. Phosphorylation of the Pol II CTD by KIN28 enhances
BUR1/BUR2 recruitment and Ser2 CTD phosphorylation near promoters. Mol Cell, 33
(6):752–762, Mar 2009.
C. Rachez, B. D. Lemon, Z. Suldan, V. Bromleigh, M. Gamble, A. M. Näär, H. Erdjument-
Bromage, P. Tempst, and L. P. Freedman. Ligand-dependent transcription activation by
nuclear receptors requires the DRIP complex. Nature, 398(6730):824–828, Apr 1999.
J. A. Ranish and S. Hahn. The yeast general transcription factor TFIIA is composed of two
polypeptide subunits. J Biol Chem, 266(29):19320–19327, Oct 1991.
J. A. Ranish, N. Yudkovsky, and S. Hahn. Intermediates in formation and activity of the
RNA polymerase II preinitiation complex: holoenzyme recruitment and a postrecruitment
role for the TATA box and TFIIB. Genes Dev, 13(1):49–63, Jan 1999.
W. M. Reeves and S. Hahn. Targets of the Gal4 transcription activator in functional tran-
scription complexes. Mol Cell Biol, 25(20):9092–9102, Oct 2005.
G. Rigaut, A. Shevchenko, B. Rutz, M. Wilm, M. Mann, and B. Séraphin. A generic protein
purification method for protein complex characterization and proteome exploration. Nat
Biotechnol, 17(10):1030–1032, Oct 1999.
B. T. Ruotolo, J. L. Benesch, A. M. Sandercock, S. J. Hyung, and C. V. Robinson. Ion
mobility-mass spectrometry analysis of large protein complexes. Nat Protoc, 3(7):1139–52,
2008.
W. Rychlik, W. J. Spencer, and R. E. Rhoads. Optimization of the annealing temperature
for DNA amplification in vitro. Nucleic Acids Res, 18(21):6409–6412, 1990.
S. Ryu, S. Zhou, A. G. Ladurner, and R. Tjian. The transcriptional cofactor complex CRSP
is required for activity of the enhancer-binding protein Sp1. Nature, 397(6718):446–450,
Feb 1999.
A. I. Saeed, V. Sharov, J. White, J. Li, W. Liang, N. Bhagabati, J. Braisted, M. Klapa,
T. Currier, M. Thiagarajan, A. Sturn, M. Snuffin, A. Rezantsev, D. Popov, A. Ryltsov,
E. Kostukovich, I. Borisovsky, Z. Liu, A. Vinsavich, V. Trush, and J. Quackenbush. TM4:
a free, open-source system for microarray data management and analysis. Biotechniques,
81
Bibliography
34(2):374–8, 2003.
J. Sambrook and D. Russell. Molecular cloning: A laboratory Manual, volume 1-3. Cold
Spring Harbor Laboratory, 3rd edition, 2001.
M. S. Santisteban, T. Kalashnikova, and M. M. Smith. Histone H2A.Z regulates transcription
and is partially redundant with nucleosome remodeling complexes. Cell, 103(3):411–22,
2000.
A. Saunders, L. J. Core, and J. T. Lis. Breaking barriers to transcription elongation. Nat
Rev Mol Cell Biol, 7(8):557–567, Aug 2006.
M. H. Sayre, H. Tschochner, and R. D. Kornberg. Reconstitution of transcription with five
purified initiation factors and RNA polymerase II from Saccharomyces cerevisiae. J Biol
Chem, 267(32):23376–23382, Nov 1992.
T. Z. Sen, H. Cheng, A. Kloczkowski, and R. L. Jernigan. A Consensus Data Mining sec-
ondary structure prediction by combining GOR V and Fragment Database Mining. Protein
Sci, 15(11):2499–506, 2006.
M. Sharon and C. V. Robinson. The role of mass spectrometry in structure elucidation of
dynamic protein complexes. Annu Rev Biochem, 76:167–93, 2007.
P. A. Sharp. RNA splicing and genes. JAMA, 260(20):3035–3041, Nov 1988.
T. W. Sikorski and S. Buratowski. The basal initiation machinery: beyond the general
transcription factors. Curr Opin Cell Biol, 21(3):344–351, Jun 2009.
R. J. Sims, R. Belotserkovskaya, and D. Reinberg. Elongation by RNA polymerase II: the
short and long of it. Genes Dev, 18(20):2437–2468, Oct 2004.
H. Singh, A. M. Erkine, S. B. Kremer, H. M. Duttweiler, D. A. Davis, J. Iqbal, R. R. Gross,
and D. S. Gross. A functional module of yeast mediator that governs the dynamic range
of heat-shock gene expression. Genetics, 172(4):2169–2184, Apr 2006.
G. K. Smyth. Linear models and empirical bayes methods for assessing differential expression
in microarray experiments. Stat Appl Genet Mol Biol, 3:Article3, 2004.
J. Soeding, A. Biegert, and A. N. Lupas. The HHpred interactive server for protein homology
detection and structure prediction. Nucleic Acids Res, 33(Web Server issue):W244–8, 2005.
H. Spåhr, J. Bève, T. Larsson, J. Bergström, K. A. Karlsson, and C. M. Gustafsson. Purifi-
cation and characterization of RNA polymerase II holoenzyme from Schizosaccharomyces
pombe. J Biol Chem, 275(2):1351–1356, Jan 2000.
C. Stark, B. J. Breitkreutz, T. Reguly, L. Boucher, A. Breitkreutz, and M. Tyers. BioGRID: a
general repository for interaction datasets. Nucleic Acids Res, 34(Database issue):D535–9,
2006.
P. W. Sternberg, M. J. Stern, I. Clark, and I. Herskowitz. Activation of the yeast HO gene
by release from multiple negative controls. Cell, 48(4):567–577, Feb 1987.
J. W. Stiller and B. D. Hall. Evolution of the RNA polymerase II C-terminal domain. Proc
Natl Acad Sci U S A, 99(9):6091–6096, Apr 2002.
82
Bibliography
K. F. Stringer, C. J. Ingles, and J. Greenblatt. Direct and selective binding of an acidic
transcriptional activation domain to the TATA-box factor TFIID. Nature, 345(6278):783–
786, Jun 1990.
X. Sun, Y. Zhang, H. Cho, P. Rickert, E. Lees, W. Lane, and D. Reinberg. NAT, a human
complex containing Srb polypeptides that functions as a negative regulator of activated
transcription. Mol Cell, 2(2):213–222, Aug 1998.
J. Q. Svejstrup, W. J. Feaver, J. LaPointe, and R. D. Kornberg. RNA polymerase transcrip-
tion factor IIH holoenzyme from yeast. J Biol Chem, 269(45):28044–28048, Nov 1994.
J. Q. Svejstrup, Y. Li, J. Fellows, A. Gnatt, S. Bjorklund, and R. D. Kornberg. Evidence
for a mediator cycle at the initiation of transcription. Proc Natl Acad Sci U S A, 94(12):
6075–6078, Jun 1997.
M. J. Swanson, H. Qiu, L. Sumibcay, A. Krueger, S. ja Kim, K. Natarajan, S. Yoon, and A. G.
Hinnebusch. A multiplicity of coactivators is required by Gcn4p at individual promoters
in vivo. Mol Cell Biol, 23(8):2800–2820, Apr 2003.
D. J. Taatjes, A. M. Näär, F. Andel, E. Nogales, and R. Tjian. Structure, function, and
activator-induced conformations of the CRSP coactivator. Science, 295(5557):1058–1062,
Feb 2002.
D. J. Taatjes, T. Schneider-Poetsch, and R. Tjian. Distinct conformational states of nuclear
receptor-bound CRSP-Med complexes. Nat Struct Mol Biol, 11(7):664–671, Jul 2004.
Y. Takagi and R. D. Kornberg. Mediator as a general transcription factor. J Biol Chem, 281
(1):80–89, Jan 2006.
Y. Takagi, G. Calero, H. Komori, J. A. Brown, A. H. Ehrensberger, A. Hudmon, F. Asturias,
and R. D. Kornberg. Head module control of mediator interactions. Mol Cell, 23(3):
355–364, Aug 2006.
H. Takahashi, K. Kasahara, and T. Kokubo. Saccharomyces cerevisiae Med9 comprises two
functionally distinct domains that play different roles in transcriptional regulation. Genes
Cells, 14(1):53–67, Jan 2009.
M. C. Teixeira, P. Monteiro, P. Jain, S. Tenreiro, A. R. Fernandes, N. P. Mira, M. Alenquer,
A. T. Freitas, A. L. Oliveira, and I. Sa-Correia. The YEASTRACT database: a tool for
the analysis of transcription regulatory associations in Saccharomyces cerevisiae. Nucleic
Acids Res, 34(Database issue):D446–51, 2006.
T. C. Terwilliger. Automated main-chain model building by template matching and iterative
fragment extension. Acta Crystallogr D Biol Crystallogr, 59(Pt 1):38–44, Jan 2003.
J. K. Thakur, H. Arthanari, F. Yang, S.-J. Pan, X. Fan, J. Breger, D. P. Frueh, K. Gulshan,
D. K. Li, E. Mylonakis, K. Struhl, W. S. Moye-Rowley, B. P. Cormack, G. Wagner, and
A. M. Näär. A nuclear receptor-like pathway regulating multidrug resistance in fungi.
Nature, 452(7187):604–609, Apr 2008.
M. C. Thomas and C.-M. Chiang. The general transcription machinery and general cofactors.
Crit Rev Biochem Mol Biol, 41(3):105–178, 2006.
83
Bibliography
C. M. Thompson and R. A. Young. General requirement for RNA polymerase II holoenzymes
in vivo. Proc Natl Acad Sci U S A, 92(10):4587–4590, May 1995.
C. M. Thompson, A. J. Koleske, D. M. Chao, and R. A. Young. A multisubunit complex
associated with the RNA polymerase II CTD and TATA-binding protein in yeast. Cell, 73
(7):1361–1375, Jul 1993.
S. J. Triezenberg, R. C. Kingsbury, and S. L. McKnight. Functional dissection of VP16, the
trans-activator of herpes simplex virus immediate early gene expression. Genes Dev, 2(6):
718–729, Jun 1988.
A. Tóth-Petróczy, C. J. Oldfield, I. Simon, Y. Takagi, A. K. Dunker, V. N. Uversky, and
M. Fuxreiter. Malleable machines in transcription regulation: the mediator complex. PLoS
Comput Biol, 4(12):e1000243, Dec 2008.
C. Uetrecht, C. Versluis, N. R. Watts, P. T. Wingfield, A. C. Steven, and A. J. Heck. Stability
and shape of hepatitis B virus capsids in vacuo. Angew Chem Int Ed Engl, 47(33):6247–51,
2008.
J. van de Peppel, N. Kettelarij, H. van Bakel, T. T. J. P. Kockelkorn, D. van Leenen, and
F. C. P. Holstege. Mediator expression profiling epistasis reveals a signal transduction
pathway with antagonistic submodules and highly specific downstream targets. Mol Cell,
19(4):511–522, Aug 2005.
B. J. Venters and B. F. Pugh. How eukaryotic genes are transcribed. Crit Rev Biochem Mol
Biol, 44(2-3):117–141, 2009.
M. A. Verdecia, M. E. Bowman, K. P. Lu, T. Hunter, and J. P. Noel. Structural basis for
phosphoserine-proline recognition by group IV WW domains. Nat Struct Biol, 7(8):639–43,
2000.
V. V. Volkov and D. I. Svergun. Uniqueness of ab initio shape determination in small-angle
scattering. J. Appl. Cryst., 36:860–864, 2003.
A. Wach, A. Brachat, R. Pöhlmann, and P. Philippsen. New heterologous modules for classical
or PCR-based gene disruptions in Saccharomyces cerevisiae. Yeast, 10(13):1793–1808, Dec
1994.
A. Wach, A. Brachat, C. Alberti-Segui, C. Rebischung, and P. Philippsen. Heterologous HIS3
marker and GFP reporter modules for PCR-targeting in Saccharomyces cerevisiae. Yeast,
13(11):1065–1075, Sep 1997.
A. C. Wallace, R. A. Laskowski, and J. M. Thornton. LIGPLOT: a program to generate
schematic diagrams of protein-ligand interactions. Protein Eng, 8(2):127–34, 1995.
X. Wu, A. Rossettini, and S. D. Hanes. The ESS1 prolyl isomerase and its suppressor BYE1
interact with RNA pol II to inhibit transcription elongation in Saccharomyces cerevisiae.
Genetics, 165(4):1687–1702, Dec 2003.
Z. Wu, R. A. Irizarry, R. Gentleman, F. Martinez-Murillo, and F. Spencer. A Model-Based
Background Adjustment for Oligonucleotide Expression Arrays. J Am Stat Assoc, 99(468):
909–917, 2004.
84
Bibliography
F. Yang, B. W. Vought, J. S. Satterlee, A. K. Walker, Z.-Y. J. Sun, J. L. Watts, R. DeBeau-
mont, R. M. Saito, S. G. Hyberts, S. Yang, C. Macol, L. Iyer, R. Tjian, S. van den Heuvel,
A. C. Hart, G. Wagner, and A. M. Näär. An ARC/Mediator subunit required for SREBP
control of cholesterol and lipid homeostasis. Nature, 442(7103):700–704, Aug 2006.
S. Yoon, H. Qiu, M. J. Swanson, and A. G. Hinnebusch. Recruitment of SWI/SNF by
Gcn4p does not require Snf2p or Gcn5p but depends strongly on SWI/SNF integrity, SRB
mediator, and SAGA. Mol Cell Biol, 23(23):8829–8845, Dec 2003.
E. T. Young, C. Tachibana, H.-W. E. Chang, K. M. Dombek, E. M. Arms, and R. Biddick.
Artificial recruitment of mediator by the DNA-binding domain of Adr1 overcomes glucose
repression of ADH2 expression. Mol Cell Biol, 28(8):2509–2516, Apr 2008.
N. Yudkovsky, J. A. Ranish, and S. Hahn. A transcription reinitiation intermediate that is
stabilized by activator. Nature, 408(6809):225–229, Nov 2000.
S. J. Zanton and B. F. Pugh. Full and partial genome-wide assembly and disassembly of the
yeast transcription machinery in response to heat shock. Genes Dev, 20(16):2250–65, 2006.
F. Zhang, L. Sumibcay, A. G. Hinnebusch, and M. J. Swanson. A triad of subunits from the
Gal11/tail domain of Srb mediator is an in vivo target of transcriptional activator Gcn4p.
Mol Cell Biol, 24(15):6871–6886, Aug 2004.
Y. Zhang. I-TASSER server for protein 3D structure prediction. BMC Bioinformatics, 9:40,
2008.
Z. Zhang and J. C. Reese. Redundant mechanisms are used by Ssn6-Tup1 in repressing
chromosomal gene transcription in Saccharomyces cerevisiae. J Biol Chem, 279(38):39240–
39250, Sep 2004.
X. Zhu, M. Wirén, I. Sinha, N. N. Rasmussen, T. Linder, S. Holmberg, K. Ekwall, and C. M.
Gustafsson. Genome-wide occupancy profile of mediator and the Srb8-11 module reveals
interactions with coding regions. Mol Cell, 22(2):169–178, Apr 2006.
J. Zlatanova and A. Thakar. H2A.Z: view from the top. Structure, 16(2):166–79, 2008.
85
Bibliography
Abbreviations
bp base pairs
BSA bovine serum albumine
CTD carboxy-terminal domain
CV column volumes
Da dalton
DMSO dimethyl sulfoxide
DTT 1,4-dithio-D,L-threitol
E. coli Escherichia coli
EM electron microscopy
GTF general transcription factor
HEPES N-2-hydroxyethylpiperazine-N’-2-ethane sulfonic acid
IPTG Isopropyl-β-D-thiogalactopyranoside
IM-MS ion mobility mass spectrometry
kDa kilo dalton
LB Luria-Bertani (media)
MCS multiple cloning site
MES (2-(N-morpholino)ethanesulfonic acid)
MOPS 4-morpholinepropanesulfonic acid
MW molecular weight
ODXnm optical density at a wavelength of X nm
ORF open reading frame
PAGE polyacrylamide gel electrophoresis
PBS phosphate buffered saline
PDB Protein Data Bank
86
Bibliography
PIC pre-initiation complex
RNA Pol RNA polymerase
rpm rounds per minute
SAGA Spt-Ada-Gcn5 acetylase complex
SAXS Small angle X-ray scattering
S. cerevisiae Saccharomyces cerevisiae
S. pombe Schizosaccharomyces pombe
SDS sodium dodecylsulfate
SLS static light scattering
SOB Super Optimal Broth (media)
SOC Super Optimal broth with Catabolite repression (media)
Srb Suppressor of RNA Pol B
TAF TBP-associated factor
TCEP tris(2-carboxyethyl)phoshine hydrochloride
TF transcription factor
Tris tris-(hydroxymethyl)-aminomethane
U units
v/v volume per volume
w/v weight per volume
wt wild type
87
List of Figures
List of Figures
1 The mRNA transcription cycle. . . . . . . . . . . . . . . . . . . . . . . . . . . 2
2 Transcription initiation. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 7
3 Med7N/31 crystals. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 36
4 Structure of the Med7N/31 Mediator subcomplex. . . . . . . . . . . . . . . . 38
5 Analysis of the Med7N/31 structure. . . . . . . . . . . . . . . . . . . . . . . . 39
6 Functional analysis of Med7N/31 in vivo and in vitro. . . . . . . . . . . . . . 42
7 Gal4-Gal4AH in vitro transcription. . . . . . . . . . . . . . . . . . . . . . . . 43
8 Transcriptome profiling analysis and phenotypic correlation. . . . . . . . . . . 44
9 Analysis of published genetic interactions of Med31 and TFIIS. . . . . . . . . 49
10 Endogenous Mediator and its middle module. . . . . . . . . . . . . . . . . . . 50
11 Destabilization of the Mediator complex. . . . . . . . . . . . . . . . . . . . . . 51
12 Recombinant Mediator middle module. . . . . . . . . . . . . . . . . . . . . . . 52
13 Native mass spectrometry analyses of Mediator middle module. . . . . . . . . 54
14 Mass spectrometry analyses of Mediator middle modules. . . . . . . . . . . . 55
15 Yeast complementation assay for MED4 . . . . . . . . . . . . . . . . . . . . . 57
16 Limited proteolysis analysis of Mediator middle module. . . . . . . . . . . . . 58
17 Intra-module subunit interactions within the middle module. . . . . . . . . . 60
18 Shape of the middle module. . . . . . . . . . . . . . . . . . . . . . . . . . . . 62
19 Structural overview of the trimeric Med7/21/31 complex architecture. . . . . 65
88
List of Tables
List of Tables
1 Complexes involved in S. cerevisiae RNA Pol II PIC assembly . . . . . . . . . 4
2 Mediator subunits S. cerevisiae. . . . . . . . . . . . . . . . . . . . . . . . . . . 9
3 E. coli strains. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 14
4 S. cerevisiae strains. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 14
5 E. coli vector list. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 16
6 Yeast vector list. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 21
7 Media. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 22
8 Media additives. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 22
9 General buffers, dyes and solutions. . . . . . . . . . . . . . . . . . . . . . . . . 23
10 Crystallization screening of M7N/31 complex. . . . . . . . . . . . . . . . . . . 37
11 Data collection and refinement statistics for Med7N/31. . . . . . . . . . . . . 37
12 Summary of Med7N mutant constructs of the polyproline stretches 1 and 2. . 40
13 GO analysis. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 45
14 Analysis of transcriptome profiling. . . . . . . . . . . . . . . . . . . . . . . . . 45
15 Comparative phenotyping of Mediator deletion strains. . . . . . . . . . . . . . 47
16 Crystallization screening. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 53
17 Mediator middle module interaction assays. . . . . . . . . . . . . . . . . . . . 59
18 Static light scattering (SLS) and Small-angle X-ray scattering (SAXS) mea-
surements. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 61
89
Curriculum Vitae
Curriculum Vitae
Tobias Koschubs
Personal Data
Date of birth: June 5, 1979
Place of birth: Hannover, Germany
Nationality: German
Martial status: married
Education
1986-1999 School education in Seesen,
Abitur equivalent to A-level at Jacobson Gymnasium
1999-2000 Community Service at Youth Center Seesen
2000-2005 Academic studies of biotechnology,
Technical University Carolo Wilhelmina, Braunschweig
2003-2004 University studies abroad in biotechnology,
Lund Institute of Technology, Sweden
2004 Student research project with Prof. Dr. D. Jahn,
Institute for Microbiology, Technical University Braunschweig
2005 Diploma thesis at Sanofi-aventis Pharma, Frankfurt/Main,
with Dr. M.K. Dreyer and Prof. Dr. D. Heinz
Departments Protein Production and Structural Biology
01/2006 Diploma degree in biotechnology
since 01/2006 Doctorate studies at the Gene Center of the
Ludwig-Maximilians-University München
with Prof. Dr. P. Cramer, Department of Biochemistry
Topic: "Structure and functional architecture of the Mediator middle
module from budding yeast"
90
